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SUMMARY	  
Fibroblast	  Growth	  Factor	  2	  (FGF2)	  is	  a	  potent	  mitogen	  with	  a	  prominent	  role	  in	  tumor-­‐
induced	  angiogenesis.	  In	  addition,	  FGF2	  exerts	  both	  direct	  and	  indirect	  effects	  at	  the	  
interface	  between	  angiogenesis	  and	  inflammatory	  processes	  as	  well	  as	  functions	  as	  a	  
survival	  factor	  of	  tumor	  cells	  by	  inhibiting	  apoptosis.	  These	  biological	  activities	  of	  FGF2	  
are	  mediated	  by	  a	  ternary	  complex	  consisting	  of	  FGF	  high	  affinity	  receptors,	  heparan	  
sulfate	   proteoglycans	   (HSPGs)	   and	   FGF2,	   a	   signaling	  module	   that	   is	   formed	   on	   the	  
surface	  of	   target	   cells.	  Despite	   these	  defined	  extracellular	   functions,	   FGF2	  does	  not	  
contain	  a	  signal	  peptide	  for	  translocation	  into	  the	  ER	  and,	  therefore,	  is	  exported	  by	  an	  
unconventional	  mechanism	  of	  protein	  secretion	  from	  cells.	  This	  process	  depends	  on	  
phosphatidylinositol-­‐4,5-­‐bisphosphate-­‐mediated	   recruitment	   and	   oligomerization	   of	  
FGF2	  at	  the	  inner	  leaflet	  of	  the	  plasma	  membrane	  concomitant	  with	  the	  formation	  of	  
a	  lipidic	  membrane	  pore.	  Subsequently,	  cell	  surface	  HSPGs	  act	  as	  an	  extracellular	  trap	  
mediating	  translocation	  of	  FGF2	  into	  the	  extracellular	  space.	  
This	   thesis	   started	   from	   the	   previous	   observation	   that	   Tec	   kinase,	   a	   gene	   product	  
identified	   in	   a	   genome-­‐wide	  RNAi	   screen,	   supports	   efficient	   secretion	  of	   FGF2	   from	  
cells.	  It	  aimed	  at	  i.)	  the	  validation	  of	  the	  role	  of	  Tec	  kinase	  in	  unconventional	  secretion	  
of	  FGF2	  using	   independent	   tools	  and	  a	  physiologically	   relevant	   read-­‐out	  system	  and	  
ii.)	   to	   obtain	   insight	   into	   the	  mechanism	  by	  which	   Tec	   kinase	   supports	   secretion	   of	  
FGF2	  from	  cells.	  
Employing	   a	   pharmacological	   inhibitor	   of	   Tec	   kinase	   in	   combination	   with	   a	   cell	  
proliferation	  assay	  as	  a	  read-­‐out	  of	  FGF2	  secretion,	  a	  requirement	  for	  the	  enzymatic	  
activity	  of	  Tec	  kinase	  in	  unconventional	  secretion	  of	  FGF2	  could	  be	  established.	  These	  
experiments	  confirmed	  the	  results	  from	  the	  RNAi	  screening	  procedure	  and,	  along	  with	  
other	   findings	   from	   our	   laboratory,	   led	   to	   discovery	   of	   FGF2	   being	   a	   substrate	   for	  
tyrosine	   phosphorylation	   catalyzed	   by	   Tec	   kinase.	   In	   the	   second	   part	   of	   this	   thesis,	  
oligomerization-­‐dependent	   membrane	   pore	   formation	   was	   found	   stimulated	   by	  
tyrosine	   phosphorylation	   of	   FGF2,	   providing	   a	   potential	   mechanism	   by	   which	   Tec	  
kinase	  may	   increase	   the	   efficiency	   of	   FGF2	   secretion	   from	   cells.	   Furthermore,	   cell-­‐
based	   assays	   analyzing	   the	   tyrosine-­‐phosphorylated	   pools	   of	   FGF2	   inside	   cells	   and	  
following	  secretion	  suggest	   that	   tyrosine	  phosphorylation	  of	  FGF2	  occurs	   transiently	  
	   	  
during	   membrane	   translocation	   as	   FGF2	   did	   not	   accumulate	   on	   cell	   surfaces	   in	   a	  
phosphorylated	  form.	  In	  order	  to	  investigate	  the	  localization	  of	  a	  metabolically	  stable,	  
phosphomimetic	   FGF2	   variant	   form	   in	   cells,	   microinjection	   experiments	   were	  
conducted	   using	   a	   recombinant	   FGF2	   variant	   that	   contains	   the	   phosphomimetic	  
unnatural	   amino	   acid	   pCMF	   in	   the	   position	   of	   the	   naturally	   occurring	   phospho-­‐
tyrosine	   residue.	   Employing	   both	   immuno-­‐electron	   microscopy	   and	   fluorescence	  
microscopy,	   phosphomimetic	   FGF2	   was	   found	   to	   accumulate	   in	   the	   cell	   periphery.	  
This	   localization	   depended	   on	   microtubules	   as	   treatment	   of	   cells	   with	   nocodazole	  
caused	  perinuclear	  localization	  of	  phosphomimetic	  FGF2.	  Finally,	  to	  test	  the	  relevance	  
of	   these	   observations	   for	   the	   overall	   process	   of	   FGF2	   export	   from	   cells,	   secretion	  
assays	  in	  the	  absence	  and	  presence	  of	  nocodazole	  were	  performed	  suggesting	  a	  role	  
for	   microtubules	   in	   intracellular	   transport	   of	   FGF2	   into	   the	   cell	   periphery	   and,	  
therefore,	  for	  efficient	  secretion	  of	  FGF2	  into	  the	  extracellular	  space.	  
Taken	  together,	   in	  this	  thesis,	   i.)	  a	  role	  for	  Tec	  kinase	   in	  the	  overall	  process	  of	  FGF2	  
secretion	  could	  be	  validated	  based	  on	  pharmacological	  evidence,	  ii.)	  a	  role	  of	  tyrosine	  
phosphorylation	   of	   FGF2	   in	   membrane	   pore	   formation	   was	   supported	   by	  
reconstitution	  experiments,	  iii.)	  evidence	  for	  transient	  phosphorylation	  of	  FGF2	  during	  
membrane	   translocation	  was	  provided	  by	   cell-­‐based	  experiments	   and	   iv.)	   a	   role	   for	  
microtubules	  in	  FGF2	  transport	  into	  the	  cell	  periphery	  as	  part	  of	  the	  overall	  process	  of	  
FGF2	  secretion	  was	  supported	  by	  a	  combination	  of	  microinjection	  and	  cell	  imaging.	  
 
	   	  
	  
ZUSAMMENFASSUNG	  
Fibroblastenwachstumsfaktor	   2	   (FGF2)	   ist	   ein	   potentes	   Mitogen,	   welches	   eine	  
bedeutende	   Rolle	   in	   der	   tumor-­‐induzierten	   Angiogenese,	   inflammatorischen	  
Prozessen	  und	  als	  Überlebensfaktor	  von	  Krebszellen	  durch	  Inhibierung	  der	  Apoptose	  
einnimmt.	   Diese	   biologischen	   Aktivitäten	   werden	   durch	   einen	   ternären	   Komplex	  
vermittelt,	   bestehend	   aus	   FGF-­‐Rezeptoren,	   Heparansulfat	   Proteoglycanen	   (HSPGs)	  
und	   FGF2,	   der	   auf	   der	   Oberfläche	   von	   Zielzellen	   gebildet	   wird.	   Obwohl	   FGF2	   diese	  
Funktionen	  extrazellulär	  ausübt,	  fehlt	  dem	  Wachstumsfaktor	  ein	  Signalpeptide	  für	  den	  
Eintritt	   in	   das	   endoplasmatische	   Retikulum	   und	   wird	   demzufolge	   mittels	   eines	  
unkonventionellen	   Mechanismus	   exportiert.	   Dieser	   Prozess	   ist	   abhängig	   von	   der	  
Phosphatidylinositol-­‐4,5-­‐bisphosphat-­‐vermittelten	  Rekrutierung	  und	  Oligomerisierung	  
von	   FGF2	   an	   der	   intrazellulären	   Seite	   der	   Plasmamembran	   und	   resultiert	   in	   der	  
Bildung	   einer	   hydrophilen	   Membranpore.	   Die	   direkte	   Translokation	   durch	   die	  
Plasmamembran	  wird	  durch	  die	  Affinität	  zu	  den	  extrazellulären	  HSPGs	  angetrieben.	  
Diese	   Arbeit	   gründet	   auf	   der	   vorhergehenden	   Beobachtung,	   dass	   die	   Tec	   Kinase,	  
welche	  in	  einer	  genomweiten	  Hochdurchsatz-­‐RNAi-­‐Analyse	  identifiziert	  wurde,	  an	  der	  
effizienten	  FGF2-­‐Sekretion	  aus	  Zellen	  beteiligt	  ist.	  Sie	  zielt	  ab	  auf	  (i)	  die	  Validierung	  der	  
Rolle	   der	   Tec	   Kinase	   in	   der	   unkonventionellen	   Sekretion	   von	   FGF2	   und	   (ii)	   die	  
Untersuchung	   des	   Mechanismus	   durch	   den	   die	   Tec	   Kinase	   in	   den	   FGF2-­‐Export	  
eingreift.	  	  
Durch	   den	   Einsatz	   eines	   pharmakologischen	   Inhibitors	   der	   Tec	   Kinase	   in	   einer	  
zellproliferationbasierten	   Analyse,	   konnte	   eine	   Abhängigkeit	   der	   unkonventionellen	  
FGF2-­‐Sekretion	   von	   der	   enzymatischen	   Aktivität	   der	   Kinase	   gezeigt	   werden.	   Diese	  
Experimente	  bestätigten	  die	  Ergebnisse	  der	  Hochdurchsatz-­‐RNAi-­‐Analyse	  und	  führten,	  
gemeinsam	  mit	  weiteren	  Beobachtungen	  unseres	  Labors,	  zur	  Identifizierung	  von	  FGF2	  
als	  Substrat	  der	  Tec	  Kinase.	  Im	  zweiten	  Teil	  dieser	  Arbeit	  konnte	  gezeigt	  werden,	  dass	  
die	   oligomerisierungsabhängige	   Membranporenbildung	   durch	   Tyrosinphosphorylie-­‐
rung	  stimuliert	  wird.	  Diese	  liefert	  einen	  potentiellen	  Mechanismus,	  durch	  den	  die	  Tec	  
Kinase	   die	   Sekretionseffizienz	   von	   FGF2	   steigern	   könnte.	   Zudem	   ergab	   eine	  
zellbasierte	  Analyse	  zur	  Untersuchung	  der	  phosphorylierten	  FGF2-­‐Population	  vor	  und	  
nach	  der	  Sekretion	  den	  Hinweis	  auf	  eine	  transiente	  Tyrosinphosphorylierung	  von	  FGF2	  
	   	  
	  
während	   der	   Membrantranslokation,	   da	   FGF2	   nicht	   in	   einem	   phosphorylierten	  
Zustand	   an	   der	   Zelloberfläche	   akkumuliert.	   Um	   die	   Lokalisierung	   einer	  metabolisch	  
stabilen,	   phosphomimetischen	   FGF2-­‐Variante	   in	   Zellen	   zu	   untersuchen,	   wurde	  
Mikroinjektionsexperimente	   durchgeführt.	   Dazu	   wurde	   eine	   rekombinante	  
phosphomimetische	   FGF2-­‐Variante	   verwendet,	   die	   ein	   metabolisch	   stabiles	  
Phosphotyrosinhomolog	   (pCMF)	   an	   der	   Position	   des	   natürlich	   vorkommenden	  
Phosphotyrosinrestes	   enthält.	   Sowohl	   durch	   immuno-­‐elektronenmikopische	  
Untersuchungen	  als	  auch	  fluoreszenmikroskopische	  Analysen	  konnte	  gezeigt	  werden,	  
dass	  phosphomimetisches	  FGF2	   in	  der	  Zellperipherie	  akkumuliert.	  Dieser	  Prozess	   ist	  
mikrotubuliabhängig,	  da	  eine	  Behandlung	  der	  Zellen	  mit	  Nocodazol	  zur	  perinukleären	  
Lokalisierung	   von	   phosphomimetischen	   FGF2	   führte.	   Um	   die	   Relevanz	   dieser	  
Beobachtung	   für	   den	   allgemeinen	   Prozess	   des	   FGF2-­‐Exports	   aus	   Zellen	   zu	  
untersuchen,	   wurden	   Sekretionsanalysen	   in	   An-­‐	   und	   Abwesenheit	   von	   Nocodazol	  
durchgeführt.	  Diese	  deuten	  auf	  eine	  Rolle	  der	  Mikrotubuli	  im	  intrazellulären	  Transport	  
von	  FGF2	   in	  die	   Zellperipherie	  hin	  und	  könnten	   somit	   an	  der	  effiziente	   Sekretion	   in	  
den	  extrazellulären	  Raum	  beteiligt	  sein.	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1 INTRODUCTION	  
Eukaryotic	   cells	   communicate	   with	   each	   other	   and	   the	   environment	   by	   secreting	  
signaling	   molecules	   into	   the	   surrounding	   space.	   However,	   before	   reaching	   its	  
extracellular	   destination,	   secretory	   proteins	   are	   synthesized	   inside	   cells	   and	  
transported	   into	   the	  periphery.	   The	  vast	  majority	  of	   secreted	  proteins	   thereby	  pass	  
the	  classical	  export	  route	  that	  includes	  distinct	  membrane-­‐enclosed	  organelles	  such	  as	  
the	   endoplasmic	   reticulum	   (ER)	   and	   the	   Golgi	   apparatus,	   providing	   a	   variety	   of	  
specialized	  environments	  within	  a	  single	  cell.	  A	  characteristic	  feature	  of	  conventionally	  
secreted	   proteins,	   which	   allows	   for	   entering	   this	   pathway	   at	   the	   stage	   of	   ER,	   is	   a	  
hydrophobic	  signal	  sequence.	  More	  recently,	  proteins	  lacking	  such	  a	  signal	  sequence	  
have	   been	   discovered,	   indicating	   an	   ER/Golgi-­‐independent	   protein	   transport	   to	   the	  
cell	  surface	  (Muesch	  et	  al.	  1990).	  In	  fact,	  extensive	  studies	  in	  the	  last	  years	  revealed	  a	  
growing	   number	   of	   proteins	   travelling	   through	   diverse,	   parallel	   and	   independent	  
mechanisms	   summarized	   under	   the	   term	   unconventional	   protein	   secretion	   (Nickel	  
and	  Seedorf	  2008).	  
	  
1.1 THE	  CLASSICAL	  EXPORT	  ROUTE	  TO	  THE	  PLASMA	  MEMBRANE	  
The	  classical	  secretion	  route	  is	  a	  highly	  complex	  process	  that	  fulfills	  a	  variety	  of	  tasks,	  
including	  protein	  biogenesis,	  quality	  control,	  modification,	  sorting	  and	  secretion	  as	  the	  
final	   step	   (Figure	   1).	   At	   the	   beginning	   of	   protein	   synthesis,	   nuclear	   DNA	  
(Deoxyribonucleic	  acid)	  is	  transcribed	  into	  mRNA	  (messenger	  ribonucleic	  acid),	  which	  
is	  transported	  into	  the	  cytoplasm	  where	  it	  binds	  to	  free	  ribosomes.	  Resulting	  nascent	  
protein	   chains	   containing	   a	   hydrophobic	   signal	   sequence	   at	   the	   N-­‐terminus	   are	  
recognized	   by	   the	   cytosolic	   signal	   recognition	   particle	   (SRP).	   Targeting	   of	   the	   SRP-­‐
ribosome-­‐nascent	   chain	   complex	   to	   the	   SRP	   receptor	   in	   the	   membrane	   of	   the	   ER	  
represents	   the	   entry	   point	   for	   proteins	   into	   the	   endomembrane	   system	   of	   the	  
conventional	  secretory	  pathway	  (Lee	  et	  al.	  2004).	  	  
	  
The	   emerging	   peptide	   chains	   are	   transferred	   from	   the	   SRP	   to	   the	   translocon,	   a	  
complex	   of	   transmembrane	   proteins,	   that	   form	   a	   pore	   through	   which	   secretory	  
proteins	  and	  cytoplasmic	  domains	  of	  membrane	  proteins	  translocate	  from	  the	  cytosol	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to	  the	  ER	  lumen	  (Johnson	  and	  van	  Waes	  1999).	  Here,	  posttranslational	  modifications	  
occur,	   such	   as	   initiation	   of	   N-­‐linked	   glycosylation	   and	   disulfide	   bond	   formation.	  
However,	   the	   main	   task	   of	   the	   ER	   is	   to	   ensure	   that	   proteins	   reach	   their	   native	  
conformation	   which	   is	   operated	   by	   ER	   chaperones.	   While	   mis-­‐folded	   proteins	   are	  
identified	  by	   the	  ER-­‐associated	  degradation	   (ERAD)-­‐machinery	  and	  transported	  back	  
into	  the	  cytoplasm	  prior	  to	  degradation	  by	  the	  proteasome,	  properly	  folded	  proteins	  
are	  delivered	  to	  the	  next	  compartment	  along	  the	  secretory	  pathway	  (Nishikawa	  et	  al.	  
2005).	  	  
Figure	   1:	   Schematic	   representation	  of	   the	   classical	   secretory	   pathway.	  Secretory	   proteins	   enter	   the	  
endoplasmic	   reticulum	   (ER)	   through	   the	   translocon.	   There,	   cargo	   destined	   for	   secretion	   is	   actively	  
sorted	   into	   ER	   exit	   sites	   (ERES)	   that	   bud	   and	   travel	   as	   membrane-­‐enclosed	   vesicles	   to	   the	   ER-­‐Golgi	  
intermediate	  compartment	  (ERGIC),	  which	  is	  then	  delivered	  to	  the	  cis-­‐Golgi	  membrane.	  After	  traversing	  
the	  Golgi,	   proteins	   are	  packaged	   into	   tubular	   structures	  or	   small	   vesicles,	  which	   finally	   fuse	  with	   the	  
plasma	   membrane.	   COPII	   CV=	   coat	   protein	   complex	   II-­‐coated	   vesicles.	   Modified	   from	   Nickel	   and	  
Rabouille	  (2009).	  
	  
Correctly	   folded	  proteins	  passing	   the	  quality	   control	   are	  packaged	   into	   coat	  protein	  
complex	  II	  (COPII)-­‐coated	  vesicles	  that	  bud	  at	  specific	  locations	  on	  the	  ER	  membrane	  
named	  ER-­‐exit	   sites	   (Orci	  et	  al.	  1991;	   Jensen	  and	  Schekman	  2011).	  As	  such,	  vesicles	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target	  compartment	  of	  COPII-­‐vesicles	  in	  plant	  and	  yeast	  cells	  is	  the	  Golgi	  apparatus.	  In	  
contrast,	   vesicles	   in	  mammalian	   cells	   initially	   fuse	   into	   a	  membrane	   system	   termed	  
ER-­‐Golgi	   intermediate	   compartment	   (ERGIC)	  which	   is	   subsequently	   delivered	   to	   the	  
Golgi	  (Lee	  et	  al.	  2004).	  	  
	  
The	  primary	  role	  of	  the	  Golgi	  is	  to	  provide	  a	  milieu	  that	  facilitates	  protein	  processing	  
before	   being	   sorted	   to	   their	   final	   destination.	   Processing	   includes	   N-­‐	   and	   O-­‐linked	  
glycosylation,	   phosphorylation	   and	   limited	   proteolytic	   cleavage,	   which	   ensure	   the	  
functionality	   of	   the	   proteins.	   Since	   the	   catalyzing	   enzymes	   are	   located	   in	   distinct	  
cisternae,	  proteins	  arriving	  at	   the	  cis-­‐Golgi	   are	  modified	  while	   traveling	   through	   the	  
stacks	   to	   the	   trans-­‐Golgi	   network	   (Emr	   et	   al.	   2009).	   Among	   these	   posttranslational	  
modifications,	  the	  Golgi	  has	  also	  been	  implicated	  as	  central	  station	  for	  protein	  sorting	  
(Griffiths	   and	   Simons	   1986).	   Constitutive	   and	   regulated	   secretory	   proteins	   are	  
packaged	   into	   multiple	   classes	   of	   carriers,	   which	   traverse	   the	   cytoplasm	   as	  
pleomorphic	   tubular	   structures	   in	   addition	   to	   small	   vesicles	   and	   finally	   fuse	   with	  
compartments	   of	   the	   endosomal	   system	   or	   the	   plasma	   membrane,	   respectively	  
(Pfeffer	  2012).	  
	  
1.2 UNCONVENTIONAL	  EXPORT	  ROUTES	  TO	  THE	  PLASMA	  MEMBRANE	  
The	  vast	  majority	  of	  secreted	  proteins	  contain	  a	  hydrophobic	  signal	  sequence,	  which	  
initiates	  their	  entry	   into	  the	  ER/Golgi-­‐dependent	  classical	  export	  pathway.	  However,	  
discovery	  of	  extracellular	  proteins	  in	  the	  early	  1990s	  devoid	  of	  such	  a	  signal	  sequence	  
and	   thereby	   excluded	   from	   the	   ER-­‐lumen	   gave	   a	   first	   hint	   for	   a	   second	   export	  
mechanism	  bypassing	  the	  ER/Golgi-­‐mediated	  route	  (Muesch	  et	  al.	  1990).	  Consistently,	  
posttranslational	  modifications,	  a	  typical	  feature	  of	  conventionally	  secreted	  proteins,	  
were	   missing	   (Baldwin	   and	   Ostergaard	   2001;	   Baldwin	   and	   Ostergaard	   2002).	  
Moreover,	   the	   demonstration	   that	   Brefeldin	   A	   (BFA),	   a	   drug	   that	   inhibits	   Golgi-­‐to-­‐
plasma	   membrane	   transport,	   does	   not	   interfere	   with	   export	   of	   those	   “leaderless”	  
proteins	  provided	  further	  evidence	  for	  an	  ER/Golgi-­‐independent	  mechanism.	  
	  
Beside	  signaling	  proteins	   lacking	  the	  N-­‐terminal	  signal	  sequence	  for	  ER	  entry,	  signal-­‐
peptide	   containing	   proteins	   have	   been	   described	   deviating	   from	   the	   conventional	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route	   at	   the	   stage	   of	   sorting	   into	   COPII-­‐coated	   vesicles	   such	   as	   yeast	   heat-­‐shock	  
protein	  150	  (Hsp150)	  or	  ER	  degradation-­‐enhancing	  mannosidase-­‐like	  1	  (EDEM1,	  Fatal	  
et	  al.	  2004;	  Zuber	  et	  al.	  2007).	  There,	  ER	  release	  occurs	  at	  special	  sites	  that	  differ	  from	  
typical	  ER	  exit	  sites	  (Grieve	  and	  Rabouille	  2011).	  Additionally,	  proteins	  like	  CD45	  have	  
been	   identified	   at	   the	   plasma	   membrane	   of	   mammalian	   cells	   equipped	   with	  
immature,	   high-­‐mannose	   N-­‐glycans	   as	   typical	   ER	   modification,	   indicating	   a	   Golgi-­‐
independent	   mechanism	   (Baldwin	   and	   Ostergaard	   2002;	   Prydz	   et	   al.	   2013).	   By	  
contrast,	   in	   the	  case	  of	   cystic	   fibrosis	   transmembrane	  conductance	   regulator	   (CFTR)	  
where	  N-­‐glycans	   are	   eventually	  modified,	   delivery	   from	   the	   ERES	   to	   the	   trans-­‐Golgi	  
network	  (TGN)	  or	  to	  endosomes	  bypassing	  the	  Golgi	  has	  been	  proposed.	  Assuming	  a	  
direct	   transport	   to	   endosomes,	   re-­‐entry	   into	   the	   TGN	   prior	   to	   plasma	   membrane	  
delivery	  has	  been	  speculated	  (Yoo	  et	  al.	  2002;	  Grieve	  and	  Rabouille	  2011).	  
	  
Unconventional	   secretion	   of	   cytoplasmic	   proteins	   lacking	   the	   N-­‐terminal	   signal	  
peptide	  is	  represented	  by	  rather	  dissimilar	  mechanisms.	  However,	  these	  are	  broadly	  
classified	   into	   (i)	   vesicular	   or	   (ii)	   non-­‐vesicular	  mechanisms	   according	   to	   an	   existing	  
membrane-­‐enclosed	   intermediate	   (Figure	   2,	   Rabouille	   et	   al.	   2012).	   The	   latter	   is	  
characterized	   by	   direct	   transport	   of	   cytoplasmic	   proteins	   to	   the	   inner	   leaflet	   of	   the	  
plasma	  membrane	   followed	  by	  membrane	  translocation.	  Some	  prominent	  examples	  
of	   this	   group	  are	   represented	  by	   FGF2	   (fibroblast	   growth	   factor	   2),	  HIV-­‐Tat	   (human	  
immunodeficiency	  virus-­‐trans-­‐activator	  of	  transcription)	  as	  well	  as	  Annexin	  A2	  (Nickel	  
2011).	  In	  contrast,	  the	  vesicular	  mechanism	  refers	  to	  proteins,	  such	  as	  interleukin-­‐1β	  
(IL-­‐1β)	  or	  acyl-­‐CoA	  binding	  protein.	  Secretion	  of	  these	  proteins	  depends	  on	  the	  uptake	  
into	   intracellular	   membrane-­‐bounded	   intermediates	   that	   require	   fusion	   with	   or	  
budding	   from	  the	  plasma	  membrane	  to	  release	  cargo	  proteins	   into	  the	  extracellular	  
space.	   These	   membrane-­‐enclosed	   intermediates	   differ	   considerably	   from	   vesicles	  
involved	   in	  the	  classical	  secretory	  pathway	  since	  they	  are	  not	  derived	  from	  ER/Golgi	  
compartments	  (Nickel	  2011).	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Figure	   2:	  Unconventional	   secretion	   pathways.	  Two	   different	   classes	   for	   unconventional	   secretion	   of	  
soluble	  proteins	  have	  been	  postulated.	  The	  first	  is	  a	  vesicular	  mechanism	  as	  proposed	  for	  interleukin	  1-­‐
beta	  (IL-­‐1β)	  and	  acyl-­‐CoA	  binding	  protein	  (Acb1	  in	  D.	  dyctiostelium).	  Regarding	  IL-­‐1β	  four	  mechanisms	  
have	  been	  suggested	  including	  secretory	  lysosomes	  (1),	  microvesicle	  shedding	  (2),	  autophagosomes	  (3)	  
and	  multi-­‐vesicular	   bodies	   (4,	  MVBs).	   Regarding	  MVBs	   it	   has	  been	  assumed	   that	   IL-­‐1β	   is	   internalized	  
either	  as	  a	  soluble	  protein	  or	  captured	  in	  autophagosomes.	  Acb1	  has	  been	  linked	  to	  autophagosome-­‐
mediated	   secretion	   (5).	   Recently,	   a	   unique	   membranous	   compartment	   for	   unconventional	   protein	  
secretion	  (CUPS)	  has	  been	  identified,	  which	  seems	  to	  be	  involved	  in	  export	  of	  Acb1.	  The	  second	  type	  of	  
unconventional	   protein	   secretion	   refers	   to	   a	   non-­‐vesicular	   mechanism	   that	   is	   represented	   by	  
phospholipid	  (PL)	  recruitment	  and	  direct	  membrane	  translocation	  as	  shown	  for	  FGF2	  (fibroblast	  growth	  
factor	  2),	  HIV-­‐Tat	  (human	  immunodeficiency	  virus-­‐trans-­‐activator	  of	  transcription)	  or	  Annexin	  A2	  (6).	  	  
	  
1.2.1 Proteins	  secreted	  by	  a	  vesicular	  mechanism	  
Three	   distinct	   pathways,	   including	   either	   exosomes	   derived	   from	   multi-­‐vesicular	  
bodies,	   secretory	   lysosomes	   or	  microvesicle	   shedding	   from	   cell	   surfaces	   have	   been	  
described	   to	  mediate	  unconventional	   secretion	  of	  proteins	  without	  a	   signal	  peptide	  
(Figure	   2,	   Nickel	   2011).	   More	   recently,	   autophagosome-­‐linked	   proteins	   have	   been	  
described	  additionally	  to	  be	  involved	  in	  transporting	  signal-­‐peptide	  lacking	  proteins	  to	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1.2.1.1 Interleukin-­‐1	  β	  
	  
Interleukin-­‐1β	   (IL-­‐1β)	   is	   a	   pleiotropic	   cytokine,	   which	   has	   been	   linked	   to	  
unconventional	   secretion	   upon	   inflammasome	   activation	   by	   either	   pathogen-­‐
associated	  molecular	  pattern	  molecules	   like	  bacterial	   lipopolysaccharide	  or	  damage-­‐
associated	   molecular	   pattern	   molecules	   such	   as	   extracellular	   ATP	   (adenosine	  
triphosphate)	  released	  by	  damaged	  cells	  (Rubartelli	  et	  al.	  1990;	  Eder	  2009).	  Therefore,	  
it	  has	  been	  concluded	   that	   IL-­‐1β	   is	  not	   secreted	   in	  a	   constitutive	  but	   in	  a	   regulated	  
mode.	   In	   this	   context,	   it	   has	   been	   assumed	   that	   secretion	   is	   initiated	   with	   the	  
synthesis	  of	  an	  inactive	  pro-­‐IL-­‐1β	  precursor	  protein	  upon	  stimulation.	  Before	  reaching	  
the	  extracellular	  space,	   this	  cytosolic	  precursor	  has	  been	  suggested	  to	  be	  processed	  
into	  mature,	  biologically	  active	  IL-­‐1β	  in	  a	  caspase-­‐1	  dependent	  manner	  (Matsushima	  
et	   al.	   1986;	   Thornberry	   et	   al.	   1992).	   Surprisingly,	   considerable	   amounts	   of	   IL-­‐1β	  
precursor	   were	   detected	   in	   the	   extracellular	   milieu	   even	   in	   the	   absence	   of	   an	  
inflammasome.	   Therefore,	   secretion	   might	   not	   be	   dependent	   on	   both	   a	   cleavage	  
process	   that	   is	   spatially	   linked	  to	  an	   intracellular	   localization	  and	  a	  stimulus	  prior	   to	  
pro-­‐IL-­‐1β	   secretion	   (Rabouille	   et	   al.	   2012).	   In	   fact,	   caspase-­‐1	   activity	   requires	   the	  
assembly	   and	   activation	   of	   inflammasomes	   and	   thus	   links	   the	   innate	   immune	  
response	  to	  activation	  of	  an	  unconventionally	  secreted	  protein	  (Eder	  2009).	  
	  
While	   the	   processes	   causing	   caspase-­‐1	   activation	   and	   pro-­‐IL-­‐1β	   cleavage	   are	   well	  
studied,	   different	  mechanisms	   leading	   to	  unconventional	   export	   of	   IL-­‐1β	  have	  been	  
described.	  Rubartelli	  and	  co-­‐workers	  postulated	  a	  model	  where	   IL-­‐1β	   is	  delivered	  to	  
the	   inner	   leaflet	   of	   the	   plasma	   membrane	   in	   secretory	   lysosomes	   of	   monocytes	  
(Figure	  2	   (1),	  Andrei	  et	  al.	  1999).	   In	  response	  to	  external	  stimuli	   such	  as	  ATP,	  which	  
causes	   an	   increased	   Ca2+	   concentration,	   secretory	   lysosomes	   are	   mobilized	   and	  
transported	   along	  microtubules	   to	   the	   plasma	  membrane	   (Eder	   2009).	   It	   has	   been	  
suggested	   that	   caspase-­‐1	   processing	   of	   the	   precursor	   occurs	   during	   this	   transport.	  
Subsequently,	  mature	   IL-­‐1β	   is	   released	   after	   ATP-­‐triggered	   fusion	   of	   both	   lysosome	  
and	  plasma	  membrane	  (Andrei	  et	  al.	  2004).	  
	  
Among	   those	   secretory	   lysosomes,	  microvesicle	   shedding	   has	   been	   proposed	   to	   be	  
involved	   in	   IL-­‐1β	   secretion	   (Figure	   2	   (2),	  MacKenzie	   et	   al.	   2001;	   Bianco	   et	   al.	   2005;	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Pizzirani	   et	   al.	   2007).	   Due	   to	   perturbation	   of	   the	   lipid	   symmetry	   of	   the	   plasma	  
membrane	   and	   subsequent	   shedding,	   microvesicles	   contain	   both	   cell	   membrane	  
components	   and	   cytoplasmic	   contents,	   including	   pro-­‐IL-­‐1β,	  mature	   IL-­‐1β	   as	  well	   as	  
caspase-­‐1	  (Ratajczak	  et	  al.	  2006;	  Eder	  2009).	  Since	  the	  IL-­‐1β	  precursor	  form	  was	  found	  
in	   those	   extracellular	   vesicles,	   processing	   of	   immature	   IL-­‐1β	   inside	   the	   vesicles	   has	  
been	   suggested	   (MacKenzie	   et	   al.	   2001;	   Bianco	   et	   al.	   2005;	   Pizzirani	   et	   al.	   2007).	  
Following	  release	  form	  cells,	  mature	  IL-­‐1β	  was	  shown	  to	  fulfill	  a	  variety	  of	  biological	  
functions.	  The	  literature	  supporting	  this	  microvesicle	  shedding	  model	  is	  not	  conclusive	  
about	  the	  mechanism	  of	  how	  IL-­‐1β	  and	  all	  other	  cytoplasmic	  components	  break	  out	  of	  
their	  membranous	  envelope.	  It	  has	  been	  hypothesized	  that	  IL-­‐1β	  is	  released	  slowly	  in	  
a	   so	   far	   unknown,	   Ca2+	   dependent	  manner.	   An	   alternative	   view	   suggested	   an	   ATP-­‐
induced	  lysis	  of	  vesicles	  in	  the	  extracellular	  milieu	  (Bianco	  et	  al.	  2005;	  Pizzirani	  et	  al.	  
2007).	  
	  
A	   third	   mechanism	   favors	   the	   release	   of	   IL-­‐1β	   from	   murine	   bone	   marrow-­‐derived	  
macrophages	   via	   multi-­‐vesicular	   bodies	   (Figure	   2	   (4),	   MVBs),	   which	   are	   formed	   by	  
inward	  budding	  of	  late	  endosomal	  membrane	  systems.	  In	  fact,	  it	  has	  been	  speculated	  
that	  caspase-­‐1	  regulates	   the	   formation	  of	   those	  specialized	  exosomes.	  Finally,	   these	  
vesicles	  filled	  with	  caspase-­‐1	  along	  with	  IL-­‐1β	  are	  released	  from	  the	  lumen	  of	  MVBs	  by	  
fusion	  with	  the	  plasma	  membrane	  (Qu	  et	  al.	  2007).	  Previously,	  a	  mechanism	  has	  been	  
published	  describing	  starvation-­‐induced	  autophagy	  to	  be	  required	  for	  IL-­‐1β	  secretion	  
(Figure	  2	  (3),	  Dupont	  et	  al.	  2011).	  So	  far,	  it	  is	  still	  unclear	  whether	  the	  release	  of	  the	  
cytokine	  is	  mediated	  by	  fusion	  with	  the	  plasma	  membrane.	  It	  might	  be	  also	  possible,	  
that	   this	   is	   a	   rather	  modified	  model	   for	  MVB-­‐mediated	  unconventional	   secretion	  as	  
autophagosomes	   are	   shown	   to	   fuse	  with	  MVBs	   in	  mammals	   (Berg	   et	   al.	   1998).	   En	  
route	   to	   the	   plasma	   membrane	   the	   monomeric	   guanosine	   triphosphatase	   (GTPase)	  
Rab8	   and	   the	   Golgi	   re-­‐assembly	   and	   stacking	   protein	   (GRASP)	   were	   found	   to	   be	  
critically	  important	  for	  IL-­‐1β	  release	  (Dupont	  et	  al.	  2011).	  While	  Rab8	  was	  shown	  to	  be	  
involved	   in	   secretory	   traffic	   at	   recycling	   endosomes,	   GRASP	   was	   recently	   seen	   in	  
connection	   with	   the	   unconventional,	   autophagosome-­‐mediated	   export	   of	   acyl-­‐CoA	  
binding	   protein	   supporting	   a	   model	   for	   an	   alternative	   autophagy-­‐based	   secretion	  
pathway	  for	  IL-­‐1β	  (Duran	  et	  al.	  2010;	  Manjithaya	  et	  al.	  2010).	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1.2.1.2 Acyl-­‐CoA	  binding	  protein	  
	  
Acyl-­‐CoA	  binding	  protein	  (known	  as	  Acb1	  in	  yeast,	  AcbA	  in	  Dictyostelium	  discoideum	  
and	   diazepam-­‐binding	   inhibitor	   in	   mammals)	   is	   a	   small	   10	   kDa-­‐protein,	   which	   is	  
extracellularly	   processed	   into	   a	   34-­‐amino	   acid	   peptide	   termed	   SDF-­‐2	   (spore	  
differentiation	  factor-­‐2).	  Once	  cleaved,	  bioactive	  SDF-­‐2	  can	  interact	  with	  its	  receptor	  on	  
the	   surface	   of	   prespore	   cells	   causing	   rapid	   encapsulation	  of	   these	   cells	   (Anjard	   and	  
Loomis	  2005).	   In	  order	  to	  reach	  the	  extracellular	  area	  of	  operation,	  cells	  need	  to	  be	  
exposed	   to	   rapamycin,	   nitrogen	   and	   nutrient	   starvation	   and	   thus,	   respond	   in	   a	  
regulated	   manner	   with	   Acb1/AcbA	   secretion	   (Duran	   et	   al.	   2010;	   Manjithaya	   et	   al.	  
2010).	  Interestingly,	  it	  has	  been	  shown	  that	  Golgi	  re-­‐assembly	  stacking	  protein	  (GrpA)-­‐
deficient	   cells	   accumulate	  AcbA	   in	   the	   cytosol	   under	   those	   conditions	   resulting	   in	   a	  
strong	  decrease	  in	  formation	  of	  viable	  spores.	  Since	  GrpA	  is	  the	  only	  GRASP	  homolog	  
in	  Dictyostelium	  discoideum,	   these	   findings	  directly	   link	  unconventional	   secretion	  of	  
AcbA	   to	   a	   recently	   identified,	  GRASP-­‐dependent	   alternative	   pathway	   (Kinseth	   et	   al.	  
2007).	  	  
	  
Two	   recent	   studies	   identified	   a	   role	   of	   autophagy	   proteins	   for	   AcbA	   and	   Acb1	  
secretion	  in	  a	  process	  that	  involves	  GRASP	  (Duran	  et	  al.	  2010;	  Manjithaya	  et	  al.	  2010).	  
Using	  yeast	  genetics,	  the	  plasma	  membrane	  t-­‐SNARE	  Sso1	  has	  additionally	  been	  found	  
to	  be	  involved	  in	  Acb1	  release	  while	  AcbA	  secretion	  required	  phospholipase	  D,	  which	  
was	   implicated	   in	  N-­‐ethylmaleimide-­‐sensitive	   factor	   (NSF)	   attachment	   (Duran	   et	   al.	  
2010;	  Manjithaya	  et	  al.	  2010).	  Indeed,	  NSF	  as	  a	  general	  membrane	  trafficking	  protein	  
has	  been	  shown	  to	  be	  important	  for	  AcbA	  release	  (Cabral	  et	  al.	  2010).	  Due	  to	  these	  
findings,	   the	   authors	   of	   both	   studies	   conclude	   that	   AcbA/Acb1	   is	   sequestered	   in	  
autophagosomes	  followed	  by	  its	  unconventional	  release	  after	  fusion	  with	  the	  plasma	  
membrane	  (Duran	  et	  al.	  2010;	  Manjithaya	  et	  al.	  2010).	  Intriguingly,	  in	  both	  studies	  it	  
has	   been	   demonstrated	   that	   mutants	   affecting	   vacuole	   fusion	   are	   competent	   in	  
Acb1/AcbA	   secretion	   indicating	   that	   those	   “secretory”	   autophagosomes	   bypass	   the	  
vacuole	   to	   prevent	   cargo	   degradation.	   Instead,	   Duran	   et	   al.	   (2010)	   proposed	   that	  
autophagosomes	   containing	   Acb1	   fuse	   first	   with	   MVBs	   and	   then	   with	   the	   plasma	  
membrane	   as	   shown	   by	   the	   requirement	   of	   proteins	   involved	   in	   ESCRT-­‐mediated	  
processes	   and	   the	   cell	   surface	   t-­‐SNARE	   (soluble	   N-­‐ethylmaleimide	   sensitive	   factor	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attachment	   protein	   receptors)	   Sso1.	   However,	   in	   a	   subsequent	   study	   Malhotra	   and	  
coworkers	   found	   yeast	   GRASP	   (Grh1)	   concentrated	   in	   unique	  membrane	   structures	  
near	   ER-­‐exit	   sites	   under	   conditions	   that	   induce	   Acb1	   secretion	   (Bruns	   et	   al.	   2011).	  
These	   punctae,	   called	   novel	   compartment	   for	   unconventional	   protein	   secretion	  
(CUPS),	  were	  believed	  to	  be	  an	  Acb1	  sorting	  station.	  Since	  CUPS	  (i)	  lack	  components	  of	  
the	   Golgi	   and	   endosome	  membranes,	   (ii)	   involve	   factors	   that	   are	   not	   required	   for	  
classical	   autophagy	  and	   (iii)	   depict	   an	  overall	  morphology	  distinct	   from	  MVBs	   it	   has	  
been	   postulated	   that	   CUPS	   might	   represent	   a	   novel	   compartment	   involved	   in	   the	  
formation	  of	  secretory	  autophagosomes,	  which	  in	  turn	  directly	  fuse	  with	  the	  plasma	  
membrane	  (Figure	  2	  (5),	  Bruns	  et	  al.	  2011;	  Rabouille	  et	  al.	  2012).	  	  
	  
1.2.2 Proteins	  secreted	  by	  a	  non-­‐vesicular	  mechanism	  
By	  contrast,	  the	  second	  group	  of	  unconventionally	  secreted	  proteins	  travels	  through	  
the	   cytoplasm	   without	   being	   captured	   by	   any	   kind	   of	   membrane-­‐bounded	  
intermediate.	  In	  the	  cell	  periphery,	  these	  proteins	  are	  recruited	  by	  lipids	  embedded	  in	  
the	  inner	   leaflet	  of	  the	  plasma	  membrane	  (Figure	  2	  (6)).	   It	  has	  been	  postulated	  that	  
the	   proteins	   transiently	   insert	   into	   membranes	   in	   order	   to	   directly	   appear	   on	   the	  




For	   the	   Human	   Immunodeficiency	   Virus	   type	   1	   (HIV-­‐1),	   the	   small	   basic	   protein	   Tat	  
(Trans-­‐Activator	  of	  Transcription)	  operates	  as	  an	  enhancer	  of	   viral	   transcription	  and	  
replication	   in	   target	   cells	   (Debaisieux	   et	   al.	   2012).	   In	   order	   to	   achieve	   this,	   newly	  
synthesized	  Tat	  is	  released	  by	  infected	  cells	  followed	  by	  reuptake	  and	  transport	  to	  the	  
nucleus	  of	  target	  cells,	  where	   it	   is	   required	  for	  viral	   transcription	  (Ensoli	  et	  al.	  1990;	  
Debaisieux	   et	   al.	   2012).	   The	   observation	   of	   such	   a	   transcellular	   transport	   pathway	  
elucidates	   a	   key	   role	   of	   exported	   Tat	   in	   virus	   replication	   boost.	   Furthermore,	  
extracellular	   Tat	   acts	   as	   a	   viral	   toxin,	   which	   induces	   various	   cell	   responses	   such	   as	  
strong	  increase	  in	  surface	  exposed	  HIV	  co-­‐receptors	  C-­‐X-­‐C	  chemokine	  receptor	  type	  4	  
(CXCR4)	  and	  C-­‐C	  chemokine	  receptor	  type	  5	  (CCR5)	  that,	   in	  turn,	  contributes	  to	  viral	  
infection	  (Rayne	  et	  al.	  2010b).	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With	  regard	  to	  the	  secretion	  process,	  it	  has	  been	  shown	  that	  Tat	  is	  not	  released	  by	  cell	  
lysis,	   which	   is	   a	   common	   outcome	   of	   viral	   infection,	   but	   by	   unconventional	  means	  
(Chang	   et	   al.	   1997;	   Rayne	   et	   al.	   2010a).	   Further	   investigations	   to	   shed	   light	   on	   the	  
molecular	   mechanism	   revealed	   that	   Tat	   interacts	   with	   phosphatidylinositol-­‐4,5-­‐
bisphosphate	   (PI(4,5)P2).	   This	   interaction	   is	   mediated	   by	   a	   sequential	   basic	   residue	  
triplet	  in	  the	  basic	  domain	  of	  Tat	  and	  leads	  to	  protein	  accumulation	  at	  the	  inner	  leaflet	  
of	  the	  plasma	  membrane	  (Rayne	  et	  al.	  2010b).	  It	  has	  been	  suggested	  that	  binding	  of	  
Tat	   to	   PI(4,5)P2	   triggers	   conformational	   changes	   in	   Tat	   resulting	   in	   protein-­‐surface	  
exposure	  and	  subsequent	  membrane	  insertion	  of	  a	  single	  tryptophan,	  which	  is	  buried	  
in	  the	  non-­‐bound	  form.	  While	  both	  binding	  to	  PI(4,5)P2	  and	  tryptophan	  insertion	  has	  
been	  shown	  to	  be	  a	  prerequisite	  for	  Tat	  secretion,	  the	  direct	  translocation	  mechanism	  
across	  the	  membrane	  still	  remains	  elusive.	  Once	  secreted,	  a	  portion	  of	  Tat	  remains	  in	  
a	   soluble	   form	  that	  binds	   to	  a	  variety	  of	   surface	   receptors	  acting	  as	  viral	   toxin	  or	   is	  
internalized	   as	   transactivator.	   The	   other	   fraction	   binds	   to	   heparan	   sulfate	  
proteoglycans	  (HSPGs)	  on	  cell	  surfaces	  of	  both	  infected	  and	  surrounding	  cells.	  HSPGs	  
are	   thought	   to	   be	   important	   for	   storage	   and	   protection	   of	   biologically	   active	   Tat	  
(Chang	   et	   al.	   1997).	   Besides	   the	   storage	   function,	   it	   has	   been	  proposed	   that	  HSPG-­‐
bound	  Tat	  modulates	  viral	  infection	  by	  recruiting	  the	  HIV-­‐1	  envelope	  glycoprotein	  120,	  
which	  consequently	  enhances	  virus	  attachment	  and	  subsequent	  cell	  entry	  (Marchio	  et	  
al.	  2005).	  	  
	  
1.2.2.2 Annexin	  A2	  
	  
Annexins	  are	  a	  highly	  conserved	  family	  of	  calcium	  and	  phospholipid	  binding	  proteins	  
that	  are	  found	  in	  multicellular	  and	  some	  single-­‐cell	  eukaryotes.	  Collectively,	  annexins	  
are	  thought	  to	  play	  a	  role	   in	  a	  variety	  of	   intracellular	  functions	  such	  as	  regulation	  of	  
membrane	  organization	  and	  membrane	  traffic.	  Moreover,	  they	  have	  been	  implicated	  
in	   a	   number	   of	   diseases	   including	   cancer	   and	   cardiovascular	   disease	   (Grieve	   et	   al.	  
2011).	   Although	   annexins	   share	   a	   high	   degree	   of	   sequence	   similarities	   only	   some	  
members	  of	  this	  family,	  namely	  annexin	  A1,	  annexin	  A2	  and	  annexin	  A5,	  are	  found	  in	  
the	  extracellular	  space.	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Annexins	   shuttle	   between	   the	   cytosol	   and	   the	   cytosolic	   surfaces	   of	   cellular	  
membranes	  in	  a	  calcium	  concentration	  dependent	  manner.	  Compared	  to	  other	  family	  
members,	  annexin	  A2	   is	  most	  sensitive	  to	  calcium	  increase	  resulting	   in	  an	  enhanced	  
affinity	   for	   PI(4,5)P2	   (Rescher	   et	   al.	   2004).	   However,	   in	   its	   most	   abundant	  
heterotetrameric	   form	  composed	  of	   two	  annexin	  molecules	  and	  two	  small,	  EF-­‐hand	  
S100A10	  proteins,	  annexin	  A2	  has	  a	  higher	  affinity	  for	  calcium	  and	  PI(4,5)P2	  than	  the	  
monomer	  (Rescher	  et	  al.	  2004).	  While	  the	  heterotetramer	  localizes	  at	  the	  inner	  leaflet	  
of	   the	   plasma	   membrane	   as	   well	   as	   specific	   membrane-­‐bound	   structures,	   such	   as	  
endosomes	   and	   transport	   intermediates,	   it	   is	   excluded	   from	  membranes	   of	   the	   ER,	  
Golgi	  or	  mitochondria	  (Grieve	  et	  al.	  2011).	  Besides	  the	  Ca2+-­‐regulated	  recruitment	  by	  
PI(4,5)P2,	   the	   tetrameric	   complex	   also	   interacts	   with	   the	   barbed-­‐ends	   of	   actin	  
filaments	   (Gerke	   and	  Weber	   1984).	   Furthermore,	   the	   complex	   has	   been	   shown	   to	  
bundle	   those	   filaments	   at	   near	   physiological	   Ca2+	   concentrations.	   Interestingly,	   this	  
bundling	  activity	  was	  completely	  inhibited	  following	  phosphorylation	  of	  annexin	  A2	  on	  
tyrosine	  23	  by	  the	  tyrosine	  kinase	  pp60c-­‐src	  (Hubaishy	  et	  al.	  1995).	  
	  
Despite	  these	  key	  features,	  little	  is	  known	  about	  the	  translocations	  process.	  Recently,	  
it	   has	   been	   shown	   that	   annexin	   A2	   is	   recruited	   to	   PI(4,5)P2	   containing	   lipid	   raft	  
microdomains	   in	  a	  Ca2+	  and	  phosphorylation	  dependent	  manner	   (Deora	  et	  al.	  2004;	  
Valapala	   and	  Vishwanatha	  2011).	   It	   is	   believed	   that,	   following	   invagination	  of	   those	  
plasma	  membrane	   rafts	   into	   endocytic	   vesicles,	   annexin	   A2	   is	   delivered	   first	   to	   the	  
early	  endosomes	  and	  later	  incorporated	  into	  MVBs	  (Valapala	  and	  Vishwanatha	  2011).	  
As	  described	  earlier,	  MVBs	  are	  able	  to	  fuse	  with	  the	  plasma	  membrane	  to	  release	  the	  
intraluminal	  exosomes	  into	  the	  extracellular	  space.	  Furthermore,	  a	  second	  mechanism	  
has	  been	  proposed	  that	  requires	  direct	  membrane	  insertion	  of	  the	  protein	  (Danielsen	  
et	  al.	  2003).	  In	  this	  model	  annexin	  A2,	  bound	  to	  the	  cytoplasmic	  surface	  of	  transport	  
vesicles,	   facilitates	   the	   docking	   with	   the	   apical	   cell	   membrane	   of	   short-­‐lived	  
enterocytes.	  It	  has	  been	  hypothesized	  that	  subsequent	  SNARE-­‐mediated	  fusion	  forces	  
annexin	  A2-­‐insertion	  into	  the	  lipidic	  interphase	  of	  both	  vesicle	  and	  plasma	  membrane	  
followed	  by	  rapid	  release	  from	  the	  hydrophobic	  phase	  either	  on	  the	  extracellular	  or	  
intracellular	  side	  in	  a	  spontaneous,	  stochastic	  process.	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1.3 FIBROBLAST	   GROWTH	   FACTORS	   AND	   THEIR	   ROLE	   IN	   SIGNALING	   AND	  
SECRETION	  
The	  discovery	  of	  a	  family	  of	  hormone-­‐like	  proteins	  termed	  growth	  factors	  was	  forced	  
by	  the	  search	  for	  molecular	  modulators	  of	  growth	  control	  in	  multicellular	  organisms.	  
FGF1	   and	   FGF2	   as	   prototypic	   members	   of	   one	   such	   family,	   the	   fibroblast	   growth	  
factors	   (FGFs),	   were	   originally	   purified	   from	   bovine	   pituitary	   and	   brain	  
(Gospodarowicz	  1975;	  Gospodarowicz	  et	  al.	  1978).	  Since	  then,	  a	  variety	  of	  structurally	  
related	   proteins	   have	   been	   identified,	   which	  were	   assigned	   to	   this	   FGF	   family	   that	  
nowadays	  comprises	  22	  members	   in	  mammals.	  And	  still,	   those	  potent	  mitogens	  are	  
object	  of	  several	  studies	  as	  they	  are	  involved	  in	  a	  diversity	  of	  biological	  functions	  such	  
as	  cell	   survival,	  proliferation	  and	  migration.	  According	   to	   their	  mode	  of	  action,	  FGFs	  
that	   are	   differentially	   expressed	   in	   many	   tissues	   can	   be	   characterized	   as	   paracrine	  
FGFs,	   endocrine	   FGFs	   and	   intracrine	   FGFs	   (Itoh	   and	   Ornitz	   2011).	   While	   the	   latter	  
population	   describes	   exclusive	   intracellular	   FGFs	   (FGF11-­‐FGF14)	   that	   have	   been	  
implicated	   as	   regulator	   of	   voltage	   gated	   sodium	   channels,	   paracrine	   FGFs	  
(FGF15/19/23)	  exert	   their	  diverse	   functions	  by	  binding	  and	  activating	   FGF-­‐receptors	  
(FGFRs)	   in	   the	   extracellular	   space	   (Goldfarb	   et	   al.	   2007;	   Itoh	   and	   Ornitz	   2011).	   In	  
comparison,	  the	  effect	  of	  secreted	  endocrine	  FGF	  proteins	  (FGF1-­‐10/16-­‐18/20/22)	   is	  
also	  mediated	  by	  extracellular	  FGFRs.	  Although	  endocrine	  FGFs	  have	  a	  low	  affinity	  to	  
cell	  surface	  exposed	  binding	  partners,	  they	  are	  able	  to	  exhibit	  their	  biological	  function	  
as	  endocrine	  hormones	  over	  long	  distances	  (Zhang	  et	  al.	  2006;	  Itoh	  and	  Ornitz	  2011).	  	  
	  
As	   secreted	  FGFs	  elicit	   their	  pleiotropic	  activities	   through	  binding	  and	  activating	  cell	  
surface	  FGFRs,	  those	  tyrosine	  kinase	  receptors	  are	  also	  in	  focus	  of	  several	  studies	  for	  
almost	  30	  years	  (Neufeld	  and	  Gospodarowicz	  1985).	  In	  humans	  and	  mice	  four	  genes	  
(FGFR1-­‐4)	   have	   been	   identified	   that	   are	   translated	   into	   seven	  major	   FGFR	   proteins	  
with	  different	   ligand	  binding	   specificities	  due	   to	  alternative	   splicing	   (Itoh	  and	  Ornitz	  
2011).	   In	   general,	   those	   FGFR	   are	   comprised	   of	   a	   glycosylated	   extracellular	   ligand-­‐
binding	  domain	  with	   three	   immunoglobulin-­‐like	  domains,	  a	   transmembrane	  domain	  
flanked	  by	  a	   juxtamembrane	   region	  and	  a	   relatively	   conserved	   intracellular	   tyrosine	  
kinase	  domain	  (Polanska	  et	  al.	  2009;	   Itoh	  and	  Ornitz	  2011).	  Besides	  FGFR,	  HSPGs	  on	  
cell	  surfaces	  have	  been	  identified	  as	  FGF	  interaction	  partners	  (Maciag	  et	  al.	  1984).	  In	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line	  with	  the	  FGFR	  affinity,	  the	  HSPG-­‐FGF	  interaction	  is	  more	  efficient	  with	  paracrine	  
FGFs	   than	   with	   endocrine	  molecules.	   However,	   once	   immobilized	   on	   HSPGs,	   these	  
FGFs	  can	  interact	  with	  FGFR	  resulting	  in	  activation	  of	  downstream	  signaling	  pathways	  
(Figure	   3,	   Itoh	   and	   Ornitz	   2011).	   Therefore,	   HSPG-­‐binding	   of	   secreted	   FGFs	   has	   an	  
effect	  on	  the	  formation	  of	  FGFR	  signaling	  complexes,	  the	  overall	  distribution	  of	  FGFs	  
within	   the	   tissue	   as	  well	   as	   on	   its	   lifetime	   and	   stability	   (Gospodarowicz	   and	   Cheng	  
1986;	  Itoh	  and	  Ornitz	  2011).	  
Figure	  3:	  Signaling	  pathways	  mediated	  by	  secreted	  FGFs.	  Following	  secretion,	  FGFs	  bind	  to	  and	  activate	  
their	   receptors	   (FGFR).	   This	   leads	   to	   stimulation	   of	   downstream	   signaling	   cascades,	   finally	   regulating	  
mitogenic	  activity.	  On	  the	  other	  hand,	  FGFs	  are	  able	  to	   induce	  cellular	  responses	  upon	  internalization	  
bound	  to	  their	  receptors.	  Negative	  regulation	  of	  FRS	  (FGFR	  substrate)	  2	  is	  marked	  in	  red.	  HSPG:	  heparan	  
sulfate	   proteoglycan;	  MAPK:	  mitogen-­‐activated	   protein	   kinase;	   PI3K:	   phosphoinositide	   3	   kinase;	   PLC:	  
phospholipase	  C.	  Modified	  from	  Sorensen	  et	  al.	  (2006).	  
	  
Once	  sequestered	  in	  the	  extracellular	  matrix,	  FGF-­‐stimulated	  signaling	  is	  mediated	  by	  
the	   formation	  of	   a	   ternary	   complex	   composed	  of	  extracellular	   FGFs,	   their	   receptors	  
and	   HSPGs.	   This	   complex	   induces	   functional	   receptor	   dimerization	   and	  
transphosphorylation	  of	   its	   intracellular	  tyrosine	  kinase	  domain.	   In	  turn,	   intracellular	  
downstream	   signals	   are	   transmitted	   by	   recruitment	   of	   signaling	   proteins	   to	   the	  
cytoplasmic	   domain	   of	   the	   ligand-­‐activated	   receptor	   (Figure	   3,	   Eswarakumar	   et	   al.	  
2005).	  In	  this	  context,	  phospholipase	  C	  (PLC)-­‐γ	  was	  shown	  to	  be	  both	  recruited	  upon	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(Mohammadi	   et	   al.	   1992;	   Falasca	   et	   al.	   1998).	   In	   addition	   to	   signaling	  proteins	   that	  
directly	  interact	  with	  the	  receptor,	  tyrosine	  phosphorylation	  of	  closely	  linked	  docking	  
proteins,	  such	  as	  FGFR	  substrate	  (FRS)	  2α	  and	  FRS2β,	  has	  been	  shown.	  In	  turn,	  these	  
proteins	  have	  been	  reported	  to	  form	  a	  complex	  with	  signaling	  proteins	  (Kouhara	  et	  al.	  
1997).	   As	   demonstrated	   in	   FRS2α	   -­‐deficient	   fibroblasts	   of	   embryonic	   mice,	   FRS2α	  
activation	   is	   critically	   important	   for	   stimulation	   of	   the	   mitogen-­‐activated	   protein	  
kinase	   (MAPK)	   and	   phosphoinositide	   3	   kinase	   (PI3K)	   pathway	   (Hadari	   et	   al.	   2001).	  
Beside	  the	  stimulation	  of	  these	  downstream	  pathways,	  activated	  FRS2α	  has	  also	  been	  
found	   to	   play	   a	   role	   in	   the	   assembly	   of	   proteins	   involved	   in	   a	   negative	   feedback	  
mechanism.	  This	  leads	  to	  a	  balanced	  FGF-­‐induced	  signaling	  by	  signal	  attenuation	  and	  
regulation	   of	   its	   own	   activity	   (Lax	   et	   al.	   2002;	   Wong	   et	   al.	   2002).	   However,	   the	  
receptor	   mediated	   signaling	   does	   not	   comprise	   the	   entire	   spectrum	   of	   biological	  
functions	   induced	   by	   FGF	  molecules.	   As	   shown	   for	   both	   FGF1	   and	   FGF2,	   the	   FGFR-­‐
bound	   growth	   factors	   were	   also	   found	   to	   be	   internalized	   by	   a	   mechanism	   that	   is	  
linked	   to	   FGFR-­‐mediated	   endocytosis	   (Figure	   3,	   Malecki	   et	   al.	   2004).	   On	  
internalization,	   FGFs	   have	   been	   shown	   to	   translocate	   to	   the	   nuclear	   compartment	  
where	  they	  finally	  mediate	  mitogenic	  responses	  by	  regulating	  the	  activity	  of	  different	  
kinases	   (Bouche	   et	   al.	   1987;	   Baldin	   et	   al.	   1990;	   Soulet	   et	   al.	   2005;	   Sorensen	   et	   al.	  
2006).	  	  
	  
Before	  reaching	  the	  extracellular	  space,	  the	  growth	  factors	  thus	  need	  to	  be	  exported.	  
Due	   to	   their	  cleavable	  signal-­‐peptide,	  most	  secreted	  FGFs	  pass	   through	   the	  classical	  
ER/Golgi-­‐dependent	   pathway	   and	   are	   efficiently	   secreted.	   Remarkably,	   this	   is	   also	  
shown	  for	  FGF9,	  -­‐16	  and	  -­‐20	  containing	  a	  non-­‐cleavable,	  bipartite	  sequence	  instead	  of	  
the	  classical	  secretory	  N-­‐terminal	  signal	  peptide	  (Miyake	  et	  al.	  1998;	  Miyakawa	  et	  al.	  
1999;	  Ohmachi	   et	  al.	   2000).	  By	   contrast,	   a	   second	   subgroup	  of	  extracellular	   FGFs	   is	  
presented	  by	  FGF1	  and	  FGF2,	  which	  lack	  a	  signal	  peptide	  and	  thus	  belong	  to	  the	  group	  
of	  unconventionally	  secreted	  proteins	  (Rabouille	  et	  al.	  2012).	  
	  
1.3.1 Fibroblast	  growth	  factor	  1	  (FGF1)	  
FGF1,	  also	  known	  as	  acidic	  FGF	  (pI	  =	  5.6),	  is	  a	  pro-­‐inflammatory	  growth	  factor,	  which	  
stimulates	  cell	  growth,	  differentiation	  and	  migration	  and	  thus	  plays	  a	  role	   in	  various	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physiological	   and	   pathological	   processes,	   including	   development,	   angiogenesis,	  
wound	   healing,	   tumor	   growth	   and	   invasion.	   Its	   biological	   effects	   are	   mediated	   by	  
export	  of	  FGF1	  upon	  cell	  stress	  as	  heat	  shock,	  hypoxia	  or	  cultivation	  under	  low	  serum	  
conditions	   (Jackson	   et	   al.	   1992;	   Shin	   et	   al.	   1996;	  Mouta	  Carreira	   et	   al.	   2001).	  Once	  
exposed	  to	  such	  cell	  stress	  conditions,	  a	  covalent	  FGF1	  homodimer	  is	  released	  into	  the	  
extracellular	  space.	  This	  homodimer	  is	  formed	  by	  disulfide	  bridge	  formation	  between	  
both	   cysteine	   residues	   in	   position	   30	   of	   two	   monomers	   as	   shown	   by	   secretion-­‐
deficient	  mutant	  proteins	  (Jackson	  et	  al.	  1995;	  Tarantini	  et	  al.	  1995).	  However,	  FGF1	  is	  
not	   merely	   secreted	   as	   a	   homodimer	   but	   as	   part	   of	   a	   non-­‐covalent	   multi-­‐protein	  
complex	   comprised	   of	   sphingosine	   kinase	   1,	   the	   p40	   form	   of	   the	   docking	   protein	  
synaptotagmin	  (p40-­‐Syt1)	  and	  a	  heterodimer	  of	  annexin	  A2	   in	  combination	  with	  the	  
small	   calcium	   binding	   protein	   S100A13	   (LaVallee	   et	   al.	   1998;	  Mouta	   Carreira	   et	   al.	  
1998;	   Soldi	   et	   al.	   2007;	   Prudovsky	   et	   al.	   2008).	   Since	   copper	   induces	   non-­‐covalent	  
interactions	  between	  p40-­‐Syt1,	   FGF1	  and	  S100A13	  as	  well	   as	   formation	  of	   covalent	  
FGF1	  dimers,	  this	  Cu2+	  cation	  is	  a	  prerequisite	  for	  the	  generation	  of	  these	  multi-­‐protein	  
aggregates,	  which	  in	  turn	  are	  required	  for	  FGF1	  secretion	  (Engleka	  and	  Maciag	  1992;	  
Landriscina	  et	  al.	  2001).	  	  
	  
Recently,	  it	  has	  been	  shown	  that	  FGF1	  in	  complex	  with	  p40-­‐Syt1	  and	  S100A13	  binds	  to	  
and	  induces	  destabilization	  of	  artificial	  membranes	  composed	  of	  acidic	  phospholipids	  
such	  as	  phosphatidylserine	  (PS,	  Graziani	  et	  al.	  2006).	  In	  a	  subsequent	  study,	  Prudovsky	  
and	   coworkers	   investigated	   FGF1	   secretion	   on	   a	   cellular	   basis	   (Kirov	   et	   al.	   2012).	  
Indeed,	  they	  found	  that	  export	  of	  FGF1	  in	  NIH	  3T3	  cells	  occurs	  in	  limited	  domains	  of	  
the	   plasma	   membrane,	   which	   contain	   externalized	   PS.	   This	   acidic	   phospholipid	  
normally	  localizes	  to	  the	  inner	  leaflet	  of	  the	  plasma	  membrane	  but	  becomes	  exposed	  
in	  abnormal	  or	  apoptotic	  cells	  (Fadok	  et	  al.	  1992).	  However,	  cell	  surface	  exposure	  of	  
PS	  has	  also	  been	  observed	   in	   the	   context	  of	   signaling	  events	   in	  non-­‐apoptotic	   cells,	  
even	  though	  only	  a	  few	  examples	  have	  been	  reported	  so	  far	  (Elliott	  et	  al.	  2005;	  Hirai	  
et	   al.	   2007;	   Smrz	   et	   al.	   2007).	   Since	   inhibition	   of	   both	   PS	   externalization	   as	  well	   as	  
membrane	   bleb	   formation	   was	   shown	   to	   interfere	   with	   FGF1	   export,	   it	   has	   been	  
hypothesized	  that	  the	  high	  curvature	  of	  those	  membrane	  blebs	  could	  facilitate	  direct	  
translocation	  of	  PS	  across	  the	  membrane	  along	  with	  an	  FGF1	  multi-­‐protein	  complex	  
(Kirov	  et	  al.	  2012).	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1.3.2 Fibroblast	  growth	  factor	  2	  (FGF2)	  
FGF2,	  also	  known	  as	  basic	  FGF	  (pI	  =	  9.6),	  is	  a	  potent	  angiogenic	  factor,	  which	  exists	  in	  
five	   human	   isoforms	   with	   different	   molecular	   weights	   deriving	   from	   alternative	  
initiation	  of	  translation	  (Sorensen	  et	  al.	  2006).	  While	  the	  low	  molecular	  weight	  (LMW)	  
isoform	  (18	  kDa)	  is	  synthesized	  from	  a	  conventional	  Kozak	  AUG	  start	  codon,	  the	  high	  
molecular	   weight	   forms	   (HMW;	   22,	   22.5,	   24	   and	   34	   kDa)	   employ	   upstream	   CUG-­‐
triplets	  as	  alternative	  translational	  start	  (Prats	  et	  al.	  1989).	  Due	  to	  diverse	  amino	  acid	  
numbering	  in	  the	  literature	  the	  first	  methionine	  of	  LMW	  FGF2	  encoded	  by	  the	  AUG-­‐
codon	  is	  denoted	  as	  number	  1	  in	  this	  thesis.	  
	  
The	  18	  kDa	  form	  represents	  the	  core	  sequence	  composed	  of	  155	  amino	  acids	  that	  can	  
be	   found	   in	   every	   isoform.	   The	   N-­‐terminal	   extension	   therefore	   provides	   a	   unique	  
characteristic	  of	  HMW	  FGF2,	  as	  it	  possesses	  several	  glutamate/arginine	  repeats	  acting	  
as	   nuclear	   localization	   sequences	   (NLS;	   Dono	   et	   al.	   1998).	   Consistently,	   the	   HMW	  
isoforms	   are	   predominantly	   located	   in	   the	   nucleus	   where	   they	   regulate	   cellular	  
processes	  in	  an	  intracrine	  fashion	  independent	  of	  FGF	  receptor	  (Sorensen	  et	  al.	  2006).	  
Additionally,	  a	  C-­‐terminal,	  bipartite	  NLS	  composed	  of	  two	  clusters	  of	  basic	  amino	  acids	  
(116RSRK119	   and	   128KR129)	   has	   been	   identified	   allowing	   the	   nuclear	   entry	   even	   of	   the	  
18	  kDa	   FGF2	   (Claus	   et	   al.	   2003;	   Sheng	   et	   al.	   2004).	  Moreover,	   in	   contrast	   to	  HMW	  
FGF2,	   the	   18	   kDa	   FGF2	   is	   present	   in	   the	   cytoplasm	   as	   well	   as	   on	   cell	   surfaces	  
stimulating	  cell	  responses	  in	  an	  endocrine	  manner	  (Sorensen	  et	  al.	  2006).	  	  
	  
1.3.2.1 Biological	  activity	  of	  FGF2	  and	  clinical	  applications	  
	  
FGF2	   is	  widely	  expressed	   in	   tissues	  such	  as	  skeletal	  and	  cardiac	  smooth	  muscle,	   the	  
dermis	  of	  the	  skin,	  the	  kidney	  and	  the	  lung.	  Furthermore	  it	  has	  been	  shown	  that	  FGF2	  
is	   an	   important	   factor	   in	   different	   stages	   of	   the	   developing	   embryo	   to	   adulthood	  
(Gonzalez	   et	   al.	   1996;	   Bikfalvi	   et	   al.	   1997).	   Once	   expressed,	   the	   growth	   factor	   has	  
pleiotropic	   effects	   on	   several	   cell	   types	   including	   myoblasts,	   chondrocytes,	  
osteoblasts,	   fibroblasts,	   neuronal	   cells	   and	   vascular	   endothelial	   cells.	   In	   particular,	  
FGF2	   induces	   many	   biological	   functions	   such	   as	   cell	   proliferation,	   differentiation,	  
survival,	  adhesion	  and	  migration	  as	  well	  as	  processes	  like	  vasculogenesis,	  angiogenesis	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and	  wound	  healing	  (Detillieux	  et	  al.	  2003).	  Due	  to	  these	  multitudes	  of	  functions,	  FGF2	  
is	   a	   highly	   promising	   candidate	   for	   medical	   research	   as	   it	   provides	   a	   potential	  
therapeutic	  target	  to	  address	  several	  diseases.	  In	  this	  context,	  a	  well-­‐studied	  example	  
is	   represented	   by	   the	   pathologic	   progression	   of	   angiogenesis	   (Folkman	   1971).	  
Angiogenesis,	   the	   formation	   of	   blood	   vessel	   form	   pre-­‐existing	   ones,	   is	   a	   health-­‐
promoting	  process	  since	  it	  is	  critically	  important	  for	  embryo	  development	  and	  wound	  
healing	  (Nugent	  and	  Iozzo	  2000).	  However,	  perturbation	  of	  the	  local	  balance	  between	  
pro-­‐	  and	  anti-­‐angiogenic	  factors	   leads	  to	  connections	  of	  avascular,	  quiescent	  tumors	  
to	  the	  vascular	  network	  by	  blood	  vessel	   formation	  (Folkman	  2002).	  This	  “angiogenic	  
switch”	   allows	   blood	   supply	   of	   tumors,	   thereby	   providing	   nutrients	   and	   oxygen	   for	  
extensive	  growth	  and	  metastasis	  (Bergers	  and	  Benjamin	  2003).	  A	  second	  example	  for	  
clinical	   approaches	   is	   the	   effect	   of	   FGF2	   on	   the	   pathophysiology	   of	   ischemic	  
cardiovascular	   diseases.	   Intriguingly,	   it	   has	   been	   shown	   that	   HMW	   FGF2	   and	   LMW	  
FGF2	   have	   opposing	   roles	   in	   ischemia	   reperfusion	   injury	   and	   cardioprotection	  
(Kardami	   et	   al.	   2007;	   Liao	   et	   al.	   2009).	  While	   HMW	   FGF2	   have	   been	   suggested	   to	  
induce	  deleterious	  effects	  as	  hypertrophy	  and	  fibrosis,	  the	  18	  kDa	  isoform	  (hereinafter	  
referred	   to	   as	   FGF2)	   was	   found	   to	   have	   a	   beneficial	   effect	   on	   cardioprotection	   by	  
modulating	  the	  activation	  of	  intracellular	  signaling	  cascades	  (House	  et	  al.	  2007;	  Jiang	  
et	  al.	  2007;	  Liao	  et	  al.	  2007).	  	  
	  
1.3.2.2 Structural	  aspects	  of	  FGF2	  and	  the	  FGF2	  signaling	  complex	  
	  
The	   three-­‐dimensional	   structure	   of	   FGF2	   has	   been	   determined	   by	   X-­‐ray	  
crystallography	   (Eriksson	   et	   al.	   1991;	   Zhu	   et	   al.	   1991;	   Kastrup	   et	   al.	   1997).	  
Interestingly,	   the	   obtained	   overall	   structure	   of	   FGF2	   showed	   strong	   homology	  with	  
the	  fold	  of	  unconventionally	  secreted	  IL-­‐1β	  as	  both	  proteins	  are	  composed	  of	  twelve	  
β-­‐strands	   (Zhang	   et	   al.	   1991;	   Murzin	   et	   al.	   1992).	   Furthermore,	   based	   on	   six	  
antiparallel	   β-­‐strands	   organized	   as	   a	   β-­‐barrel	   both	   adopt	   a	   trigonal	   pyramidal	  
structure	  (Figure	  4A).	  Of	  note,	  in	  the	  crystal	  structure	  of	  FGF2	  determined	  by	  Kastrup	  
et	   al.	   (1997),	   a	   phosphate	   ion	   has	   been	   detected	   within	   a	   “binding	   pocket”	  
(asparagine	  36,	  arginine	  129	  and	  lysine	  134,	  Figure	  4B)	  as	  well	  as	  a	  β-­‐mercaptoethanol	  
molecule	  forming	  a	  disulfide	  bridge	  to	  Cys77	  (Figure	  4A).	  Even	  though	  FGF2	  is	  highly	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soluble	   and	   tends	   to	   fast	   crystal	   growth,	   the	   first	   27	   amino	   acids	   of	   FGF2	  have	  not	  
been	  crystallized,	  as	  they	  are	  disordered	  and	  highly	  flexible	  (Kastrup	  et	  al.	  1997).	  
By	  contrast,	  Moy	  et	  al.	  (1996)	  identified	  only	  eleven	  β-­‐strands	  but	  an	  additional	  helix-­‐
like	  structure	  composed	  of	  residues	  131-­‐136,	  which	  has	  been	  suggested	  to	  be	  part	  of	  
the	  heparin-­‐binding	  site	  using	  NMR	  spectroscopy.	  However,	  crystallization	  studies	  of	  
FGF2	   in	   presence	   of	   heparin	   revealed	   that	   Lys134	   (among	   seven	   further	   residues:	  
asparagine	   36,	   arginine	   129,	   threonine	   130,	   lysine	   138,	   glutamine	   143,	   lysine144,	  
alanine145,	   Figure	   4C)	   is	   located	   at	   the	   heparin	   interface	   (Faham	   et	   al.	   1996;	  
Schlessinger	  et	  al.	  2000).	  	  
Figure	   4:	   X-­‐ray	   crystal	   structure	   of	   FGF2.	   (A)	   Three	   dimensional	   structure	   of	   FGF2	   including	   the	  
observed	  phosphate	  ion	  (PO4)	  and	  β-­‐mercaptoethanol	  molecule	  (β-­‐ME).	  Yellow:	  β-­‐strand;	  green:	  loops;	  
cyan:	  3/10	  helix.	   (B)	  Highlighted	   residues	  asparagine	  36,	   lysine	  128	  and	  arginine	  129	   form	  a	  “binding	  
pocket”	  for	  the	  phosphate	  ion.	  (C)	  FGF2	  is	  shown	  in	  complex	  with	  heparin.	  Those	  residues	  forming	  the	  
binding	  interface	  are	  indicated.	  A	  and	  B:	  published	  by	  Kastrup	  et	  al.	  (1997;	  PDB:	  1BFF);	  C:	  published	  by	  
Schlessinger	  et	  al.	  (2000;	  PDB:	  1FQ9).	  
	  
In	  addition	  to	  HSPG-­‐binding,	  FGF2-­‐induced	  signaling	  depends	  on	  interaction	  with	  and	  
activation	  of	  FGF	  receptors	  (Eswarakumar	  et	  al.	  2005).	  The	  earliest	  model	  supported	  
the	   idea	   that	   heparin	   facilitates	   FGF2	   dimerization	   leading	   in	   turn	   to	   FGFR-­‐
dimerization	   and	   in	   this	  way	   to	   its	   activation	   (Ornitz	   et	   al.	   1992;	   Herr	   et	   al.	   1997).	  
However,	   based	   on	   the	   interactions	   observed	   in	   the	   structure	   of	   a	   ternary	   FGF2-­‐
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binding	  promotes	   the	   interaction	  of	  FGF2	  with	  FGFR1	  through	  a	  primary	   interaction	  
site	  by	  forming	  a	  monomeric	  FGF2-­‐FGFR1	  complex	  (Schlessinger	  et	  al.	  2000).	  Further	  
interactions	   observed	   in	   this	   crystal	   structure	   suggested	   that	   the	   ligand	   of	   the	   first	  
monomeric	   FGF2-­‐FGFR1	   complex	  promotes	  dimerization	  with	  a	   second	  FGF2-­‐FGFR1	  
complex	  through	  secondary	   interactions	  of	  FGF2	  with	  the	  receptor	  of	  the	  secondary	  
FGF-­‐FGFR1.	  Moreover,	   the	   dimer	   interface	   is	   formed	   by	   direct	   interaction	   between	  
the	   two	  adjacent	   FGFR	  molecules	   resulting	   in	   an	   active,	   dimeric	   FGF2-­‐FGFR-­‐heparin	  
complex	  (2:2:2;	  Schlessinger	  et	  al.	  2000,	  Mohammidi	  et	  al.	  2005).	  	  
	  
1.3.2.3 Unconventional	  secretion	  of	  FGF2	  
Although	  FGF2	  was	  found	  outside	  cells	  despite	  lacking	  a	  signal	  peptide,	  in	  early	  times	  
it	  has	  been	  assumed	  that	  the	  growth	  factor	  is	  released	  as	  a	  consequence	  of	  cell	  death	  
or	  disruption	  of	  membrane	  integrity	  (Abraham	  et	  al.	  1986;	  McNeil	  et	  al.	  1989).	  Since	  
then,	   various	   lines	  of	   evidence	  pointed	   in	   the	  direction	  of	   a	   cell	   death-­‐independent	  
release	  mechanism	  but	   rather	   supported	   a	   translocation	   process	   across	   the	   plasma	  
membrane	   of	   viable	   cells	   (Kandel	   et	   al.	   1991;	   Florkiewicz	   et	   al.	   1995;	   Trudel	   et	   al.	  
2000).	  In	  contrast	  to	  other	  unconventionally	  secreted	  proteins,	  which	  are	  released	  in	  
response	   to	   external	   stimuli,	   FGF2	   export	   occurs	   in	   a	   constitutive	   manner.	   In	   fact,	  
FGF2	   secretion	   is	   inhibited	   under	   stress	   conditions	   such	   as	   low	   temperature	   and	  
serum	  starvation	  (Jackson	  et	  al.	  1992;	  Mignatti	  et	  al.	  1992;	  Shin	  et	  al.	  1996;	  Giuliani	  et	  
al.	  2011;	  Nickel	  2011).	  
	  
Regarding	  the	  transport	  of	  FGF2	  within	  the	  cell,	   translokin,	  a	  ubiquitously	  expressed	  
protein,	  has	  been	  identified	  as	  a	  binding	  partner	  essential	  for	  cytoplasmic	  trafficking	  
of	  FGF2	  (Bossard	  et	  al.	  2003;	  Meunier	  et	  al.	  2009).	  Using	  yeast	  genetics,	   it	  has	  been	  
reported	   that	   translokin	   along	   with	   three	   further	   binding	   partners	   mediates	   both	  
retrograde	  and	  anterograde	  transport	  of	  FGF2	   (Meunier	  et	  al.	  2009).	  Therefore,	   the	  
formation	   of	   two	   different	   and	   mutually	   exclusive	   complexes	   has	   been	   suggested	  
including	  (i)	  a	  retrograde	  transport	  complex	  composed	  of	  sorting	  nexin	  6	  (SNX6)	  and	  
Ran-­‐binding	   protein	   M	   (RanBPM)	   as	   well	   as	   (ii)	   anterograde	   transport	   complex	  
associated	   with	   the	   microtubule-­‐based	   motor	   protein	   kinesin	   KIF	   (kinesin	  
superfamily)-­‐3A.	   Intriguingly,	   endogenous	   FGF2	   has	   been	   shown	   to	   interact	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exclusively	  with	  components	  of	  the	  export	  machinery	  in	  mammalian	  cells.	  In	  contrast,	  
exogenously	  added	  FGF2	  has	  only	  been	  found	  associated	  with	  translokin-­‐complexes,	  
assumed	   to	   be	   involved	   in	   retrograde	   transport	   processes	   (Meunier	   et	   al.	   2009).	  
However,	  in	  that	  work	  anterograde	  as	  well	  as	  retrograde	  movement	  of	  FGF2	  has	  been	  
shown	  to	  occur	  along	  microtubules,	  in	  contrast	  to	  Vitorelli	  and	  coworkers.	  In	  the	  latter	  
study	   it	  has	  been	  reported	  that	  actin	  filaments	  but	  not	  microtubules	  are	   involved	   in	  
trafficking	   of	   the	   microscopically	   observed	   so	   called	   “FGF2	   granules”	   toward	   the	  
plasma	   membrane	   in	   SK-­‐Hep1	   cells	   whereas	   microtubule-­‐based	   transport	   was	  
observed	  in	  retrograde	  direction	  (Taverna	  et	  al.	  2008).	  	  
	  
Once	   in	   the	   cell	   periphery,	   several	   FGF2	   export	  mechanisms	   have	   been	   postulated.	  
Regarding	  this,	  Taverna	  et	  al.	  (2008)	  believed	  that	  FGF2	  is	  released	  from	  cells	  through	  
membrane	   blebbing	   and	   subsequent	  membrane	   shedding.	   However,	   noteworthy	   in	  
the	  context	  of	  this	  work	  is	  the	  induction	  of	  extensive	  membrane	  blebbing	  by	  a	  serum	  
shock	   upon	   prolonged	   serum	   starvation.	   By	   contrast,	   a	   second	   vesicular	   export	  
mechanism	   has	   been	   suggested	   that	   involves	   exosomes	   derived	   from	   MVB´s	  
(Ceccarelli	   et	  al.	   2007).	   Even	   though	   these	  vesicular	  models	  have	  been	  described,	   a	  
recent	   study	   addressing	   vesicular	   export	   mechanisms	   revealed	   that	   FGF2	   is	   not	  
present	   in	   supernatants	   of	   serum-­‐exposed	   CHO	   cells,	   neither	   in	   vesicles	   nor	   in	   the	  
soluble	  form.	  Instead,	  the	  protein	  has	  been	  found	  in	  the	  extracellular	  space	  bound	  on	  
cell	   surfaces	   (Seelenmeyer	   et	  al.	   2008).	   The	  model	  of	   a	  direct	   translocation	  process	  
across	  the	  plasma	  membrane	  is	  further	  supported	  by	  the	  finding	  that	  an	  inhibitor	  of	  
plasma	  membrane	  blebbing	  did	  not	  affect	  the	  amount	  of	  cell	  surface-­‐bound	  FGF2	  as	  
monitored	   by	   a	   quantitative	   FACS	   (fluorescence	   activated	   cell	   sorting)-­‐based	   assay	  
(Seelenmeyer	  et	  al.	  2008).	  
	  
In	  an	  early	  attempt	  to	  better	  understand	  the	  export	  mechanism,	  the	  cardiac	  glycoside	  
ouabain	   has	   been	   shown	   to	   partially	   inhibit	   secretion	   of	   FGF2	   from	   COS-­‐1	   cells	  
(Florkiewicz	   et	   al.	   1998).	   Since	   ouabain	   affects	   the	   membrane	   potential	   through	  
inhibiting	   the	   Na+/K+	   ATPase,	   the	   role	   of	   this	   enzyme	   was	   subsequently	   addressed	  
with	  respect	  to	  FGF2	  export	  from	  COS-­‐1	  cells.	  The	  data	  of	  this	  study	  including	  rescue	  
and	   co-­‐immunoprecipitation	   experiments	   led	   to	   the	   conclusion	   that	   the	   Na+/K+	  
ATPase	   indeed	   is	   involved	   in	   FGF2	   secretion.	   Interestingly,	   lowering	   of	   the	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extracellular	   K+	   concentration	   had	   no	   effect	   on	   secretion	   indicating	   that	   an	  
electrochemical	   gradient	  maintained	  by	   the	  Na+/K+	  ATPase	   is	   not	   required	   for	   FGF2	  
export	   (Florkiewicz	   et	   al.	   1998).	   In	   accordance,	   Schafer	   et	   al.	   (2004)	   confirmed	   a	  
membrane	  potential-­‐independent	  process	  by	  demonstrating	  FGF2	  translocation	  using	  
a	  plasma	  membrane-­‐derived	   inside-­‐out	   vesicle	   system	   in	   the	  absence	  of	  ATP.	  More	  
strikingly,	  this	  experiment	  provided	  a	  first	  hint	  that	  FGF2	  traverses	  the	  membrane	  in	  
an	  ATP	   independent	  manner	  rather	   than	  employing	  an	  active	   transport	  mechanism.	  
However,	  a	  Na+/K+	  ATPase	  independent	  FGF2	  secretion	  process	  has	  been	  proposed,	  as	  
ouabain	  had	  no	  effect	  on	  membrane	  translocation	   in	  the	   inside-­‐out	  vesicle	  based	   in	  
vitro	   assay	   (Schafer	   et	  al.	   2004).	  Taken	   together,	  while	  both	  ATP	  hydrolysis	  and	   the	  
membrane	  potential	  are	  not	  required,	  it	  still	  remains	  elusive	  whether	  the	  interaction	  
between	   FGF2	   and	   the	   Na+/K+	   ATPase	   plays	   a	   role	   in	   the	   translocation	   process	   of	  
FGF2.	  
	  
To	  date	  several	  key	   features	   regarding	  direct	  membrane	  translocation	  of	  FGF2	  have	  
been	   addressed	   in	   subsequent	   studies	   (reviewed	   in	   Nickel	   2011).	   Since	   export	   via	  
protein	   conducting	   channels	   as	   found	   in	   the	   ER	   or	   mitochondria	   usually	   requires	  
protein	  unfolding,	  the	  folding	  state	  of	  FGF2	  concerns	  one	  major	  issue	  (Rapoport	  2007;	  
Nickel	  2011).	  Therefore,	  dihydrofolate	  reductase	  (DHFR),	  which	  is	  highly	  stable	  in	  the	  
presence	   of	   aminopterin	   or	   methotrexate,	   was	   used	   to	   discriminate	   between	   a	  
translocation	  process	  across	  membranes	  that	  depends	  either	  on	  unfolding	  or	  a	  native	  
protein	  conformation	  (Eilers	  and	  Schatz	  1986;	  Wienhues	  et	  al.	  1991).	  Regarding	  FGF2,	  
the	  fusion	  to	  the	  DHFR	  moiety	  even	  in	  the	  aminopterin-­‐stabilized	  state	  had	  no	  effect	  
on	   FGF2	   export	   (Backhaus	   et	   al.	   2004).	   In	   a	   subsequent	   study,	   unconventionally	  
secreted	  FGF2	  as	  well	  as	  cytoplasmic	  GFP	   (green	   fluorescent	  protein)	  were	   fused	   to	  
proteins	  that	  strongly	  interact	  with	  each	  other	  in	  their	  native	  conformation.	  Using	  this	  
piggyback	  system,	  FGF2-­‐fusion	  proteins	  were	  able	  to	  pull	  GFP-­‐fusion	  proteins	  out	  of	  
the	   cell.	   Therefore,	   it	   has	   been	   shown	   that	   FGF2	   physically	   traverses	   the	   plasma	  
membrane	  in	  a	  folded	  conformation	  (Torrado	  et	  al.	  2009).	  	  
	  
A	   further	  major	   issue	   concerns	   the	   initial	   step	   at	   the	   plasma	  membrane	   leading	   to	  
unconventional	  secretion	  of	  FGF2.	  The	  phosphate	  ion	  observed	  in	  the	  crystal	  structure	  
provided	  a	  fist	  hint	  that	  FGF2	  might	  be	  able	  to	  interact	  with	  phosphoinositides,	  which	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are	   a	  major	   component	   of	   the	   cellular	  membrane	   system	   (Figure	   4B,	   Kastrup	  et	   al.	  
1997;	  Temmerman	  et	  al.	  2008).	  In	  order	  to	  challenge	  this	  hypothesis,	  the	  interaction	  
with	   different	   phospholipids	   including	   PI(4)P,	   PI(4,5)P2	   and	   PI(3,4,5)P3	   has	   been	  
analyzed.	   Intriguingly,	   FGF2	   was	   found	   to	   interact	   most	   efficiently	   with	   liposomes	  
containing	   PI(4,5)P2	   in	   a	   lipid	   background	   resembling	   plasma	   membranes	  
(Temmerman	  et	  al.	  2008).	  FGF2	  variant	  forms	  mutated	  in	  the	  PI(4,5)P2	  binding	  pocket,	  
which	  has	  been	  observed	  in	  the	  crystal	  structure,	  were	  less	  efficiently	  secreted	  from	  
CHO	   cells.	   Thus,	   FGF2	   recruitment	   to	   the	   inner	   leaflet	   of	   the	   plasma	   membrane	  
depends	   on	   transient	   binding	   to	   PI(4,5)P2	   (Temmerman	  et	   al.	  2008,	   Figure	   5)	   .	   This	  
initial	   step	   in	   secretion	   requires	   a	   proper	   FGF2	   folding	   as	   shown	   by	   the	   impaired	  
binding	   to	   PI(4,5)P2-­‐containing	   liposomes	   in	   the	   presence	   of	   urea	   (Torrado	   et	   al.	  
2009).	  In	  line,	  the	  interaction	  with	  heparin	  has	  also	  been	  found	  to	  be	  impaired,	  even	  
though	   residual	   binding	   of	   FGF2	   to	   heparin	   was	   still	   detected.	   On	   the	   basis	   of	   the	  
presented	   data	   an	   intrinsic	   quality	  mechanism	   has	   been	   proposed,	   suggesting	   that	  
PI(4,5)P2-­‐bound	  FGF2	  directly	  passes	  the	  plasma	  membrane	  in	  its	  folded	  state	  (Nickel	  
and	  Seedorf	  2008;	  Torrado	  et	  al.	  2009).	  Furthermore,	  PI(4,5)P2	  bound	  FGF2	  has	  been	  
speculated	  to	  be	  a	  prerequisite	  for	  potential	  formation	  of	  oligomeric	  complexes	  at	  the	  
plasma	  membrane.	  Likely,	  these	  oligomers	  are	  membrane	  active	  FGF2-­‐structures,	  able	  
to	  insert	  and	  traverse	  through	  a	  hydrophilic	  pore	  that	  is	  formed	  within	  the	  lipid	  bilayer	  
of	  the	  plasma	  membrane	  (Nickel	  2010;	  Nickel	  2011).	  
	  
On	  the	  extracellular	  side,	  FGF2	  mediates	  intracellular	  signaling	  as	  part	  of	  the	  ternary	  
complex	   along	  with	   both	   HSPGs	   and	   FGFR	   (section	   1.3.2.2).	   Since	   FGF2	   is	   secreted	  
from	   CHO	   cells	   lacking	   endogenous	   FGFRs,	   it	   has	   been	   speculated	   whether	   HSPGs	  
might	  work	   as	   an	   extracellular	   trap	   (Engling	   et	   al.	   2002;	   Zehe	   et	   al.	   2006).	   Indeed,	  
FGF2	   mutant	   proteins	   defective	   in	   HSPG-­‐binding	   were	   not	   released	   into	   the	  
extracellular	   space.	   This	   was	   in	   line	   with	   the	   observation	   that	   HSPG-­‐deficient	   cells	  
expressing	  FGF2	  were	  found	  to	  have	  a	  secretion	  defect.	  However,	  in	  close	  proximity	  to	  
cocultivated	  HSPG-­‐expressing	  acceptor	   cells	   the	  ability	   to	  export	   FGF2	  was	   restored	  
(Zehe	   et	   al.	   2006).	   The	   combined	   data	   led	   to	   the	   conclusion	   that	   the	   affinity	   to	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Figure	   5:	   Potential	  mechanisms	  of	   FGF2	   secretion.	  FGF2	   translocation	   across	   the	  plasma	  membrane	  
depends	   on	   intracellular	   PI(4,5)P2	   (PIP2)	   and	   HSPGs	   in	   the	   extracellular	   space.	   Tec	   kinase	   has	   been	  
identified	  as	  a	  further	  key	  player	  involved	  in	  FGF2	  secretion.	  (A)	  Tec-­‐mediated	  phosphorylation	  of	  FGF2	  
occurs	  at	   the	  plasma	  membrane.	   In	   this	  model,	   Tec	   is	   recruited	   to	   the	  plasma	  membrane	  via	   its	  PH-­‐
domain	  where	  the	  kinase	  phosphorylates	  FGF2.	   (B)	   In	  a	  second	  scenario,	  Tec	  phosphorylates	  FGF2	   in	  
the	  cytoplasm	  as	  kind	  of	  a	  recruiting	  signal.	  As	  to	  whether	  FGF2	  is	  secreted	  in	  its	  phosphorylated	  state	  
or	  whether	  dephosphorylation	   is	   a	  prerequisite	   is	   currently	  unclear.	  PIP3:	   phosphatidylinositol-­‐3,4,5-­‐
trisphosphate.	  
	  
In	   order	   to	   identify	   components	  within	   the	   translocation	  machinery	   besides	   HSPGs	  
and	   PI(4,5)P2,	   a	   genome-­‐wide	   screening	   approach	   based	   on	   RNA	   interference	   was	  
conducted	   (Ebert	   et	   al.	   2010).	   Subsequently,	   Tec	   (tyrosine	   kinase	   expressed	   in	  
hepatocellular	  carcinoma)	  kinase	  has	  been	  discovered	  to	  play	  a	  role	  in	  FGF2	  secretion	  
(Figure	   5).	   Furthermore,	   FGF2	   was	   found	   to	   be	   phosphorylated	   both	   in	   the	   whole	  
lysate	  of	  HeLa	  cells	  and	  in	  a	  biochemical	  in	  vitro	  assay	  employing	  recombinant	  Tec	  as	  
enzymatically	  active	  kinase.	  Analysis	  of	  this	  FGF2	  population	  revealed	  phosphorylation	  
of	   the	   tyrosine	   residue	   in	   position	   82.	   In	   line,	  mutant	   analyses	   exhibited	   a	   strongly	  
impaired	  interaction	  with	  Tec	  in	  vitro	  as	  well	  as	  a	  significant	  secretion-­‐defect	  in	  HeLa	  
cells.	   Reduced	   secretion	   efficiency	  was	   also	   observed	   in	   cells	   treated	  with	   LFM-­‐A13	  
(leflunomide	   metabolite	   analog),	   a	   pharmacological	   inhibitor	   of	   Tec	   kinase.	   Taken	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FGF2	   is	   linked	   to	   its	   secretion	   (Ebert	   et	   al.	   2010).	   However,	   in	   which	   way	  
phosphorylation	   exactly	   is	   required	   for	   FGF2	   export	   is	   presently	   unclear.	   One	  
possibility	   could	   be	   that	   phosphorylation	   of	   FGF2	   triggers	   conformational	   changes,	  
which	   in	  turn	  allow	  for	  membrane	   insertion	  resulting	   in	  posttranslationally	  modified	  
FGF2	   on	   cell	   surfaces	   (Figure	   5).	   With	   regard	   to	   translokin,	   FGF2	   could	   also	   be	  
transiently	   phosphorylated	   in	   the	   cytoplasm	   as	   kind	   of	   a	   signal	   required	   for	  
intracellular	   trafficking	  processes	  along	  cytoskeletal	  elements	   into	   the	  cell	  periphery	  
(Nickel	  2010).	  	  	  
	  
1.4 TEC	  KINASES	  AND	  THEIR	  MECHANISM	  OF	  ACTIVATION	  
In	  the	  early	  1990s,	  mutations	  in	  the	  gene	  encoding	  for	  Btk	  (Brutons´s	  tyrosine	  kinase),	  
a	   new	   tyrosine	   kinase,	   were	   linked	   to	   the	   human	   diseases	   X-­‐linked	  
agammaglobulinemia	   (Tsukada	   et	   al.	   1993;	   Vetrie	   et	   al.	   1993).	   This	   kinase	   has	  
subsequently	   been	   identified	   as	   member	   of	   the	   family	   of	   non-­‐receptor	   protein	  
tyrosine	  kinases	  of	  which	  Tec	  was	  the	  first	  protein	  described	  (Takesono	  et	  al.	  2002).	  
The	  family	  of	  Tec	  kinases	  now	  comprises	  five	  members	  in	  mammals,	  namely	  Tec	  and	  
Btk	  as	  well	  as	  Itk	  (interleukin-­‐2	  inducible	  T	  cell	  kinase,	  also	  known	  as	  EMT	  or	  TSK),	  Rlk	  
(resting	  lymphocyte	  kinase,	  also	  known	  as	  Txk)	  and	  Bmx	  (bone	  marrow	  kinase	  gene	  on	  
chromosome	  X,	  also	  known	  as	  ETK).	  Although	  Tec	  kinases	  have	  been	  found	  in	  cells	  of	  
fluid	   enclosing	   structures	   such	   as	   endothelial	   cells	   in	   developing	   mice,	   they	   are	  
primarily	   expressed	   in	   cells	   of	   the	   hematopoietic	   lineage	   in	   several	   mammalian	  
species	  (Kluppel	  et	  al.	  1997;	  Gomez-­‐Rodriguez	  et	  al.	  2007).	  	  
	  
Tec-­‐kinases	  share	  a	  similar	  modular	  structure	  with	  Src	   (sarcoma)	   family	  members	  of	  
non-­‐receptor	   tyrosine	   kinases	   that	   include	   Src-­‐homology	   SH3	   and	   SH2	   domains	  
followed	  by	  a	  tyrosine	  kinase	  catalytic	  domain	  (Figure	  6A).	  However,	  Tec	  kinases	  are	  
characterized	   by	   the	   organization	   of	   their	  N-­‐terminus	   upstream	  of	   the	   SH3	   domain	  
which	  possesses	  a	  pleckstrin	  homology	   (PH)	  domain	  and	  an	  adjacent	  Tec	  homology	  
(TH)	  domain	  composed	  of	  a	  Btk	  homology	  (BH)	  region	  and	  one	  or	  two	  proline-­‐rich	  (PR)	  
regions	  (Gomez-­‐Rodriguez	  et	  al.	  2007).	  The	  PH	  domain	  is	  required	  for	  recruitment	  of	  
Tec	  kinases	  to	  the	  plasma	  membrane	  in	  a	  PI(3,4,5)P3-­‐	  dependent	  manner,	  the	  level	  of	  
which	   is	   regulated	   by	   PI3K	   as	   well	   as	   both	   phospholipid	   phosphatases	   SHIP	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(SH2-­‐containing	  inositol	  5´-­‐phosphatase)	  and	  PTEN	  (phosphatase	  and	  tensin	  homolog;	  
August	   et	   al.	   1997;	   Shan	   et	   al.	   2000;	   Tomlinson	   et	   al.	   2004a).	   The	   second	   unique	  
region,	  the	  TH	  domain,	  has	  been	  shown	  to	  be	  important	  for	  intra	  and	  intermolecular	  
protein-­‐protein	   interactions	  and	  protein-­‐lipid	   interactions.	  While	  a	  bona	  fide	  PH	  and	  
TH	  domain	  are	  found	  in	  Btk,	  Tec	  and	  Itk,	  the	  Bmx	  kinase	  lacks	  the	  PR-­‐region.	  On	  the	  
contrary,	   both	   the	   BH	   region	   and	   the	   PH	   domain,	   upstream	   of	   the	   TH	   region,	   are	  
absent	   in	   Rlk	   (Figure	   6A,	   Smith	   et	   al.	   2001).	   Therefore,	   Rlk	   is	   not	   recruited	   via	   its	  
PH	  domain	  but	  rather	  by	  a	  palmitoylation-­‐dependent	  association	  with	  the	  membrane	  
using	  a	  myristoyl	  anchor	  (Debnath	  et	  al.	  1999).	  	  
	  
Figure	  6:	  Structural	  organization	  of	  Tec	  kinases	  and	  their	  mechanism	  of	  activation.	  (A)	   Illustration	  of	  
the	   protein	   domains	   found	   in	   the	   five	   mammalian	   Tec	   kinases.	   The	   C-­‐terminus	   is	   composed	   of	   the	  
kinase	  domain,	  SH3	  (Src	  homology)	  and	  SH2	  domains	  that	  are	  also	  typical	  for	  Src	  kinases.	  However,	  the	  
N-­‐terminus	  possesses	  unique	  domains	  including	  differently	  organized	  Tec	  homology	  domains	  (TH)	  and	  a	  
pleckstrin	   homology	   domain	   (PH).	   Regarding	   the	   PH	   domain	   Rlk	   is	   the	   only	   exception	  which	   instead	  
possesses	   a	   cysteine	   string	   motif,	   allowing	   for	   myristoylation.	   (B)	   Exemplarily,	   the	   activation	   of	   BTK	  
kinase	  is	  depicted.	  Based	  on	  the	  interaction	  between	  the	  proline-­‐rich	  region	  (PR)	  in	  the	  TH	  and	  SH3	  the	  
kinase	   is	  retained	  in	  an	   inactive	  state.	  Following	  phosphorylation	   in	  the	  kinase	  domain	  by	  Src	  kinases,	  
autophosphorylation	  of	   its	   own	  SH3	  domain	   results	   in	   an	  open,	   fully	   active	   state.	  BH:	  BTK	  homology	  
domain.	  Modified	  from	  Gomez-­‐Rodrigues	  et	  al.	  (2009)	  and	  Mano	  (1999).	  
	  
Tec	  kinases	  receive	  input	  signals	  from	  cell	  surface	  exposed	  molecules	  such	  as	  cytokine	  
receptors,	   heterotrimeric	   G-­‐protein	   coupled	   receptors,	   integrins	   and	   lymphocyte	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(TCR),	  Src	  kinases	  (in	  particular	  Lck	   in	  T	  cells)	  are	  activated	  which	  in	  turn	  recruit	  and	  
activate	   ZAP70	   (ζ-­‐chain-­‐associated	   protein	   kinase	   of	   70	   kDa)	   and	   PI3K.	   ZAP-­‐70	   then	  
phosphorylates	   LAT	   (linker	   for	   activation	   of	   T	   cells)	   and	   SLP-­‐76	   (SH2-­‐domain-­‐
containing	   leukocyte	   protein	   of	   76	   kDa)	   adaptor	   proteins	   that	   together	   serve	   as	   a	  
recruiting	  platform	  for	  a	  variety	  of	   signaling	  molecules	  such	  as	  PLC-­‐γ,	  VAV1	  and	  Tec	  
kinases	   (Bunnell	   et	   al.	   2002;	   Tomlinson	   et	   al.	   2004b;	   Kane	   and	   Watkins	   2005;	  
Schwartzberg	  et	  al.	  2005).	  Before	  binding	  to	  this	  so-­‐called	  TCR-­‐signaling	  complex	  Tec	  
kinases	  become	  first	  activated,	  which	  occurs	  in	  three	  interrelated	  steps	  (Mano	  1999).	  
The	  initial	  step	  encompasses	  the	  recruitment	  of	  Tec	  to	  the	  plasma	  membrane	  through	  
the	   interaction	   of	   its	   PH-­‐domain	   and	   PI(3,4,5)P3.	   Second,	   Tec	   kinases	   are	  
phosphorylated	  by	   Src	   family	   kinases	   at	   a	   conserved	   tyrosine	   in	   the	   activation	   loop	  
followed	  by,	  third,	  autophosphorylation	  of	  a	  tyrosine	  residue	  within	  the	  SH3	  domain,	  
which	  in	  turn	  leads	  to	  enhanced	  Tec	  kinase	  activity	  (Figure	  6B,	  Takesono	  et	  al.	  2002;	  
Schwartzberg	  et	   al.	   2005).	   Finally,	   as	   part	   of	   the	   TCR-­‐signaling	   complex	   Tec	   kinases	  
have	  been	  shown	  to	  induce	  downstream	  signaling	  cascades	  involved	  in	  the	  regulation	  
of	   phospholipase	   C-­‐gamma,	   Ca2+mobilization,	   the	   activation	   of	   the	   MAP	   kinase	  
pathway	  and	  regulation	  of	  the	  actin	  cytoskeleton	  (Schwartzberg	  et	  al.	  2005).	  
	  
1.5 THE	  CYTOSKELETON	  AND	  ITS	  ROLE	  AS	  PHYSICAL	  TRANSPORT	  SYSTEM	  
The	  eukaryotic	  cytoskeleton	  forms	  a	  rigid	  network	  of	  interconnected	  components	  that	  
is	   important	   for	   maintaining	   the	   overall	   morphology	   of	   cells	   along	   with	   many	  
fundamental	   functions	   such	   as	   intracellular	   trafficking,	   proliferation	   and	   migration	  
(Fuchs	   and	   Karakesisoglou	   2001).	   Thus,	   the	   cytoskeleton	   is	   not	   simply	   a	   static	  
structure	   providing	   the	   cell´s	   scaffold	   but	   rather	   a	   highly	   dynamic	   system.	   This	  
dynamic	   behavior	   is	   driven	   by	   assembly	   and	   disassembly	   of	   each	   cytoskeletal	  
component	  comprising	  microtubules	   (about	  25	  nm	  external	  diameter),	   intermediate	  
filaments	   (about	  10	  nm	  external	  diameter)	  and	  actin	   filaments	   (F-­‐actin,	  about	  8	  nm	  
external	  diameter).	  In	  order	  for	  this	  to	  be	  achieved,	  each	  component	  is	  composed	  of	  
smaller	   subunits,	  which	   include	  α-­‐	  and	  β-­‐	   tubulin	   in	  microtubules,	  G-­‐actin	   in	  F-­‐actin	  
and,	   with	   respect	   to	   many	   types	   of	   intermediate	   filaments	   such	   as	   keratins	   and	  
lamins,	  different	  pools	  of	  soluble	  subunits	  (Straub	  and	  Feuer	  1950;	  Bryan	  and	  Wilson	  
1971;	  Frixione	  2000).	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In	   contrast	   to	   the	   intermediate	   filaments,	   microtubules	   and	   F-­‐actin	   both	   require	  
nucleotide	   hydrolysis	   (GTP	   and	   ATP,	   respectively)	   for	   rapid	   remodeling	   of	   these	  
cytoskeleton	  elements	  and	  are	  polar	  structures	  with	  two	  topologically	  different	  ends	  
(Moore	   et	   al.	   1970;	   Bergen	   and	   Borisy	   1980).	   The	   plus	   end	   of	   cortical	   actin	  
predominantly	   points	   toward	   the	   plasma	   membrane	   whereas	   the	   remaining	   actin	  
network	   is	   randomly	  oriented	   (Gross	  2004).	  By	   contrast,	   almost	  50	   years	   ago	   it	   has	  
been	  shown	  that	  microtubules	  are	  not	  arranged	  randomly	  but	  are	  organized	  around	  
one	  or	  more	  separated	  centers.	  Later	  on,	  it	  has	  been	  demonstrated	  that	  microtubules	  
were	   found	   both	   to	   be	   attached	   to	   and	   initially	   arise	   from	   these	   microtubule	  
organizing	   centers	   (MTOCs),	   which	   in	   animal	   cells	   most	   often	   is	   the	   centrosome	  
located	  adjacent	  to	  the	  nucleus	  (Pereira	  and	  Schiebel	  1997).	  There,	  microtubules	  are	  
nucleated	   by	   interactions	   between	   the	  minus	   ends	   of	   the	  α/β-­‐tubulin	   subunits	   and	  
MTOC-­‐associated	  γ-­‐tubulin	  complexes	  whereas	  its	  plasma	  membrane	  facing	  plus	  ends	  
assemble	   and	   disassemble	   in	   response	   to	   cellular	   signals	   (McIntosh	   and	   Euteneuer	  
1984;	   Oakley	   and	   Oakley	   1989;	   Zheng	   et	   al.	   1995).	  While	   there	   are	   some	   proteins	  
facilitating	  microtubule	   disassembly,	   the	   inherent	   instability	   of	  microtubules	   can	   be	  
modified	  by	  microtubule-­‐associated	  proteins	  including	  MAP	  1	  and	  tau	  proteins.	  These	  
proteins	   bind	   to,	   stabilize	   and	   promote	   polymerization	   by	   regulating	   assembly	   of	  
microtubules	  (Mandelkow	  and	  Mandelkow	  1995).	  However,	  antimitotic	  drugs	  such	  as	  
colchicine	   and	   nocodazole,	  which	   bind	   to	  β-­‐	   tubulin,	   prevent	  microtubule	   assembly	  
and	  promote	  their	  depolymerization	  (Olmsted	  and	  Borisy	  1973;	  Hoebeke	  et	  al.	  1976).	  
	  
Although	   initial	   studies	   suggested	   that	   (i)	   actin	   plays	   a	   role	   in	   cell	   polarity	   and	  
migratory	  processes,	  (ii)	  intermediate	  filaments	  in	  providing	  mechanical	  strength	  and	  
(iii)	   microtubules	   in	   trafficking	   of	   intracellular	   cargo,	   extensive	   research	   in	   the	   last	  
years	  demonstrated	  that	  all	  components	  operate	  in	  conjunction	  to	  perform	  many	  of	  
their	   tasks	   (Fuchs	  and	  Karakesisoglou	  2001).	  Regarding	   this,	   it	  has	  been	   shown	   that	  
microtubules	  and	  actin	  provide	  a	  physical	   transport	   system	  along	  which	   the	  motor-­‐
protein	   bound	   cargo	   molecules	   travel	   (Fuchs	   and	   Karakesisoglou	   2001;	   Mallik	   and	  
Gross	   2004).	   In	   order	   to	   spatially	   and	   temporally	   regulate	   the	   transport	   of	   specific	  
proteins,	  RNA	  and	  organelles,	  motor	  proteins	  actively	  move	  these	  cargoes	  within	  the	  
cell	   (Hirokawa	   et	   al.	   2009).	  While	   actin	   typically	   executes	   local	   transport	   processes	  
using	  myosin	   as	  motor-­‐protein,	  microtubules	  move	   their	   cargo	   over	   long	   distances	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employing	   kinesins	   and	   dyneins	   as	   motors	   (Gross	   2004).	   On	  microtubules,	   cargoes	  
alternate	   between	   transport	   toward	   the	   minus	   end	   by	   employing	   proteins	   of	   the	  
dynein	  family	  and	  movement	  into	  the	  plus-­‐end	  direction	  into	  the	  cell	  periphery	  driven	  
by	   kinesin	   motors	   (Mallik	   and	   Gross	   2004).	   These	   anterograde	   KIF	   motors	   are	  
comprised	  of	  15	  kinesin	  families	  that	  are	  termed	  kinesin	  1	  to	  kinesin	  14B.	  Several	  of	  
these	  motors,	  such	  as	  KIF3A/B	  (kinesin	  2	  family)	  and	  KIF5A/B/C	  (kinesin	  1	  family),	  are	  
shown	   to	   transport	   vesicles	   and	   organelles	   in	   the	   axon	   and	   are	   involved	   in	   the	  
conventional	   secretion	   pathway	   in	   neurons	   and	   non-­‐neuronal	   cells	   (Hirokawa	   et	   al.	  
2009).	  However,	   it	  has	  also	  been	  found	  that	  some	  KIFs	  are	   involved	   in	  multi-­‐protein	  
complex	   trafficking.	   Regarding	   this,	   investigations	   with	   the	   focus	   on	   schizophrenia	  
have	  been	  revealed	  that	  KIF5	  motors	  are	  linked	  to	  its	  cargo	  proteins	  nudel	  (NudE-­‐like),	  
LIS1	   (lisencephaly	   1)	   and	   14-­‐3-­‐3ε	   via	   the	   adaptor	   protein	   DISC1	   (disrupted	   in	  
schizophrenia	  1)	  regulating	  the	  transport	  of	  the	  complex	  to	  axons	  (Taya	  et	  al.	  2007).	  
So	   far,	   more	   than	   40	   anterograde	   cargo	   molecules	   have	   been	   reported	   that	   are	  
transported	  either	  enclosed	  in	  vesicles	  and	  different	  organelles	  or	  as	  part	  of	  a	  protein-­‐
complex	  (Hirokawa	  et	  al.	  2009).	  What	  they	  all	  have	  in	  common	  is	  the	  transport	  along	  
microtubules	  bound	  to	  a	  defined	  set	  of	  motor	  proteins	  either	  by	  direct	  interactions	  or	  
via	  different	  scaffold	  proteins	  to	  reach	  their	  final	  destinations.	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1.6 AIM	  OF	  THIS	  THESIS	  
With	  regard	   to	  FGF2-­‐secretion,	  previous	  work	  revealed	  several	   fundamental	  aspects	  
pointing	  to	  a	  mechanism	  of	  direct	  membrane	  translocation.	  In	  this	  model,	  binding	  of	  
FGF2	   to	   PI(4,5)P2	   at	   the	   inner	   leaflet	   of	   the	   plasma	   membrane	   is	   the	   initial	   step	  
followed	   by	   direct	   translocation	   in	   a	   folded,	   and	   probably	   oligomeric,	   state.	  
Furthermore,	  this	  process	  is	  driven	  by	  the	  affinity	  to	  HSPGs	  in	  the	  extracellular	  space.	  
In	   addition	   to	   PI(4,5)P2	   and	   HSPGs,	   phosphorylation	   of	   FGF2	   at	   position	   82	   by	   Tec	  
kinase	  has	  recently	  been	  found	  to	  be	  relevant	  for	   its	  secretion.	  Considering	  this	  first	  
link	  between	  Tec-­‐mediated	  phosphorylation	  of	  FGF2	  and	  its	  export	  the	  present	  study	  
was	  designed	  to	  extend	  the	  state	  of	  knowledge	  regarding	  the	  functional	  role	  of	  FGF2	  
phosphorylation	  on	  a	  molecular	  basis.	  	  
	  
First,	   this	   thesis	   aimed	  at	   the	  validation	  of	   the	   role	  of	   Tec	   kinase	   in	  unconventional	  
secretion	   of	   FGF2	   using	   independent	   tools	   and	   a	   physiologically	   relevant	   read-­‐out	  
system.	  A	  further	  key	  question	  was	  addressed	  by	  analyzing	  the	  phosphorylation	  status	  
of	  FGF2	  on	  both	  the	  extracellular	  and	  intracellular	  side	  in	  vivo.	  Moreover,	  employing	  a	  
FGF2	  version	  containing	  a	  stable	  homolog	  of	  phosphotyrosine	  (pCMF)	  in	  position	  82,	  
detailed	   analyses	   regarding	   a	   potential	   function	   of	   FGF2	   phosphorylation	   were	  
performed.	   Included	   were	   liposome-­‐based,	   biochemical	   investigations	   on	   (i)	   the	  
PI(4,5)P2-­‐binding	   efficiency,	   (ii)	   the	   oligomerization	   state	   and	   (iii)	   the	   membrane	  
insertion	   activity.	   The	   question	   of	   whether	   phosphorylation	   has	   an	   effect	   on	   well-­‐
known	   post-­‐secretion	   aspects	   such	   as	   HSPG	   binding	   and	   subsequent	   induction	   of	  
signaling	  pathways	  was	  addressed	  by	  studying	  the	  effect	  of	  phosphomimetic	  FGF2	  in	  a	  
cellular	   system.	   In	   order	   to	   investigate	   pre-­‐secretion	   properties	   of	   phosphomimetic	  
FGF2	   in	  vivo,	  a	  cell-­‐based	  microinjection	  assay	  was	  established	   in	  this	  work	  allowing	  
the	  microscopic	  analysis	  of	  exclusively	   intracellular	  FGF2	  proteins	  prior	   to	   secretion.	  
Using	   this	   approach,	   the	   localization	   of	   phosphomimetic	   FGF2	   was	   analyzed	   by	  
confocal	   and	   electron	   microscopy.	   Due	   to	   a	   time-­‐dependent	   accumulation	   of	  
phosphomimetic	  FGF2	  at	  the	  plasma	  membrane,	  both	   its	  distribution	  and	  the	  effect	  
on	  secretion	  from	  cells	  expressing	  FGF2-­‐GFP	  wild	  type	  proteins	  in	  the	  presence	  of	  the	  
microtubule-­‐depolymerizing	  drug	  nocodazole	  were	  investigated.	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2 RESULTS	  
Extracellular	   FGF2	   mediates	   diverse	   cellular	   responses	   such	   as	   proliferation,	   cell	  
survival	  and	  differentiation.	  The	  initial	  step	  in	  unconventional	  secretion	  of	  FGF2	  is	  its	  
recruitment	  to	  the	  inner	  leaflet	  of	  the	  plasma	  membrane	  by	  PI(4,5)P2	  (Temmerman	  et	  
al.	  2008).	  On	  the	  extracellular	  side,	  the	  affinity	  to	  HSPGs	  has	  been	  proposed	  to	  be	  the	  
driving	  force	  of	  direct	  translocation	  across	  the	  plasma	  membrane	  (Zehe	  et	  al.	  2006).	  In	  
addition	  to	  PI(4,5)P2	  and	  HSPGs,	  phosphorylation	  of	  FGF2	  at	  position	  82	  by	  Tec	  kinase	  
was	   recently	   identified	   to	   be	   relevant	   for	   its	   secretion	   (Ebert	   et	   al.	   2010).	   So	   far,	   a	  
mechanism	   of	   how	   phosphorylation	   facilitates	   FGF2	   secretion	   has	   not	   been	  
demonstrated.	  The	  goal	  of	  this	  study	  was	  to	  gain	  first	  insights	  into	  a	  phosphorylation-­‐
dependent	  regulation	  mechanism	  involved	  in	  FGF2	  export.	  	  
	  
2.1 FGF2-­‐SECRETION-­‐INDUCED	   PROLIFERATION	   DEPENDS	   ON	   TEC	   KINASE	  
ACTIVITY	  
It	   has	   been	   shown	   previously	   that	   a	   chemical	   Tec	   kinase	   inhibitor,	   LFM-­‐A13,	  
specifically	  targets	  FGF2	  secretion	  by	  affecting	  Tec	  kinase	  activity.	  In	  that	  study,	  FGF2	  
cell	   surface	  signals	  of	  LFM-­‐A13	  treated	  cells	  were	  significantly	  reduced	  compared	  to	  
mock	  treated	  cells	  as	  shown	  by	  flow	  cytometry	  (Ebert	  et	  al.	  2010).	  In	  order	  to	  further	  
corroborate	   these	   findings	   by	   a	   second	   line	   of	   evidence,	   metabolic	   activity	   as	   an	  
indicator	   of	   proliferation	   was	   studied	   in	   3T3	   fibroblasts	   cultured	   for	   48	   h	   in	   the	  
presence	  or	  absence	  of	  LFM-­‐A13.	  Metabolic	  activity	  was	  quantified	  by	  the	  colorimetric	  
MTT	  (3-­‐(4,5-­‐Dimethylthiazol-­‐2-­‐yl)-­‐2,5-­‐diphenyltetrazolium	  bromide)-­‐readout.	  
As	   displayed	   in	   Figure	   7,	   treatment	   of	   cells	   with	   LFM-­‐A13	   cultured	   in	   medium	  
containing	  10%	  calf	  serum	  (CS)	  did	  not	   impair	  metabolic	  activity.	  Limiting	  availability	  
of	   growth	   supporting	   factors,	   which	  was	   achieved	   by	   reducing	   CS-­‐concentration	   to	  
0,1%,	  lead	  to	  a	  strong	  decrease	  in	  metabolic	  activity.	  This	  could	  be	  observed	  for	  both,	  
mock	  and	  LFM-­‐A13	  treated	  cells.	  However,	  under	  mock	  conditions	  this	  lack	  of	  growth	  
was	   partially	   rescued	   following	   induction	   of	   FGF2-­‐expression.	   Intriguingly,	   in	   the	  
presence	   of	   the	   Tec-­‐kinase	   inhibitor	   significant	   inhibition	   of	   proliferation	   was	   still	  
observed.	   In	   order	   to	   rule	   out	   an	   effect	   of	   LFM-­‐A13	   on	   the	   signaling	   pathway	  
mediated	  by	  already	  secreted	  FGF2,	  recombinant	  protein	  was	  added	  to	  the	  medium.	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Here,	  no	  significant	  difference	  in	  metabolic	  activity	  between	  mock-­‐treated	  and	  LFM-­‐
A13	  treated	  cells	  was	  detected.	  
Figure	   7:	   FGF2-­‐secretion-­‐induced	   proliferation	   of	   3T3	   fibroblasts	   depends	   on	   Tec	   kinase	   activity.	  
Stable	   3T3	   cells	   expressing	   FGF2-­‐GFP	   in	   a	   doxycycline	   dependent-­‐manner	   were	   starved	   for	   5	   h.	  
Following	  addition	  of	  either	  doxycycline	  (Dox,	  3	  µg/ml),	  10%	  calf	  serum	  (CS)	  or	  recombinant	  FGF2-­‐GFP,	  
cells	  were	  incubated	  for	  48	  h.	  As	  indicated,	  cells	  were	  grown	  in	  the	  absence	  (mock-­‐treated,	  blue	  bars)	  or	  
presence	   of	   LFM-­‐A13	   (40	   µM,	   green	   bars).	   Metabolic	   activity	   was	   analyzed	   using	   the	   MTT-­‐assay.	  
Metabolic	   activity	   of	   cells	   grown	   in	  medium	   supplemented	  with	   10%	  CS	  was	   set	   to	   100%.	   The	   chart	  
represents	  the	  average	  and	  standard	  deviation	  of	  5	  independent	  experiments,	  which	  were	  performed	  in	  
triplicates,	   respectively.	   In	   order	   to	   assess	   statistical	   significance	   an	   unpaired	   two-­‐tailed	   t	   test	   was	  
performed	   using	   GraphPad	   Prism	   5	   (ns	   =	   not	   significant;	   *	   =	   p-­‐value	   ≤	   0.05;	   **	   =	   p-­‐value	   ≤	   0.01;	  
***	  =	  p-­‐value	  ≤	  0.001).	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2.2 LOCALIZATION	  STUDIES	  ON	  PHOSPHORYLATED	  FGF2	  IN	  LIVING	  CELLS	  
Since	  FGF2	  secretion	  depends	  on	  Tec	  kinase	  activity,	  we	  aimed	  for	  the	  localization	  of	  
phosphorylated	  FGF2	  in	  cells.	  According	  to	  recent	  studies,	  phosphorylated	  FGF2	  was	  
detected	   in	   total	   lysates	   of	   stable	   HeLa	   cells	   expressing	   FGF-­‐GFP	   in	   a	   doxycycline-­‐
dependent	  manner	   (Ebert	  et	  al.	  2010).	  However,	   the	  total	  FGF2-­‐GFP	  population	  has	  
been	  shown	  to	  be	  distributed	  throughout	  the	  cytoplasm	  and	  nucleus,	  as	  well	  as	  bound	  
to	  the	  extracellular	  surface	  of	  CHO	  cells	  (Engling	  et	  al.	  2002).	  	  
For	   the	   purpose	   of	   localization	   studies,	   antibodies	   are	   widely	   used	   to	   specifically	  
detect	   a	   protein	   of	   interest.	   Regarding	   posttranslational	   modifications,	   various	  
phospho-­‐antibodies	   are	   available	   which	   are	   specific	   for	   the	   phosphorylated	   amino	  
acids	   tyrosine,	   serine	   and	   threonine.	   In	   order	   to	   specifically	   detect	   phosphorylated	  
FGF2,	   a	   site-­‐specific	   phospho-­‐antibody	   is	   a	   valuable	   tool,	   as	   it	   provides	   not	   only	  
information	  about	  the	  phosphorylation	  state	  of	  a	  protein	  but	  also	  about	  its	  sequence.	  
Since	  Tec-­‐mediated	  phosphorylation	  was	  observed	  at	  tyrosine	  82	  as	  demonstrated	  by	  
a	   biochemical	   kinase	   assay	   and	   subsequent	  mass	   spectrometric	   analysis,	   a	   peptide	  
mimicking	  the	  selected	  region	  of	  interest	  was	  synthesized	  and	  injected	  into	  animals.	  
	  
2.2.1 Generation	  of	  a	  phospho-­‐specific	  FGF2	  antibody	  
In	  order	  to	  maximize	  the	  probability	  that	  antibodies	  raised	  against	  a	  synthetic	  peptide	  
recognize	  phosphorylated	   full-­‐length	  protein,	  antigen	  design	   is	   the	  key	   to	   select	   the	  
most	   ideal	   peptide	   sequence.	   In	   general,	   hydrophilic,	   flexible	   and	   surface	   oriented	  
regions	  represent	  most	  suitable	  antigenic	  epitopes.	  Since	  a	  peptide	  sequence	  of	  8-­‐20	  
amino	  acids	  was	  recommended	  to	  avoid	  the	  risk	  of	  specificity	  loss	  (Trier	  et	  al.	  2012),	  a	  
potential	  epitope	  including	  tyrosine	  82	  was	  chosen	  comprising	  the	  region	  from	  amino	  
acid	  62	  to	  102.	  Furthermore,	  the	  position	  of	  the	  posttranslationally	  modified	  residue	  is	  
very	   important,	   as	   a	   location	   in	   the	  middle	  of	   the	  peptide	   increases	   the	  probability	  
that	   all	   produced	   antibodies	   contain	   epitopes	   including	   the	   phospho	   residue.	   Thus,	  
the	  specific	  region	  of	  interest	  was	  restricted	  to	  residues	  72-­‐92	  (Table	  1	  and	  Figure	  8,	  
highlighted	  in	  gray).	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Figure	   8:	   Amino	   acid	   sequence	   of	   FGF2.	   The	   amino	   acid	   sequence	   is	   shown	   in	   single	   letter	   code	  
starting	   with	   the	   first	   amino	   acid	   of	   FGF2.	   Tyrosine	   82,	   which	   is	   phosphorylated	   by	   Tec	   kinase,	   is	  
highlighted	  in	  red.	  The	  peptide	  sequence	  that	  was	  obtained	  by	  positioning	  tyrosine	  82	  in	  the	  middle	  
of	  a	  20-­‐amino	  acid	  peptide	  is	  highlighted	  in	  gray.	  
In	   order	   to	   consider	   intrinsic	   characteristics	   of	   the	   amino	   acid	   sequence,	   peptide	  
selection	   was	   refined	   by	   (i)	   addressing	   structural	   aspects	   and	   (ii)	   predictions	   of	  
physico-­‐chemical	  protein	  properties	  regarding	  antigenicity.	  
In	  a	  first	  attempt,	  the	  native	  protein	  structure	  was	  analyzed	  since	  it	  is	  proposed	  that	  
most	  surface-­‐exposed	  regions	  are	  potentially	  antigenic	  (Jameson	  and	  Wolf	  1988).	  As	  
illustrated	   in	   Figure	   9,	   the	   OH-­‐group	   of	   tyrosine	   82,	   which	   is	   the	   target	   of	  
phosphorylation,	   protrudes	   on	   the	   surface.	   However,	   both	   adjacent	   leucine	   83	   and	  
proximal	  methionine	  85	  are	  buried	  in	  the	  interior	  of	  the	  molecule.	  By	  contrast,	  amino	  
acids	  of	  the	  reduced	  sequence	  between	  isoleucine	  74	  and	  leucine	  91	  are	  found	  on	  the	  
protein	  surface.	  	  
	   	  
Figure	   9:	   Potential	   immunogenic	   peptide	  
within	  the	  X-­‐Ray	  crystal	  structure	  of	  FGF2.	  
Side	  chains	  72-­‐92	  of	  FGF2	  are	  highlighted.	  
Surface	  exposed	  side	  chains	  are	  colored	  in	  
red	   while	   buried	   amino	   acids	   are	  
numbered	   and	   shown	   in	   green.	   Tyrosine	  
82,	   which	   is	   phosphorylated	   by	   Tec,	   is	  
illustrated	   as	   ball	   and	   stick	   presentation.	  
The	  structure	  was	  published	  by	  Kastrup	  et	  
al.	   (1997;	   PDB:	   1BFF)	   and	  modified	   using	  
PyMOL.	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In	   order	   to	   collect	   more	   information	   relevant	   for	   antigenicity,	   algorithms	   were	  
employed	  that	  provide	  data	  about	  hydrophobicity,	  flexibility	  and	  accessibility	  (Table	  1,	  
described	  in	  section	  4.3.1)	  	  
	  Table	   1:	   Antigenicity	   predictions	   for	   a	   peptide	   as	   immunogen	   containing	   tyrosine	   82	   of	   FGF2.	   A	  
reduced	  amino	  acid	  sequence	  of	  FGF2	  containing	  tyrosine	  82	  (highlighted	  in	  red)	  in	  the	  middle	  of	  a	  20	  
amino	  acid	  stretch	  is	  listed.	  Buried	  amino	  acids	  are	  shown	  in	  green.	  The	  most	  suitable	  peptide	  sequence	  
of	  each	  analysis	  is	  highlighted	  in	  light	  blue.	  The	  final	  peptide	  sequence	  is	  framed	  in	  red.	  AA=	  amino	  acid,	  
HyPhil=	   Hydrophilicity	   according	   to	   Kyte-­‐Doolittle,	   FlexPr=	   Flexibility	   prediction	   according	   to	   Karplus-­‐
Schulz,	  SurfPr=	  Surface	  prediction	  according	  to	  Emini,	  AI-­‐Ind=	  antigenicity	  index	  according	  to	  Jameson-­‐
Wolf.	  
	  
Regarding	  hydrophobicity,	   the	   sequence	  prediction	   suggested	   that	  most	   hydrophilic	  
amino	   acids	   within	   the	   region	   of	   interest	   are	   located	   C-­‐terminally	   to	   tyrosine	   82	  
(residues	   83	   to	   90).	   In	   order	   to	   search	   for	   the	   most	   mobile	   and	   thus	   possibly	  
antigenic	  surface-­‐exposed	  residues,	  flexibility	  analysis	  were	  performed.	  In	  FGF2,	  one	  
single	  lysine	  in	  position	  75	  and	  one	  sequence	  stretch	  (86	  to	  90)	  were	  found	  to	  share	  
high	  flexibility	  values.	  Amino	  acids	  of	  this	  stretch	  correspond	  to	  the	  C-­‐terminal	  part	  of	  
the	   sequence	  determined	   as	   the	  most	   hydrophilic	   region.	   In	   contrast,	   using	   surface	  



















75	   K	   1.811	   1.001	   0.17	   -­‐0.45	  
76	   G	   0.956	   0.995	   0.128	   -­‐0.6	  
77	   V	   -­‐0.011	   0.98	   0.293	   -­‐0.6	  
78	   C	   -­‐0.067	   0.97	   0.287	   0.6	  
79	   A	   -­‐0.144	   0.966	   0.455	   0.7	  
80	   N	   0.489	   0.969	   0.505	   -­‐0.2	  
81	   R	   0.744	   0.967	   0.952	   -­‐0.3	  
82	   Y	   -­‐0.156	   0.948	   0.933	   0.3	  
83	   L	   -­‐0.822	   0.939	   1.16	   0.75	  
84	   A	   -­‐1.411	   0.941	   1.026	   0.75	  
85	   M	   -­‐1.067	   0.96	   1.093	   0.75	  
86	   K	   -­‐1.067	   1.007	   1.312	   0.9	  
87	   E	   -­‐0.5	   1.041	   2.543	   0.9	  
88	   D	   -­‐0.5	   1.055	   1.119	   0.9	  
89	   G	   -­‐0.5	   1.054	   0.874	   0.75	  
90	   R	   -­‐0.8	   1.023	   0.51	   0.45	  
91	   L	   -­‐0.133	   0.997	   0.409	   -­‐0.3	  
92	   L	   0.722	   0.986	   0.827	   0.3	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probability	  predictions,	   the	  most	  promising	  sequence	  embedded	   in	   the	  pre-­‐selected	  
peptide	  around	   tyrosine	  82	   shifted	   to	  amino	  acid	  81	   to	  88.	   Finally,	   the	   antigenicity	  
index	   was	   calculated,	   the	   formula	   of	   which	   combines	   hydrophobicity,	   flexibility,	  
accessibility	  and	  secondary	  structure	  predictions.	  In	  fact,	  the	  region	  appearing	  on	  the	  
antigenicity	  index	  as	  highest	  peak	  comprises	  the	  central	  core	  (amino	  acid	  83-­‐89)	  of	  
all	  conducted	  prediction	  techniques.	  Taken	  together,	  the	  most	  likely	  region	  exposed	  
on	   the	   surface	   and	   thereby	   most	   suitable	   epitope	   for	   a	   site-­‐specific	   phospho-­‐
antibody	  directed	  against	  tyrosine	  82	  of	  FGF2	  contains	  one	  major	  amino	  acid	  stretch	  
ranging	   from	   amino	   acid	   81-­‐90.	   Considering	   the	   tertiary	   structure,	   position	   of	  
tyrosine	   rather	   in	   the	  middle	   of	   the	   sequence	   and	   a	  minimum	   length	   of	   8	   amino	  




Since	  the	  antibody	  was	  intended	  to	  recognize	  phosphorylated	  FGF2	  derived	  from	  cells,	  
the	  peptide	  sequence	  was	  compared	  to	  proteins	  in	  the	  NCBI-­‐database	  to	  limit	  the	  risk	  
of	   cross-­‐reactivity.	   Using	   the	   NCBI	   BLAST	   online-­‐tool,	   no	   sequence	   similarities	   to	   a	  
listed	  protein	  other	  than	  FGF2	  were	  detected.	  	  
	  
Peptide	   synthesis,	   immunization	   and	   reactivity	   analysis	   were	   performed	   in	  
collaboration	  with	  Peptide	   Specialty	   Laboratories	   (Heidelberg).	   Briefly,	   an	   additional	  
cysteine	  was	  attached	  C-­‐terminally	  to	  the	  peptide	  sequence	  that	  allows	  for	  coupling	  to	  
the	  carrier	  protein	  keyhole	   limpet	  hemocyanin.	  Polyclonal	  antibodies	  were	  raised	  by	  
injecting	  2	  mg	  of	  coupled	  peptide	  into	  two	  New	  Zealand	  White	  rabbits.	  Animals	  were	  
immunized	  over	  a	  period	  of	  70	  days	  conducting	  3	  booster	  injections	  (days:	  28,	  42	  and	  
56)	  and	   finally	  bled	  by	  heart	  puncture.	   Serums	  collected	   from	  rabbit	  1	  and	   rabbit	  2	  
were	   tested	   for	   reactivity	   by	   enzyme-­‐linked	   immunosorbent	   assays	   (ELISA)	   on	  
peptide-­‐ovalbumin	  conjugates.	  Both	  antiserums	  displayed	  a	  high,	  constant	  reactivity	  
(Figure	   10).	   However,	   serum	   obtained	   from	   rabbit	   2	   revealed	   a	   slightly	   decreased	  
immune	  response	  as	  the	  dilution	  of	  serum	  was	  increased.	  When	  incubated	  with	  non-­‐
peptide	  coupled	  ovalbumin	  antiserum	  of	  rabbit	  1	  did	  not	  react.	  	  
Therefore,	  antiserum	  of	  rabbit	  1	  was	  used	  for	  antibody	  purification.	  For	  this	  purpose,	  
the	   antiserum	   was	   first	   incubated	   with	   a	   non-­‐phosphopeptide	   affinity	   column	   to	  
79A	  N	  R	  pY	  L	  A	  M	  K	  E	  D88	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capture	  non-­‐phosphopeptide-­‐specific	  antibodies	  followed	  by	  incubation	  of	  the	  flow	  
through	  with	   a	   phospho-­‐specific	   peptide	   column	   (section	   4.3.1).	   The	   purified	   site-­‐
specific	  phospho-­‐antibody	  was	  designated	  α-­‐pY82.	  
Figure	  10:	  Characterization	  of	  peptide	  specific	  anti-­‐FGF2	  pY82	  antiserums	  by	  ELISA.	  ELISA	  tests	  were	  
performed	  with	  100	  µl	   serial-­‐diluted	   serum	  samples	   from	   rabbit	  1	   (Rb1)	   and	   rabbit	  2	   (Rb2)	  obtained	  
after	   the	   third	   booster	   injection.	   ELISA	   plates	   were	   coated	   with	   10	   ng	   of	   the	   antigenic	   peptide	  
conjugated	  on	  ovalbumin	   (ova-­‐pep).	  Serum	  was	   incubated	  at	   room	  temperature	   followed	  by	  an	  anti-­‐
rabbit	   secondary	   antibody	   coupled	   to	   horseradish	   peroxidase.	   After	   incubation	   with	   a	   substrate	  
solution,	   absorbance	   at	   450	   nm	  was	  measured.	   As	   a	   control,	   serum	   of	   Rb1	  was	   added	   to	   uncoated	  
ovalbumin	  (ova).	  
	  
2.2.2 Characterization	  of	  the	  phospho-­‐specific	  α-­‐pY82	  antibody	  
Dot	   blots	   were	   employed	   as	   a	   quick	   and	   effective	   method	   for	   testing	   the	   binding	  
efficiency	   and	   optimizing	   the	   primary	   antibody	   dilution	   required	   for	   quantitative	  
detection	   of	   phosphorylated	   FGF2.	   To	   that	   end,	   pY–peptide	   (Figure	   11A,	  
ANRpYLAMKED)	  dots	  were	  spotted	  on	  a	  nitrocellulose	  membrane	  and	  incubated	  with	  
different	   dilutions	   of	   α-­‐pY82	   followed	   by	   staining	   with	   secondary	   antibodies.	   As	  
expected,	   the	  antigenic	  phosphopeptide,	  which	  represents	   the	  optimal	  antigen,	  was	  
clearly	  detected	  by	  α-­‐pY82	  (Figure	  11B).	  A	  linear	  decrement	  in	  reactivity	  was	  observed	  
by	  serial	  dilution	  of	  the	  antibody.	  Since	  a	  dilution	  of	  1:200	  gave	  an	  adequate	  signal	  of	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Figure	  11:	  Specificity	  of	  anti-­‐FGF2	  pY82	  antibody	  tested	  by	  dot	  blot	  analysis.	  (A)	  Sequence	  of	  peptides	  
dotted	   to	   the	   membrane	   as	   indicated.	   (B)	   Dot	   blot	   analysis	   of	   antigenic	   phospho-­‐peptide.	   A	  
nitrocellulose	   membrane	   was	   spotted	   with	   the	   pY-­‐peptide	   at	   0.82	   pmol.	   The	   dried	   membrane	   was	  
incubated	  with	  different	  dilutions	  of	  α-­‐pY82	  as	  indicated	  followed	  by	  staining	  with	  Alexa	  Fluor680	  goat	  
anti-­‐rabbit	   secondary	   antibodies.	   (C)	   The	   specificity	   of	   α-­‐pY82	  was	   ascertained	   by	   dot	   blot	   analysis.	  
Binding	  of	  α-­‐pY82	  to	  the	  pY-­‐peptide,	  its	  non-­‐phospho	  counterpart	  (Y),	  a	  phosphomimetic	  peptide	  (E),	  a	  
non-­‐related	  phosphotyrosine-­‐peptide	  (nr-­‐pY)	  or	  full-­‐length	  His6-­‐FGF2	  protein	  was	  investigated.	  Each	  dot	  
contained	  0.41	  pmol	  of	  either	  full	  length	  FGF2	  or	  one	  of	  the	  peptides	  indicated.	  As	  a	  control,	  binding	  of	  
polyclonal	   anti-­‐FGF2	   antibody	   (α-­‐FGF2,	   rabbit)	  was	   analyzed	   in	   parallel.	   (D)	  Quantification	   of	   binding	  
efficiencies	  detected	  by	  dot	  blot	  analysis	   in	  C.	  Pixel	   intensity	   values	  were	  measured	  using	   the	   LI-­‐COR	  
Odyssey	  infrared	  imaging	  system.	  	  
	  
Using	  the	  optimized	  concentration,	  specificity	  of	  the	  antibody	  was	  tested.	  In	  order	  to	  
examine	   if	   α-­‐pY82	   specifically	   binds	   to	   the	   phosphopeptide	   population,	   i.e.	  
pY-­‐peptides,	  equimolar	  amounts	  of	  the	  corresponding	  non-­‐phospho	  Y-­‐peptide	  and	  a	  
glutamate-­‐containing	  peptide	   (E)	  were	   spotted	  on	  a	  membrane	   (Figure	  11A	  and	  C).	  
The	   latter	   was	   included	   as	   a	   control,	   mimicking	   phosphotyrosine	   as	   a	   negatively	  
charged	   amino	   acid.	   Additionally,	   the	   option	   that	   α-­‐pY82	   detects	   phosphotyrosines	  
even	  in	  the	  context	  of	  a	  non-­‐related	  amino	  acid	  sequence	  was	  considered	  by	  including	  
a	  phosphopeptide	  composed	  of	  a	   completely	  different	  amino	  acid	   sequence	   (Figure	  
11A).	   Finally,	   recombinant	   protein	  was	   carried	   along	   as	   negative	   control	   to	   further	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shown	  in	  Figure	  11C,	  α-­‐pY82	  strongly	  binds	  to	  the	  corresponding	  phosphopeptide	  but	  
not	  to	  any	  of	  the	  control	  peptides.	  A	  weak	  background	  staining	  for	  recombinant	  FGF2	  
was	   observed,	   however,	   the	   percentage	   of	   the	   signal	   is	   negligible	   as	  monitored	   by	  
quantification	   (less	   than	   3%,	   Figure	   11D).	   For	   comparison,	   the	   well-­‐characterized	  
standard	   antibody	   against	   FGF2	   gave	   a	   strong	   signal	   for	   recombinant	   His6-­‐FGF2.	  
Notably,	   this	   polyclonal	   antibody	   raised	   against	   the	   entire	   FGF2-­‐molecule	   did	   not	  
detect	  the	  Y-­‐peptide.	  As	  expected,	  this	  antibody	  was	  found	  to	  react	  with	  none	  of	  the	  
other	  three	  peptides.	  	  
	  
As	   previously	   shown	   by	   employing	   [γ32P]ATP,	   a	   GST	   fused	   FGF2	   protein	   was	  
specifically	  phosphorylated	  by	  Tec	  kinase	  in	  an	  in	  vitro	  kinase	  assay	  (Ebert	  et	  al.	  2010).	  
In	   order	   to	   determine	   whether	   α-­‐pY82	   recognizes	   in	   vitro	   phosphorylated	   FGF2,	  
recombinant	  His6-­‐FGF2-­‐GFP	   fusion	   protein	  was	   incubated	  with	   autoactivated	   Tec	   in	  
the	   presence	   or	   absence	   of	   ATP.	  Here,	  GFP	   served	   as	   a	   negative	   control.	   Following	  
SDS-­‐PAGE	  and	  Western	  blot	   transfer,	  membranes	  were	  stained	  with	  α-­‐pY82	  (rabbit)	  
as	  well	   as	   anti-­‐GFP	  antibody	   (mouse)	   as	   loading	   control.	  As	  depicted	   in	   Figure	  12A,	  
addition	  of	  ATP	  caused	  moderate	  phosphorylation	  of	  full	  length	  His6-­‐FGF2-­‐GFP	  (upper	  
panel,	   lane	   6).	   However,	   there	   was	   an	   even	   stronger	   immunoreactivity	   against	   its	  
degradation	  products,	  which	  were	  not	  detected	  by	  the	  anti-­‐GFP	  antibody	  (lane	  4	  to	  6).	  
Remarkably,	  full-­‐length	  His6-­‐FGF2-­‐GFP	  was	  observed	  as	  a	  green	  band	  during	  SDS-­‐PAGE	  
even	   under	   denaturing	   and	   reducing	   conditions.	   With	   regard	   to	   GFP,	   a	  
phosphorylation	   signal	  was	  observed	  neither	   in	   the	  presence	  nor	   in	   the	   absence	  of	  
ATP	  (upper	  panel,	   lane	  2	  and	  3).	  Of	  note,	  Tec	  kinase	  was	  detected	  by	  α-­‐pY82,	  which	  
was	   even	   stronger	   in	   the	   presence	   of	   both	   ATP	   and	   His6-­‐FGF2-­‐GFP	   (upper	   panel,	  
lane	  6).	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Figure	  12:	  Phosphorylated	  FGF2	  was	  recognized	  by	  α-­‐pY82	  in	  vitro.	  Recombinant	  His6-­‐FGF2-­‐GFP,	  His6-­‐
FGF2	  and	  GFP,	  respectively,	  were	  incubated	  with	  or	  without	  autoactivated	  His-­‐Tec	  kinase	  either	  in	  the	  
presence	  or	  absence	  of	  ATP	  as	  indicated.	  The	  reaction	  was	  terminated	  by	  addition	  of	  and	  boiling	  in	  SDS	  
sample	  buffer.	  Samples	  were	  subjected	  to	  SDS-­‐PAGE	  (40%	  in	  A	  and	  and	  10%	  in	  B)	  Western	  blot	  analysis.	  
For	  the	  detection	  of	  bound	  primary	  antibodies	  Alexa	  Fluor	  680	  goat	  anti-­‐rabbit	  and	  IRDye	  800CW	  goat	  
anti-­‐mouse	  secondary	  antibodies	  were	  used.	  (A)	  Membranes	  were	  stained	  with	  a	  mixture	  of	  anti-­‐GFP	  
antibody	   (α-­‐GFP,	   mouse)	   and	   rabbit	   α-­‐pY82	   (rabbit)	   primary	   antibodies.	   (B)	   In	   order	   to	   monitor	  
phosphorylation	  of	  FGF2,	  membranes	  were	   incubated	  with	  both	  primary	  rabbit	  α-­‐pY82	  (rabbit)	  and	  a	  
commercially	  available	  phosphotyrosine	  antibody	  (α-­‐pY,	  mouse).	  Mr:	  molecular	  weight	  marker.	  
	  
Due	   to	   strong	  signals	  obtained	   for	  FGF2-­‐GFP	  degradation	  products,	  phosphorylation	  
was	  then	  analyzed	  in	  the	  context	  of	  a	  non-­‐GFP	  tagged	  His6-­‐FGF2	  protein.	  Additionally,	  
phosphorylation	  was	  monitored	  using	  a	  commercially	  available	  anti-­‐phosphotyrosine	  
antibody	   (α-­‐pY,	   mouse).	   Interestingly,	   in	   the	   presence	   of	   ATP	   an	   obvious	  
immunoreaction	  of	  α-­‐pY82	  against	  His6-­‐FGF2	  was	  observed	  whereas	  α-­‐pY-­‐signals	  were	  
nearly	   equal	   to	   background	   levels	   (Figure	   12B,	   lane	   9).	   Under	   these	   experimental	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signals	  with	  respect	  to	  the	  degradation	  products	  of	  His6-­‐FGF2-­‐GFP	  (upper	  panel,	  lane	  
6).	  This	  observation	  was	  in	  line	  with	  the	  immunoreactivity	  of	  α-­‐pY	  (middle	  panel,	  lane	  
6).	   Nonetheless,	   there	   was	   a	   striking	   difference	   between	   both	   antibodies	   as	   α-­‐pY	  
recognized	   full	   length	   His6-­‐FGF2-­‐GFP	   much	   better	   than	   site-­‐specific	   α-­‐pY82.	  
Furthermore,	   a	   different	   pattern	   in	   terms	   of	   intensities	   was	   also	   seen	   for	   the	  
degradation	   products	   (lower	   panel,	   lane	   6).	   As	   expected,	   GFP	  was	   not	   detected	   by	  
both	  α-­‐pY82	  and	  α-­‐pY	  (lane	  1	  and	  3).	  
	  
2.2.3 Localization	  of	  phosphorylated	  FGF2	  in	  vivo	  	  
Having	  a	  site-­‐specific	  phospho-­‐antibody	  that	  properly	  fulfills	  its	  intended	  purpose,	  the	  
localization	  of	  phosphorylated	  FGF2	  in	  cells	  was	  addressed.	  As	  a	  consequence	  of	  the	  
aforementioned	   phosphorylation	   experiments	   in	   vitro	   (section	   2.2.2),	   HeLa	   S3	   cells	  
inducibly	  expressing	  a	  non-­‐tagged	  version	  of	   FGF2	  were	  used.	  Considering	   that	   full-­‐
length	   FGF2-­‐GFP	  was	  detected	  only	   to	   a	   less	   extent	  by	  α-­‐pY82,	   probably	   due	   to	   its	  
native	  conformation	  (Figure	  12A,	  lane	  6),	  biotinylation	  experiments	  were	  conducted.	  
Firstly,	  this	  method	  has	  the	  advantage	  that	  extracellular	  FGF2	  molecules	  can	  be	  easily	  
captured	  and,	  secondly,	  proteins	  are	  finally	  separated	  by	  SDS-­‐PAGE	  under	  denaturing	  
conditions.	   Therefore,	   extracellular	   proteins	   were	   labeled	   with	   membrane-­‐
impermeable	   Biotin	   that	   reacts	   with	   free	   amino	   groups.	   After	   cell	   lysis,	   these	  
biotinylated	   cell	   surface	   proteins	  were	   captured	   using	   streptavidin	   beads.	   The	   flow	  
through	   containing	   the	   entire	   population	   of	   intracellular	   proteins	   was	   collected.	  
Following	   SDS-­‐PAGE	   and	  membrane	   transfer,	   proteins	  were	   probed	  with	   α-­‐pY82	   to	  
detect	  phosphorylated	  FGF2.	   In	  order	  to	  visualize	  the	  total	  amount	  of	  FGF2	  an	  anti-­‐
FGF2	  antibody	  was	  used.	   In	   addition,	  membranes	  were	   incubated	  with	  an	  antibody	  
against	   the	   house-­‐keeping	   protein	   GAPDH	   (glyceraldehyde	   3-­‐phosphate	  
dehydrogenase)	   serving	   as	   a	   control	   for	  maintained	   cell	   integrity	   during	   incubation	  
with	   the	  biotin-­‐reagent.	   Figure	  13	   shows	   that	  FGF2	  molecules	  were	  detected	   in	   the	  
unbound	   fraction	   containing	   intracellular	   proteins	   as	   well	   as	   in	   the	   cell-­‐surface	  
exposed,	  biotinylated	  fraction	  (upper	  panel,	  lane	  2	  and	  3).	  Since	  GAPDH	  was	  detected	  
only	   in	   the	   input	   and	   intracellular	   fraction	   (lower	   panel,	   lane	   1	   and	   2),	   all	   proteins	  
captured	   by	   streptavidin	   were	   considered	   to	   be	   exclusively	   cell	   surface-­‐bound	  
molecules.	   The	   pool	   of	   extracellular	   FGF2-­‐GFP	   was	   less	   prominent	   than	   that	   of	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intracellular	  FGF2-­‐GFP	  (upper	  panel;	   lane	  3	  and	  2,	  respectively),	  which	  is	   in	  line	  with	  
earlier	   results	   obtained	   from	   CHO	   cells	   expressing	   FGF2-­‐GFP	   (Zehe	   et	   al.	   2006).	  
However,	  despite	  being	  present	  in	  both	  fractions,	  a	  phosphorylated	  FGF2	  population	  
was	  not	  detected	  by	  α-­‐pY82	  (upper	  panel,	  lane	  4	  to	  6).	  
	  
Figure	  13:	  α-­‐pY82	  did	  not	  recognize	  phosphorylated	  FGF2	  in	  vivo.	  Stable	  FGF2	  expressing	  HeLa	  S3	  cells	  
grown	  in	  10	  cm	  plates	  were	  induced	  with	  Doxycycline	  for	  20	  h.	  After	  incubation	  with	  the	  biotin	  reagent,	  
cell	   lysate	   was	   prepared	   and	   centrifuged	   (cleared	   lysate,	   Input)	   in	   presence	   of	   protease	   and	  
phosphatase	   inhibitors.	   Extracellular	   material	   was	   captured	   using	   streptavidin	   beads.	   Proteins	   were	  
eluted	  by	  addition	  of	  SDS	  sample	  buffer.	  Input	  (I,	  10%),	  unbound	  (UB,	  10%)	  and	  bound	  fractions	  (B,	  35%)	  
were	   analyzed	   by	   SDS-­‐PAGE	   and	  Western	   blotting.	   Immunodetection	  was	   performed	  with	   anti-­‐FGF2	  
(mouse),	   anti-­‐GAPDH	   (mouse)	   as	   well	   as	   α-­‐pY82	   (rabbit)	   primary	   antibodies.	   Signals	   shown	   in	   red	  
derived	   from	   Alexa	   Fluor	   680	   goat	   anti-­‐rabbit	   antibody	   whereas	   green	   signals	   derived	   from	   IRDye	  
800CW	  goat	  anti-­‐mouse	  antibody.	  
	  
While	  the	  immunolabeling-­‐based	  method	  was	  properly	  not	  sensitive	  enough	  to	  detect	  
phosphorylated	   FGF2,	   radioactive	   labeling	   represents	   a	   highly	   sensitive	  method.	   To	  
that	   end,	   cells	   were	   grown	   in	   the	   presence	   of	   [32P]-­‐phosphoric	   acid	   followed	   by	  
isolation	   of	   extracellular	   FGF2	   molecules.	   Since	   all	   phosphorylated	   proteins	   are	  
radiolabeled	  by	  this	  method,	  FGF2	  molecules	  were	  subsequently	  separated	  from	  the	  
total	  protein	  pool	  by	  immunoprecipitation	  (IP).	  Capturing	  extracellular	  FGF2	  proteins	  
by	   IP,	   however,	   cannot	   be	   performed	   while	   these	   biotinylated	   molecules	   are	   still	  
bound	   to	   streptavidin.	   For	   this	   reason,	   HSPG-­‐bound	   FGF2	   was	   removed	   from	   cell	  
surfaces	   by	   exploiting	   its	   affinity	   to	   heparin,	   which	   competes	   with	   HSPGs	   for	   FGF2	  
interactions.	   Therefore,	   cells	   seeded	   on	   culture	   plates	   were	   exposed	   to	   a	   solution	  
containing	  soluble	  heparin	  followed	  by	  collection	  of	  the	  supernatant	  and	  subsequent	  
IP	  of	  heparin-­‐eluted	  FGF2	  proteins.	  As	  shown	   in	  Figure	  14,	  considerable	  amounts	  of	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respectively).	  In	  order	  to	  compare	  the	  efficiency	  of	  this	  new	  heparin	  approach	  to	  the	  
biotinylation	  experiment,	  both	  assays	  were	  conducted	  in	  parallel	  using	  the	  same	  cell	  
number.	   The	   amount	   of	   heparin-­‐eluted	   extracellular	   FGF2	   was	   comparable	   to	   that	  
captured	  by	  biotin-­‐streptavidin	  affinity	  (lane	  2	  and	  6),	  indicating	  an	  efficient	  elution	  of	  
extracellular	  proteins	  from	  cell	  surfaces	  using	  soluble	  heparin.	  	  
	  
Figure	  14:	  Extracellular	  FGF2	  is	  efficiently	  removed	  from	  cell	  surfaces	  by	  heparin.	  Stable	  HeLa	  S3	  cells	  
expressing	   FGF2	   in	   a	   doxycycline-­‐dependent	   manner	   were	   induced	   for	   20	   h.	   In	   order	   to	   harvest	  
extracellular	   FGF2	   from	  cell	   surfaces,	   cells	  were	   incubated	  with	  a	  heparin-­‐solution	   for	  30	  min	  at	  4°C.	  
While	  the	  supernatant	  was	  subjected	  to	   immunoprecipitation	  using	  an	  anti-­‐FGF2	  antibody,	   remaining	  
cells	  were	   lysed.	  The	  biotinylation-­‐assay	  was	   conducted	  as	  described	  before.	  Cleared	   lysate	   (lys,	  2%),	  
bound	   (B,	   100%,)	   and	  unbound	   (UB,	   0,5%	   for	  heparin	   separation	   and	  2	  %	   for	  biotinylation)	   fractions	  
were	   subjected	   to	   SDS-­‐PAGE	   and	   Western	   blot	   analysis.	   In	   addition,	   the	   pellet	   resulting	   from	  
centrifugation	   of	   the	   total	   lysate	   was	   included	   (15%).	   Membranes	   were	   incubated	   with	   anti-­‐FGF2	  
(mouse)	   and	   anti-­‐GAPDH	   (mouse)	   primary	   antibodies,	   respectively,	   followed	   by	   incubation	   with	  
secondary	   anti-­‐mouse	   antibodies	   coupled	   to	   IRDye	   800CW.	   Mr:	   molecular	   weight	   marker,	   kDa:	  
kilodalton.	  
	  
Once	  the	  protocol	  was	  successfully	  established,	  cells	  were	  grown	   in	  the	  presence	  of	  
[32P]-­‐phosphoric	   acid	   followed	   by	   heparin	   elution	   and	   immunoprecipitation.	   After	  
SDS-­‐PAGE	  and	  Western	  blotting,	  immunosignals	  were	  analyzed	  by	  an	  infrared	  imaging	  
system	   while	   a	   phosphorimager	   was	   used	   to	   read	   out	   signals	   derived	   from	  
radiolabeling.	   GAPDH	   was	   stained	   as	   a	   loading	   control.	   Since	   phosphorylation	   of	  
inducibly	  expressed	  FGF2-­‐GFP	  in	  HeLa	  cells	  has	  already	  been	  shown	  previously	  (Ebert	  
et	  al.	   2010),	   the	   same	  cell	   line	  was	  used	   to	  examine	  where	  phosphorylated	  FGF2	   is	  
located.	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Intriguingly,	   phosphorimaging	   of	   the	   intracellular	   material	   revealed	   considerable	  
amounts	  of	  a	  [32P]-­‐labeled	  protein	  with	  an	  apparent	  molecular	  weight	  of	  about	  45	  kDa	  
(Figure	  15,	  upper	  panel,	   lane	  10,	  asterisk).	   In	  fact,	  merging	  both	  the	  protein	  and	  the	  
phospho	   signals,	   this	   [32P]-­‐labeled	   protein	   did	   overlap	   with	   the	   45-­‐kDa-­‐band	  
corresponding	  to	  the	  FGF2-­‐GFP	  fusion	  protein	  (merge	  not	  shown).	  By	  contrast,	  HeLa	  
cells	  expressing	  no	  FGF2-­‐GFP	  construct	  were	  negative	  for	  both	  a	  FGF2	  derived	  signal	  
on	  protein	  level	  (lower	  panel,	   lane	  1	  and	  9)	  and	  a	  phospho-­‐signal,	   indicating	  specific	  
radiolabeling	   of	   FGF2-­‐GFP	   (upper	   panel,	   lane	   9).	   As	   observed	   in	   the	   previous	  
experiment	   (Figure	  14),	  a	   substantial	  protein	  amount	  of	  FGF2-­‐GFP	  was	   found	   in	   the	  
intracellular	   fraction	   whereas	   the	   signal	   derived	   from	   extracellular	   FGF2-­‐GFP	   was	  
detected	  to	  a	  less	  extent	  (lower	  panel,	  lanes	  10	  and	  8).	  In	  contrast	  to	  the	  intracellular	  
material,	   this	   minor	   pool	   of	   extracellular	   FGF2-­‐GFP	   was	   not	   found	   to	   be	  
phosphorylated	   (upper	   panel,	   lane	   8).	   No	   protein-­‐signal	   derived	   from	   extracellular	  
FGF2-­‐GFP	  was	  observed	  in	  the	  TCA-­‐precipitated	  unbound	  fraction,	  indicating	  that	  the	  
vast	   majority	   of	   extracellular	   FGF2-­‐GFP	   was	   captured	   during	   immunoprecipitation	  
(upper	  panel,	  lane	  6).	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Figure	  15:	  Intracellular	  FGF2-­‐GFP	  is	  phosphorylated	  in	  vivo.	  HeLa	  cells	  expressing	  an	  FGF2-­‐GFP	  fusion	  
protein	  as	  well	  as	  cells	  expressing	  no	  FGF2	  (MT)	  were	  grown	  in	  phosphate-­‐free	  medium	  containing	  0,1%	  
dialyzed	   FCS	   and	   Doxycycline.	   After	   48	   h,	   medium	   was	   supplemented	   with	   10%	   dialyzed	   FCS,	   [32P]	  
phosphoric	   acid	   and	   Doxycycline.	   Following	   18	   h,	   extracellular	   FGF2-­‐GFP	   was	   captured	   by	   soluble	  
heparin	   as	   described	  before.	   Cells	  were	   lysed	   and	  both	   cleared	   lysates	   (input	   intracellular	   FGF2)	   and	  
extracellular	  fractions	  were	  subjected	  to	  immunoprecipitation	  using	  an	  anti-­‐GFP	  antibody.	  While	  bound	  
proteins	  (B)	  were	  eluted	  by	  addition	  of	  SDS	  sample	  buffer,	  supernatants	  (=unbound,	  UB)	  were	  collected.	  
Highly	   diluted	   extracellular	   proteins	   in	   the	   supernatant	   fraction	  were	   concentrated	  by	   trichloroacetic	  
acid	  treatment.	  All	  fractions	  were	  analyzed	  by	  SDS-­‐PAGE	  (lanes	  1-­‐4:	  0,5%,	  lanes	  5-­‐10:	  44%)	  and	  Western	  
blot	  analysis	  with	  a	  subsequent	  exposure	  to	  a	  phosphorimaging	  screen	  (lanes	  1-­‐6:	  2	  h,	  lanes	  7-­‐10:	  12	  h).	  
Proteins	  were	   labeled	  with	   both	   anti-­‐FGF2	   (mouse)	   and	   anti-­‐GAPDH	   primary	   antibodies	   followed	   by	  
incubation	  with	   IRDye	  800CW-­‐coupled	  anti-­‐mouse	  antibody.	  Protein	   levels	  and	  phospho-­‐signals	  were	  
analyzed	   by	   infrared	   imaging	   and	   phosphorimaging,	   respectively.	   The	   band	   detected	   by	  
phosphorimaging	   that	   is	   highlighted	   with	   “*”	   merges	   with	   immunoprecipitated	   FGF2-­‐GFP.	   Mr:	  
molecular	  weight	  marker;	  kDa:	  kilodalton.	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2.3 ANALYSIS	   OF	   PHOSPHORYLATION-­‐DEPENDENT	   EFFECTS	   OF	   FGF2	   USING	   A	  
PHOSPHOMIMETIC	  PROTEIN	  
In	   order	   to	   study	   the	   role	   of	   phosphorylation	   in	   FGF2	   secretion	   more	   directly,	   a	  
phosphomimetic	   protein	   was	   introduced	   containing	   p-­‐carboxylmethylphenylalanine	  
(pCMF,	   Xie	   et	   al.	   2007,	   Young	   et	   al.	   2010),	   a	   metabolically	   stable	   analogue	   of	  
phosphotyrosine,	   in	   position	   82	   of	   FGF2	   (FGF2-­‐Y82pCMF).	   This	   residue	   was	   first	  
identified	  by	  an	  in	  vitro	  kinase	  assay	  combined	  with	  mass	  spectrometric	  analysis	  and	  
verified	  by	  mutational	  analysis	  (Ebert	  et	  al.	  2010).	  
	  
2.3.1 Analysis	  of	  phosphomimetic	  FGF2	  regarding	  its	  post-­‐secretion	  properties	  	  
Since	   extracellular	   FGF2	   was	   not	   found	   to	   be	   phosphorylated,	   the	   question	   was	  
addressed	   whether	   dephosphorylation	   is	   a	   prerequisite	   for	   extracellular	  
characteristics.	  Therefore,	  binding	  to	  HSPGs	  as	  a	  well-­‐known	  extracellular	  property	  of	  
FGF2	  was	  investigated.	  In	  order	  to	  examine	  whether	  the	  pCMF	  substitution	  as	  well	  as	  
a	   non-­‐phosphorylatable	   FGF2	   variant	   form,	   where	   tyrosine	   82	   was	   replaced	   by	  
phenylalanine	   (His6-­‐FGF2-­‐Y82F),	   affect	   binding	   to	   cell-­‐surface	   bound	   HSPGs,	   flow-­‐
cytometry	  analyses	  were	  performed.	  As	  an	  additional	  control	  to	  the	  wild	  type	  protein,	  
a	  FGF2	  mutant	  protein	  was	  included	  where	  arginine	  128	  and	  lysine	  129	  residues	  were	  
replaced	   by	   glutamine	   (PIP2-­‐Mut).	   This	   FGF2	   mutant	   protein	   deficient	   in	   PI(4,5)P2-­‐
binding	  also	  caused	  a	  slight	  reduction	  in	  binding	  to	  HSPGs	  on	  the	  surface	  of	  CHO	  cells	  
(Temmerman	   et	   al.	   2008).	   Even	   though	   protein	   purification	   by	   heparin	   affinity	  
chromatography	   provided	   a	   first	   hint	   that	   binding	   of	   phosphomimetic	   FGF2	   is	   not	  
affected,	   flow-­‐cytometry	   analyses	   were	   conducted	   in	   terms	   of	   quantitative	  
monitoring.	   As	   illustrated	   in	   Figure	   16A,	   incubation	   with	   different	   protein	  
concentrations	  did	  not	  alter	  binding	  to	  HSPGs	  on	  the	  cell	  surface	  of	  HeLa	  cells.	  These	  
findings	  were	  confirmed	  by	  microscopic	  analysis	  (Figure	  16B).	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Figure	  16:	  Binding	  behavior	  of	  phosphomimetic	  FGF2	  to	  HSPGs.	  HeLa	  cells	  were	  incubated	  either	  with	  
serial	  diluted	  wild	  type	  His6-­‐FGF2	  (WT),	  His6-­‐FGF2	  Y82pCMF,	  His6-­‐FGF2	  Y82F	  or	  His6-­‐FGF2	  K128Q	  R129Q	  
(PIP2	   Mut),	   respectively.	   (A)	   Proteins	   were	   stained	   with	   a	   polyclonal	   anti-­‐FGF2	   antibody	   (rabbit)	  
followed	  by	  a	  goat	  anti-­‐rabbit	  antibody	  coupled	  to	  allophycocyanin.	  Signal	  intensities	  were	  analyzed	  by	  
FACS.	   Each	   measurement	   was	   carried	   out	   in	   triplicates.	   Means	   with	   standard	   deviations	   of	   3	  
independent	  experiments	  are	  shown.	  (B)	  For	  microscopic	  analysis,	  proteins	  were	  added	  to	  HeLa	  cells	  at	  
a	  final	  concentration	  of	  2.5	  nM.	  Polyclonal	  anti-­‐FGF2	  antibody	  and	  a	  secondary	  rabbit-­‐antibody	  coupled	  
to	  Alexa	  Fluor	  488	  were	  used	  to	  detect	   recombinant	  FGF2	  variant	   forms.	  HSPG	  binding	  was	  analyzed	  
using	  a	  confocal	  fluorescence	  microscope.	  All	  samples	  were	  scanned	  with	  identical	  settings.	  	  
	  
Since	   there	   was	   no	   difference	   in	   HSPG	   binding	   either	   of	   His6-­‐FGF2-­‐Y82pCMF	   or	  
His6-­‐FGF2-­‐Y82F,	  the	  effect	  of	  these	  mutant	  forms	  on	  proliferation,	  which	  is	  mediated	  
by	  a	  complex,	  highly	  concerted	  signaling	  pathway	  was	  analyzed.	  In	  addition	  to	  HSPG-­‐
binding,	  stimulation	  of	  its	  receptor	  as	  well	  as	  internalization	  and	  transport	  of	  FGF2	  to	  
the	   nucleus	   has	   been	   reported	   to	   induce	   proliferation	   (Itoh	   and	   Ornitz	   2011).	  
Metabolic	  activity	  as	  an	  indicator	  for	  proliferation	  was	  analyzed	  as	  already	  described	  
in	  section	  2.1.	  As	  observed	  before,	  activity	  of	  cells	  grown	  under	  low	  serum	  conditions	  
was	   drastically	   reduced,	   whereas	   expression	   of	   FGF2-­‐GFP	   resulted	   in	   increased	  
proliferation	  (Figure	  17).	  This	  rescue	  was	  even	  higher	  in	  the	  presence	  of	  recombinant	  
His6-­‐FGF2	   WT.	   However,	   replacement	   of	   tyrosine	   82	   by	   neither	   pCMF	   nor	  
phenylalanine	  did	  affect	  metabolic	  activity	  of	  cells.	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Figure	   17:	   Analysis	   of	   phosphomimetic	   FGF2	   with	   regard	   to	   cell	   proliferation.	   Stable	   3T3	   cells	  
expressing	  FGF2-­‐GFP	   in	  a	  doxycycline	  dependent-­‐manner	  were	   starved	   for	  5	  h.	   Following	  addition	  of	  
either	  doxycycline	   (Dox,	  3	  µg/ml),	  10%	  calf	   serum	  (CS)	  or	   recombinant	  FGF2	  variant	   forms	   (His6-­‐FGF2	  
(WT),	  His6-­‐FGF2	  Y82pCMF,	  His6-­‐FGF2	  Y82F),	  cells	  were	  incubated	  for	  48	  h.	  Metabolic	  activity	  as	  indicator	  
for	   cell	   proliferation	   was	   analyzed	   using	   the	   MTT-­‐assay.	   Proliferation	   of	   cells	   grown	   in	   medium	  
supplemented	   with	   10%	   CS	   was	   set	   to	   100%.	   The	   chart	   represents	   the	   average	   of	   3	   independent	  
experiments	  each	  of	  which	  was	  performed	  in	  triplicates.	  
	  
2.3.2 Analysis	  of	  phosphomimetic	  FGF2	  regarding	  its	  pre-­‐secretion	  properties	  
After	   monitoring	   extracellular	   properties,	   phosphorylation-­‐dependent	   effects	  
occurring	   at	   the	   intracellular	   leaflet	   of	   the	   plasma	   membrane	   were	   examined.	  
Previously,	   binding	   of	   FGF2	   to	   PI(4,5)P2	   has	   been	   shown	   to	   be	   the	   initial	   step	   in	  
unconventional	   secretion	   of	   FGF2	   (Temmerman	   et	   al.	   2008).	   Furthermore,	   this	  
interaction	   was	   speculated	   to	   trigger	   formation	   of	   higher	   oligomers	   prior	   to	   direct	  
membrane	   translocation	   (Nickel	   2011).	   In	   an	   attempt	   to	   elucidate	   whether	  
phosphorylation	  may	  be	   critically	   important	   for	   these	  processes,	   (i)	   the	  property	   to	  
form	   higher	   oligomers,	   (ii)	   the	   affinity	   to	   PI(4,5)P2-­‐containing	   liposomes	   and	  
(iii)	  membrane	  activity	  were	  analyzed	  in	  vitro.	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2.3.2.1 Analysis	  of	  PI(4,5)P2-­‐dependent	  oligomerization	  on	  membrane	  surfaces	  	  
First	   of	   all,	   the	   property	   of	   phosphomimetic	   FGF2	   to	   form	   higher	   oligomers	   was	  
examined.	   Therefore,	   liposomes	   resembling	   the	   plasma	   membrane	   were	  
reconstituted	  either	  in	  the	  presence	  or	  absence	  of	  5	  mol%	  PI(4,5)P2.	  For	  the	  purpose	  
of	  separating	   liposomes	  with	  bound	  FGF2	  variant	   forms	  from	  unbound	  proteins	  and	  
aggregates	   in	   particular,	   the	   total	   liposome-­‐protein	   mixture	   was	   subjected	   to	   a	  
Nycodenz	  density	  gradient,	  as	  described	  by	  Weber	   et	  al.	   (1998).	  Proteins	   in	   the	   top	  
(liposome-­‐containing),	  middle	  and	  bottom	  regions	  (unbound	  proteins	  and	  aggregates)	  
of	   the	   gradient	   were	   analyzed	   by	   SDS-­‐PAGE	   and	   Western	   blotting.	   As	   depicted	   in	  
Figure	  18,	  FGF2	  wild	  type	  and	  both	  phosphomimetic	  and	  non-­‐phosphorylatable	  FGF2	  
bind	  to	  liposomes	  containing	  PI(4,5)P2	  (upper	  panel,	   lanes	  3,	  9	  and	  15),	  respectively.	  
As	   previously	   shown	   by	   sedimentation	   of	   liposomes	   and	   thereby	   membrane-­‐
associated	  material	  (Julia	  P.	  Steringer,	  PhD	  thesis),	  wild	  type	  FGF2	  was	  found	  to	  form	  
SDS	   resistant	   dimers	   and	   higher	   oligomers	   following	   incubation	   with	   liposomes	  
containing	   PI(4,5)P2.	   Here,	   these	   findings	  were	   confirmed	   (upper	   panel,	   lane	   3).	   Of	  
note,	  these	  dimers	  and	  oligomers	  are	  no	  protein	  aggregates	  since	  they	  were	  detected	  
in	   the	   floated,	  membrane-­‐containing	   fraction	   (lane	   3).	   Regarding	   both	   FGF2	   variant	  
forms,	  dimers	  and	  higher	  oligomers	  were	  also	  present	  after	  incubation	  with	  liposomes	  
resembling	   plasma	   membranes	   (lanes	   9	   and	   15).	   Liposomes	   lacking	   PI(4,5)P2	   were	  
used	  as	  a	  control.	  As	  expected,	  only	  residual	  amounts	  of	  FGF2	  monomers	  and	  dimers	  
were	   observed	   membrane	   associated	   (lower	   panel,	   lanes	   3,	   9	   and	   15)	   while	   most	  
FGF2	   remained	   in	   the	   bottom	   fraction	   that	   corresponds	   to	   unbound	   protein	   and	  
aggregates	  (lower	  panel,	  lanes	  6,	  12	  and	  18).	  Under	  these	  conditions,	  higher	  oligomers	  
were	  completely	  absent	  (lower	  panel,	  lanes	  3,	  9	  and	  15).	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Figure	   18:	   Analysis	   of	   PI(4,5)P2-­‐dependent	   oligomerization	   on	   membrane	   surfaces.	   Liposomes	  
resembling	  plasma	  membranes	   (PM)	  were	   reconstituted	  with	  or	  without	  2	  mol%	  PI(4,5)P2.	  His6-­‐FGF2	  
variant	  forms	  indicated	  were	  diluted	  to	  a	  final	  concentration	  of	  5	  µM	  (I).	  Following	  incubation,	  10%	  of	  
the	   total	  mixture	  was	   collected	   (L)	   and	   bound	   proteins	  were	   separated	   from	   unbound	   proteins	   and	  
aggregates	   by	   flotation	   in	   Nycodenz	   density	   gradients	   (1=	   top	   fraction,	   4=	   bottom	   fraction).	   3.3%	   of	  
each	   sample	   was	   anaylzed	   by	   SDS-­‐PAGE	   under	   reducing	   conditions	   and	   Western	   blot	   analysis.	  
Polyclonal	  anti-­‐FGF2	  antibody	  and	  a	  secondary	  rabbit-­‐antibody	  coupled	  to	  Alexa	  Fluor	  680	  were	  used	  to	  
detect	  recombinant	  FGF2	  variant	  forms.	  
	  
2.3.2.2 Analysis	  of	  binding	  to	  PI(4,5)P2	  incorporated	  in	  membrane	  surfaces	  
After	  obtaining	  qualitative	  data	  on	  PI(4,5)P2-­‐binding	  properties	  of	  FGF2	  variant	  forms,	  
a	  more	  quantitative	  flow-­‐cytometry	  based	  method	  was	  applied.	  In	  a	  previous	  study	  by	  
Temmerman	  and	  Nickel	   (2009),	  a	  KD	  of	  2.89	  ±	  0.26	  µM	  for	  wild	   type	  FGF2-­‐GFP	  was	  
calculated	  based	  on	  this	  read-­‐out.	  In	  order	  to	  compare	  PI(4,5)P2-­‐binding	  efficiencies	  of	  
the	   phosphomimetic	   variant	   with	   wild	   type	   FGF2,	   both	   proteins	   were	   analyzed	   in	  
parallel.	  For	  this	  purpose,	  His6-­‐FGF2-­‐GFP-­‐Y82pCMF	  and	  His6-­‐FGF2-­‐GFP	  wild	  type	  were	  
incubated	  with	  PI(4,5)P2-­‐containing	  liposomes	  at	  different	  concentrations	  followed	  by	  
flow-­‐cytometry.	  As	  can	  be	  seen	   in	  Figure	  19A,	  affinity	  of	  His6-­‐FGF2-­‐GFP-­‐Y82pCMF	  to	  
PI(4,5)P2-­‐containing	  liposomes	  was	  slightly	  reduced.	  Although	  this	  effect	  was	  observed	  
for	  all	  concentrations,	  the	  decrease	  in	  binding	  of	  phosphomimetic	  His6-­‐FGF2-­‐GFP	  was	  
more	   substantial	   at	   higher	   protein	   concentrations.	   In	   fact,	   signal	   intensities	   of	   His6-­‐
FGF2-­‐GFP-­‐Y82pCMF	  reached	  a	  plateau	  at	  7.5	  µM	  to	  10	  µM	  whereas	  those	  of	  the	  wild	  
type	   protein	   still	   increased	   in	   a	   dose-­‐dependent	   manner.	   This	   observation	   was	   in	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accordance	   with	   the	   analysis	   of	   protein	   binding	   by	   sedimentation	   of	   liposomes	  
combined	  with	  SDS-­‐PAGE	  analysis	  of	  the	  pelleted	  fraction	  and	  subsequent	  Coomassie	  
staining	  (Figure	  19B).	  Even	  though	  the	  input	  material	  was	  moderately	  increased,	  signal	  
of	  phosphomimetic	  His6-­‐FGF2-­‐GFP	  bound	  to	  liposomes	  was	  clearly	  reduced.	  	  
Figure	  19:	  Analysis	  of	  FGF2-­‐Y82pCMF-­‐GFP	  with	   regard	   to	  binding	   to	  PI(4,5)P2-­‐containing	   liposomes.	  
Liposomes	  with	  a	  plasma	  membrane-­‐like	  lipid	  composition	  containing	  2	  mol%	  PI(4,5)P2	  were	  incubated	  
with	  either	  His6-­‐FGF2-­‐GFP	  (WT)	  or	  His6-­‐FGF2-­‐Y82pCMF-­‐GFP	  at	  different	  concentrations	  as	  indicated.	  (A)	  
Following	   incubation	   for	   90	  min,	   liposomes	   were	   analyzed	   by	   FACS.	   For	   the	   purpose	   of	   background	  
correction,	   signals	   derived	   from	   liposomes	   incubated	   with	   GFP	   were	   measured	   in	   parallel	   and	  
subtracted	  from	  each	  sample.	  Data	  were	  normalized	  according	  to	  Temmerman	  and	  Nickel	  (2009).	  Each	  
experiment	   was	   performed	   in	   triplicates.	   The	   highest	   value	   per	   experiment	   was	   set	   to	   100%	   and	  
triplicates	  were	  subsequently	  averaged.	  Means	  with	  standard	  deviations	  of	  3	  independent	  experiments	  
are	   shown.	   (B)	   Following	   incubation	   for	   90	  min,	   5%	   of	   the	  mixture	  was	   removed	   (input).	   Liposomes	  
were	  sedimented,	  washed	  in	  HK	  buffer	  and	  resuspended	  in	  SDS	  sample	  buffer.	  Input	  (1,5%)	  and	  bound	  
fractions	   (15%)	   were	   analyzed	   by	   SDS-­‐PAGE	   and	   subsequent	   Coomassie	   staining.	   C.F.U.:	   corrected	  
fluorescence	  units.	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2.3.2.3 Analysis	  of	  PI(4,5)P2-­‐dependent	  membrane	  activity	  	  
Based	   on	   the	   formation	   of	   oligomers	   and	   on	   previous	   findings	   demonstrating	   that	  
FGF2	  proteins	  are	   still	   present	   in	   the	   liposome-­‐bound	   fraction	  even	  after	   carbonate	  
treatment	   (Julia	  P.	  Steringer,	  PhD	   thesis),	   the	  question	  was	  addressed	  whether	   self-­‐
association	  of	   FGF2	   in	   the	  presence	  of	  PI(4,5)P2-­‐containing	   lipid	  bilayers	   leads	   to	   its	  
direct	  membrane	  insertion.	  Therefore,	  membrane	  activity	  of	  His6-­‐FGF2-­‐WT,	  His6-­‐FGF2-­‐
Y82F	   and	   His6-­‐FGF2-­‐Y82pCMF	   was	   examined	   by	   studying	   protein-­‐induced	  
carboxyfluorescein	  (CF)	  release	  from	  liposomes.	  This	  experimental	  system	  is	  based	  on	  
a	  dequenching	  principle.	  While	  the	  fluorescence	  intensity	  of	  membrane-­‐impermeable	  
CF	   is	   quenched	   at	   high	   concentrations	   within	   the	   lumen	   of	   liposomes,	  
permeabilization	   of	   liposomes	   and	   subsequent	   dilution	   into	   the	   surrounding	   buffer	  
results	  in	  dequenching,	  i.e.	  the	  dye	  fluoresces	  brightly.	  	  
In	  order	   to	   stress	   the	   importance	  of	   PI(4,5)P2-­‐dependent	   recruitment,	   PC-­‐liposomes	  
were	   included	  where	  PI(4,5)P2	  was	   replaced	  by	  a	  Ni-­‐NTA	   lipid.	   In	   this	   case,	  proteins	  
were	   still	   recruited	   to	   liposomes	   via	   the	   His-­‐tag,	   albeit	   in	   a	   PI(4,5)P2-­‐independent	  
manner.	   Furthermore,	   the	   FGF2	   variant	   form	   that	   does	   not	   bind	   to	   PI(4,5)P2	   was	  
carried	  along	  as	  a	  negative	  control	  (PIP2-­‐Mut).	  As	  can	  be	  seen	  in	  Figure	  20,	  membrane	  
activity	  of	  His6-­‐FGF2-­‐WT	  and	  His6-­‐FGF2-­‐Y82F	  were	  nearly	  twice	  as	  high	  as	  that	  for	  His6-­‐
FGF2-­‐PIP2-­‐Mut,	   which	   was	   considered	   as	   background.	   When	   analyzing	   His6-­‐FGF2-­‐
Y82pCMF,	  a	  membrane	  activity	  up	  to	  50%	  of	  total	  CF-­‐release	  was	  detected.	  Thus,	  end	  
values	  were	   increased	   almost	   8	   fold.	   However,	   the	   steep	   slope	  within	   the	   first	   ten	  
minutes	  is	  even	  more	  striking.	  Intriguingly,	  these	  observations	  completely	  disappeared	  
in	   the	   presence	   of	   PC-­‐liposomes	   containing	   the	   Ni-­‐NTA	   lipid.	   Here,	   none	   of	   the	  
proteins	  causes	  CF	  release.	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Figure	   20:	   Analysis	   of	   PI(4,5)P2-­‐dependent	  membrane	   activity	   of	   phosphomimetic	   FGF2.	   Liposomes	  
reconstituted	   in	   the	   presence	   of	   carboxyfluorescein	   and	   either	   PI(4,5)P2	   (A)	   or	  Ni-­‐NTA	   lipid	   (B)	  were	  
separated	   from	   non-­‐enclosed	   dye	   by	   using	   desalting	   columns.	   The	   input	   material	   of	   both	   liposome	  
preparations	   was	   adjusted	   according	   to	   the	   fluorescence	   of	   phosphatidylethanolamine-­‐coupled	  
rhodamine	  incorporated	  in	  both	  liposome	  populations.	  Liposomes	  were	  incubated	  either	  with	  His6-­‐FGF2	  
(WT),	   His6-­‐FGF2-­‐Y82pCMF,	   His6-­‐FGF2-­‐Y82F	   or	   His6-­‐FGF2-­‐K128Q	   R129Q	   (PIP2-­‐Mut)	   inside	   a	   Gemini	   XS	  
(Molecular	   Devices)	   fluorescence	   plate	   reader.	   Fluorescence	   intensities	   of	   dequenched	  
carboxyfluorescein	   were	   measured	   every	   second	   minute	   over	   a	   period	   of	   90	   min.	   Liposomes	   were	  
completely	   lysed	  with	  Triton	  X-­‐100.	  These	  signals	  were	  set	   to	  100%	  for	  normalization	  purposes.	  Each	  
experiment	  was	  performed	  in	  duplicates.	  Means	  of	  3	  independent	  experiments	  are	  shown	  (except	  for	  
His6-­‐FGF2-­‐K128Q	   R129Q,	   this	   was	   done	   twice).	   PM=	   liposomes	   resembling	   plasma	  membranes;	   PC=	  
liposomes	  with	  a	  phosphatidylcholine	  background.	  
	  
2.3.3 Analysis	  of	  phosphomimetic	  FGF2	  in	  a	  cellular	  context	  
After	  characterization	  of	  phosphomimetic	  FGF2	  in	  vitro,	  intracellular	  dynamics	  of	  this	  
protein	  were	  analyzed	  in	  vivo.	  Since	  incorporation	  of	  pCMF	  into	  proteins	  expressed	  in	  
a	  mammalian	  model	  system	  is	  not	  achievable	  so	  far,	  microinjection	  is	  a	  powerful	  tool	  
to	   selectively	   analyze	   the	   phosphomimetic	   protein	   at	   a	   defined	   time	   and	   location	  
inside	  a	  cell.	  For	  this	  purpose,	  His6-­‐FGF2	  wild	  type	  and	  variant	  forms	  were	  covalently	  
linked	  to	  the	  fluorescent	  dye	  Cy3	  via	  the	  two	  surface-­‐accessible	  cysteines	  in	  FGF2.	  In	  
order	   to	   compare	   the	   fluorescence	   intensities	   of	  His6-­‐FGF2-­‐WT,	  His6-­‐FGF2-­‐Y82F	   and	  
His6-­‐FGF2-­‐Y82pCMF,	   the	  degree	  of	   labeling	   (DOL)	  was	  spectroscopically	  determined.	  
The	  differences	   in	  DOL	  among	   the	   FGF2	   variant	   forms	   is	   shown	   in	   Figure	  21.	  While	  
both	  His6-­‐FGF2-­‐Y82F	  and	  His6-­‐FGF2-­‐Y82pCMF	  were	  statistically	  coupled	  to	  at	  least	  one	  
dye	  per	  molecule,	   the	  dye	  to	  protein	  ratio	  of	   the	  wild	   type	  protein	  was	   less	   than	  1.	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Concentrations	   of	   labeled	   proteins	   and	   their	   quality	   were	   additionally	   validated	   by	  
SDS-­‐PAGE	  (Figure	  21).	  
Figure	  21:	  Analysis	  of	  Cy3-­‐labeled	  FGF2	  variant	   forms.	  Following	   labeling	  of	   FGF2	  variant	   forms,	   the	  
degree	   of	   labeling	   (DOL)	   was	   determined.	   Therefore,	   the	   absorption	   of	   conjugated	   proteins	   was	  
measured	  at	  280	  and	  552	  nm.	  The	  DOL	  was	  calculated	  according	   to	   the	  manufacture´s	   information.	  
Protein	   concentrations	   and	   qualities	   were	   monitored	   by	   SDS-­‐PAGE.	   For	   visualization,	   proteins	   were	  
stained	  with	  Coomassie	  and	  scanned	  using	  the	  LI-­‐COR	  Odyssey	  infrared	  imaging	  system.	  	  
	  
In	  order	  to	  exclusively	  examine	  events	  inside	  cells,	  CHO-­‐K1-­‐pgsA-­‐745	  cells	  (hereinafter	  
referred	  to	  as	  CHO-­‐745)	  were	  used.	  These	  cells	  are	  deficient	  in	  synthesizing	  heparan	  
sulfate	   chains	   and	   thus	   incapable	   of	   FGF2	   secretion	   as	   well	   as	   HSPG-­‐dependent	  
storage	   and	   internalization	   of	   the	   growth	   factor	   (Zehe	   et	   al.	   2006).	   For	   injection	  
purposes,	   cells	  were	  plated	  on	  3.5	   cm	  glass-­‐bottom	  dishes	  24	  h	  before.	   In	  order	   to	  
minimize	  the	  risk	  of	  a	  clogged	  needle,	  FCS	  concentration	  in	  the	  medium	  was	  reduced	  
from	   10%	   to	   1%	   prior	   to	   injection.	   Since	   microinjection	   was	   performed	   at	   room	  
temperature	   without	   a	   CO2	   chamber,	   injection	   was	   stopped	   after	   15	   min.	  
Subsequently,	  cells	  were	  shifted	  back	  to	  medium	  containing	  10%	  FCS	  and	  dishes	  were	  
placed	  in	  a	  CO2	  incubator.	  
	  
2.3.3.1 Analysis	  of	  time-­‐dependent	  accumulation	  at	  the	  plasma	  membrane	  
In	  a	  first	  attempt,	  distribution	  of	  His6-­‐FGF2	  variant	  forms	  in	  HSPG-­‐deficient	  CHO-­‐745	  
cells	   was	   analyzed	   by	   confocal	   fluorescence	   microscopy	   at	   different	   time	   points	  
following	  microinjection	  (0	  h,	  1	  h,	  3	  h).	  Shortly	  after	  injecting	  phosphomimetic	  FGF2,	  a	  
diffuse	  staining	  throughout	  the	  whole	  cell	  could	  be	  detected,	   i.e.	   the	  cytoplasm	  and	  
nucleus,	   similar	   to	   those	  observed	   for	  His6-­‐FGF2-­‐WT	  and	  His6-­‐FGF2-­‐Y82F	   (Figure	  22,	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as	  nuclear	  localization	  was	  also	  detected	  at	  later	  time	  points	  (1	  h	  and	  3	  h).	  By	  contrast,	  
injection	  of	  His6-­‐FGF2-­‐Y82pCMF	  resulted	   in	   its	   time-­‐dependent	  accumulation	  on	   the	  
intracellular	   side	   of	   the	   plasma	   membrane.	   While	   a	   few	   punctate	   structures	   were	  
already	  found	  in	  the	  cytoplasm	  one	  hour	  after	  microinjection	  the	  “mature”	  punctate	  
pattern	  was	  observed	  only	  after	  longer	  incubation	  times	  (3	  h).	  	  	  
Figure	  22:	  Distribution	  of	   fluorescently	   labeled	  FGF2	  variant	   forms	   in	  HSPG-­‐deficient	  CHO-­‐745	  cells.	  
Cy3	  labeled	  FGF2	  variant	  forms	  (His6-­‐FGF2	  (WT),	  His6-­‐FGF2	  Y82pCMF	  and	  His6-­‐FGF2	  Y82F)	  were	  studied	  
in	   a	   cellular	   context.	   Following	   cytoplasmic	   injection,	   a	   time	   course	  was	  performed.	  Using	  a	   confocal	  
fluorescence	  microscope	  (63x	  magnification),	  localization	  of	  each	  FGF2	  variant	  protein	  was	  analyzed	  in	  
HSPG-­‐deficient	   cells,	   which	   were	   fixed	   with	   PFA	   (paraformaldehyde)	   directly	   after	   injection	   (0	  h)	   or	  
following	  incubation	  times	  of	  1	  h	  and	  3	  h,	  respectively.	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In	   order	   to	   confirm	   the	   observed	   localization	   of	   phosphomimetic	   FGF2	   near	   the	  
plasma	  membrane	  at	   longer	  time	  points,	  total	   internal	  reflection	  fluorescence	  (TIRF)	  
analysis	  was	  performed.	  TIRF	  selectively	  provides	  excitation	  of	  fluorophores	  near	  the	  
adherent	  cell	  surface	  while	  minimizing	  fluorescence	  from	  intracellular	  regions.	  Three	  
hours	  after	  microinjection,	  live	  cell	  imaging	  of	  adherent	  CHO-­‐745	  cells	  displayed	  major	  
signal	  clusters	  derived	  from	  Cy3-­‐labeled	  His6-­‐FGF2-­‐Y82pCMF	  indicating	  accumulation	  
at	   or	   near	   the	   plasma	   membrane	   (Figure	   23).	   While	   nucleus-­‐derived	   and	   most	  
cytoplasmic	   signals	   detected	   with	   epifluorescence	   were	   eliminated	   in	   TIRF	   images,	  
phosphomimetic	  FGF2	  was	  predominantly	  observed	  at	  the	  tips	  of	  the	  cell.	  
	  
Figure	  23:	  Phosphomimetic	  FGF2	  accumulates	  predominantly	  at	  the	  tips	  of	  the	  cell	  near	  the	  plasma	  
membrane.	  After	  microinjecting	  phosphomimetic	  FGF2,	  medium	  was	  replaced	  by	  imaging	  medium	  and	  
cells	  were	  subsequently	  subjected	  to	  a	  CO2-­‐incubator.	  Following	  incubation	  for	  3h	  cells	  were	  placed	  into	  
a	  live	  cell	  chamber	  connected	  to	  a	  TIRF	  (total	  internal	  reflection	  fluorescence)	  microscope	  and	  imaged	  
using	  both	  epifluorescence	  and	  TIRF	  illumination	  (100x	  magnification).	  
	  
2.3.3.2 Ultrastructural	  analysis	  of	  phosphomimetic	  FGF2	  	  
In	  order	  to	  achieve	  higher	  resolution	  images	  of	  those	  clustered	  structures	  in	  the	  cell	  
periphery	  and	  perinuclear	  region,	  electron	  microscopy	  (EM)	  was	  applied.	  	  
Since	  only	  a	  limited	  number	  of	  cells	  can	  be	  manually	  microinjected,	  a	  major	  issue	  is	  to	  
unambiguously	   identify	   these	   cells	   under	   the	   electron	   microscope.	   In	   order	   to	  
overcome	   this	   problem,	  most	   cells	   grown	   on	   cover	   slips	  were	   scraped	   off	   one	   day	  
before	   so	   that	   approximately	   200-­‐400	   cells	   were	   left	   (Figure	   24).	   All	   of	   these	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remaining	  cells	  were	  microinjected.	  Cells	  were	  then	  subjected	  to	  chemical	  fixation	  and	  
embedding	  in	  an	  adequate	  resin.	  Regarding	  this,	  multitudes	  of	  protocols	  are	  available	  
in	  the	  literature	  dealing	  with	  a	  non-­‐limited	  number	  of	  cells.	  Here,	  the	  main	  challenge	  
was	  to	  optimize	  a	  protocol	  suitable	  for	  the	  small	  quantity	  of	  microinjected	  cells.	  For	  
this	   purpose,	   plastic	   embedding	   using	   Lowicryl	   HM20	   represented	   an	   excellent	  
method,	  as	   it	  allows	  embedding	  of	  cells	  still	   remaining	  on	  the	  glass	  surface	  of	  cover	  
slips.	  Furthermore,	  this	  advantageous	  embedding	  procedure	  can	  be	  complemented	  by	  
post-­‐embedding	  immunogold	  labeling	  to	  detect	  proteins	  of	  interest.	  
Figure	   24:	   Preparation	   of	  microinjected	   CHO-­‐745	   cells	   for	   electron	  microscopic	   analysis.	  Cells	  were	  
seeded	   on	   cover	   slips.	   After	   24	   h,	  most	   cells	  were	   scraped	   off.	   Remaining	   cells	   (200-­‐400	   cells)	  were	  
grown	  for	   further	  24	  h.	  Following	  microinjection,	  cells	  were	   incubated	   for	  3	  h	  and	  subsequently	   fixed	  
with	  both	  PFA	  and	  glutaraldehyde.	  Shown	  are	  two	  different	  substitutions-­‐methods	  that	  can	  be	  used	  for	  
dehydration	  purposes.	  Progressive	  lowering	  of	  temperature	  (plt,	  on	  the	  left)	  is	  the	  first	  method	  starting	  
at	  4°C	  and	  dropping	  to	  -­‐40°C.	  This	  temperature	  was	  maintained	  during	  infiltration	  (20	  h).	  By	  contrast,	  
the	   second	   method	   requires	   high	   pressure	   freezing	   of	   samples	   (on	   the	   right).	   Thus,	   the	   initial	  
temperature	  for	  freeze-­‐substitution	  is	  -­‐90°C	  and	  increases	  during	  dehydration	  of	  samples	  up	  to	  -­‐50°C.	  
Subsequently,	  infiltration	  occurs	  at	  -­‐50°C	  for	  4	  h.	  After	  infiltration,	  samples	  were	  embedded	  in	  Lowicryl	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After	  defining	  general	  conditions,	  the	  first	  aim	  was	  to	  optimize	  current	  Lowicryl	  HM20	  
protocols	   to	   obtain	   a	   good	   ultrastructural	   representation	   of	   samples.	   In	   a	   first	  
embedding-­‐approach,	   a	   “progressive	   lowering	   of	   temperature”	   (plt)-­‐technique	   was	  
applied	   to	   process	   cells	   for	   EM.	   The	   principle	   of	   this	  method	   is	   defined	   by	   gradual	  
reduction	   in	   temperature,	   as	   concentration	   of	   the	   dehydrating	   agent	   is	   stepwise	  
increased	   (Figure	   24,	   on	   the	   left).	   An	   illustration	   of	   the	   result	   achieved	   with	   plt-­‐
substitution	   is	   shown	   in	   Figure	   25A.	   The	   potential	   of	   this	   method	   to	   maintain	   the	  
morphology	   is	   not	   optimal	   as	   the	   ultrastructural	   details	   (e.g.	   nuclear	   envelop	   and	  
organelles)	  of	  CHO-­‐745	  cells	  were	  barely	  identifiable	  even	  after	  sample	  contrasting.	  	  
	  
Figure	   25:	   Comparison	   between	   plt-­‐substituted	   and	   hpf-­‐substituted	   CHO-­‐745	   cells	   embedded	   in	  
Lowicryl	  HM20.	   Transmission	  microscope	   images	  of	   thin	   sections	   (60	  nm)	   that	  were	   contrasted	  with	  
uranyl	  acetate	  and	  lead	  citrate.	  (A)	  Cells	  were	  processed	  using	  the	  plt-­‐technique.	  (B)	  Cells	  were	  freeze-­‐
substituted	  after	  high-­‐pressure	  freezing.	  C	  =	  cytoplasm;	  N	  =	  nucleus;	  M	  =	  mitochondria,	  *	  =	  Golgi.	  Scale	  
bar:	  500	  nm.	  
	  
In	  order	  to	  obtain	  a	  better	  structural	  preservation	  and	  higher	  membrane	  contrast,	  the	  
strategy	  was	  adapted	  proceeding	  with	  high-­‐pressure	  freezing	  (hpf)	  followed	  by	  freeze	  
substitution	  (Figure	  24,	  on	  the	  right).	  In	  contrast	  to	  the	  plt-­‐technique,	  dehydration	  was	  
started	   at	   -­‐90°C	   after	   fast	   liquid	   nitrogen	   freezing	   of	   samples	   under	   high	   pressure.	  
Furthermore,	   the	   time	   for	   Lowicryl	   HM20-­‐infiltration	   was	   drastically	   reduced.	   As	  
shown	  in	  Figure	  25B	  many	  fine	  structural	  details	  of	  CHO-­‐745	  cells	  are	  visible	  such	  as	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nuclear	  envelope.	  Thus,	  a	  better	  preservation	  of	  fine	  structures	  was	  achieved	  with	  hpf	  
followed	  by	  freeze-­‐substitution.	  	  
Finally,	  microinjected	  cells	  were	  analyzed.	  As	   shown	   in	  Figure	  26A,	   small	   clusters	  of	  
gold	  particles,	   indicating	   FGF-­‐Y82pCMF,	   are	   located	  near	   the	  plasma	  membrane.	  Of	  
note,	  a	  membranous	  envelope	  around	  these	  gold	  particles	  was	  never	  observed	  in	  all	  
of	   the	   imaged	   samples.	   In	   order	   to	   examine	   the	   specificity	   of	   the	   antibody,	  
immunogold	   labeling	   of	   ultrathin	   sections	   of	   microinjected	   CHO-­‐745	   cells	   was	  
quantified.	  Non-­‐injected	  CHO-­‐745	  cells	  served	  as	  a	  negative	  control	  for	  the	  specificity	  
of	  the	  antibody.	  As	  shown	  in	  Figure	  26B,	  0.54	  gold	  particles	  per	  µm2	  were	  detected	  in	  
cells	   injected	   with	   His6-­‐FGF2	   Y82pCMF.	   By	   contrast,	   no	   gold	   labeling	   at	   all	   was	  
observed	   in	  non-­‐injected	  cells,	   indicating	  that	  all	   signals	  derived	  from	  the	  polyclonal	  
FGF2	  antibody	  were	  highly	  specific.	  
Figure	  26:	   Immunogold	   labeling	  of	  microinjected	  His6-­‐FGF2	  Y82pMCF	   in	  CHO-­‐745	   cells.	   (A)	  Samples	  
were	   prepared	   applying	   hpf	   and	   subsequent	   freeze-­‐substitution.	   Thin	   sections	   (60	   nm)	   of	   Lowicryl	  
HM20	  embedded	  samples	  were	   incubated	  with	  anti-­‐FGF2	   (rabbit)	   followed	  by	  gold-­‐labeled	  protein	  A	  
(arrows).	   After	   contrasting	   with	   uranyl	   acetate	   and	   lead	   citrate,	   samples	   were	   analyzed	   using	   a	  
transmission	   electron	   microscopy.	   C	   =	   cytoplasm;	   PM	   =	   plasma	   membrane.	   Scale	   bar:	   500	   nm.	   (B)	  
Quantification	  of	  gold-­‐particles	  comparing	  microinjected	   (His6-­‐FGF2	  Y82pMCF)	  and	  non-­‐injected	  CHO-­‐
745	  cells	   (neg.	  control).	  Samples	  were	   imaged	  (10,000x).	  All	  particles	   in	  this	  region	  were	  counted	  and	  
the	   image	   surface	  area	   (µm2)	  was	  determined	  using	   iTEM	  software.	  N	  =	  10	   injected	   cells	   and	  5	  non-­‐
injected	  cells.	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2.3.3.3 Analysis	  of	  nocodazole-­‐induced	  accumulation	  in	  the	  perinuclear	  region	  
Due	  to	  the	  time-­‐dependent	  accumulation	  at	  the	  plasma	  membrane	  it	  was	  speculated	  
that	  cytoskeletal	  elements	  might	  be	  involved	  in	  transporting	  Cy3-­‐His6-­‐FGF2-­‐Y82pCMF	  
into	   the	   cell	   periphery.	   In	   order	   to	   challenge	   this	   hypothesis,	   CHO-­‐745	   cells	   were	  
treated	   with	   2	   µM	   nocodazole	   immediately	   after	   microinjecting	   Cy3-­‐His6-­‐FGF2-­‐
Y82pCMF	   and	   Cy3-­‐His6-­‐FGF2-­‐Y82F,	   respectively.	   Intriguingly,	   disruption	   of	  
microtubules	   by	   nocodazole	   led	   to	   a	   shift	   from	   peripheral	   accumulation	   of	  
phosphomimetic	   FGF2	   to	   clustering	   in	   the	   perinuclear	   region	   (Figure	   27).	   Besides	  
different	   localization,	  a	  decreased	  number	  of	  these	  clusters	  was	  observed	  that	  were	  
bigger	  in	  size.	  This	  perinuclear	  accumulation	  was	  not	  seen	  for	  cells	  microinjected	  with	  
Cy3-­‐His6-­‐FGF2-­‐Y82F.	  	  
Figure	  27:	  Analysis	  of	  nocodazole-­‐induced	  accumulation	  of	  phosphomimetic	  FGF2	  in	  the	  perinuclear	  
region.	  CHO-­‐745	  cells	  were	  microinjected	  with	  either	  Cy3-­‐His6-­‐FGF2	  Y82pCMF	  or	  Cy3-­‐His6-­‐FGF2	  Y82F	  as	  
indicated.	  Injection	  medium	  was	  then	  replaced	  by	  complete	  medium	  supplemented	  with	  DMSO	  (mock)	  
and	   2	   µM	  nocodazole,	   respectively.	   Cells	  were	   incubated	   for	   3	   h,	   fixed	  with	   PFA	   and	   imaged	  with	   a	  
confocal	  fluorescence	  microscope	  (40x	  magnification).	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In	   order	   to	   monitor	   the	   disruption	   of	   the	   microtubule	   network,	   staining	   of	   these	  
cytoskeletal	  structures	  with	  anti-­‐tubulin	  antibodies	  was	  performed	  following	  injection	  
of	  Cy3-­‐labeled	  phosphomimetic	  FGF2.	  As	  shown	  in	  Figure	  28,	  an	  obvious	  correlation	  
between	   microtubule	   network	   disturbance	   and	   perinuclear	   accumulation	   of	  
phosphomimetic	  FGF2	  was	  observed.	  
Figure	  28:	  Tubulin	  staining	  in	  nocodazole-­‐treated	  CHO-­‐745	  cells	  microinjected	  with	  phosphomimetic	  
FGF2.	  Following	  injection	  of	  Cy3-­‐His6-­‐FGF2	  Y82pCMF,	  medium	  was	  replaced	  by	  complete	  medium.	  Cells	  
were	  incubated	  either	  in	  the	  absence	  (mock)	  or	  presence	  of	  2	  µM	  nocodazole	  for	  1.5	  h.	  Samples	  were	  
then	   fixed	   with	   both	   PFA	   and	   glutaraldehyde,	   permeabilized	   and	   incubated	   with	   an	   anti-­‐tubulin	  
antibody	  coupled	  to	  Alexa	  Fluor	  488.	  Localization	  of	  both	  phosphomimetic	  FGF2	  and	  microtubules	  was	  
analyzed	  using	  a	  confocal	  fluorescence	  microscope	  (63x	  magnification).	  The	  focus	  was	  set	  to	  the	  layer	  
with	  the	  highest	  fluorescence	  intensity	  prior	  to	  image	  samples.	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2.4 ANALYSIS	  OF	  NOCODAZOLE-­‐INDUCED	  ALTERATION	  ON	  FGF2-­‐SECRETION	  
Finally,	   the	  effect	  of	  nocodazole	  on	   secretion	  efficiencies	   in	   vivo	  was	  examined.	   For	  
this	  purpose,	  a	  well-­‐established	  cell-­‐based	  assay	  was	  applied,	  which	  combines	  On-­‐Cell-­‐
Western	  analysis	  with	  In-­‐Cell-­‐Western	  analysis	  to	  quantify	  cell	  surface-­‐bound	  FGF2-­‐GFP	  
as	  a	  percentage	  of	  total	  protein	  levels	  (Ebert	  et	  al.	  2010).	  	  
Briefly,	  CHO	  and	  HeLa	  S3	  cells	  expressing	  FGF2-­‐GFP	  fusion	  proteins	  were	  grown	  in	  12-­‐
well	   plates	   in	   the	   presence	   of	   doxycycline	   and	   either	   DMSO	   (mock)	   or	   nocodazole.	  
Following	  fixation	  one	  of	  two	  replica	  plates	  was	  directly	  subjected	  to	  antibody	  staining	  
to	  determine	  cell	  surface-­‐bound	  FGF2-­‐GFP	  molecules.	  For	  detection	  of	  the	  total	  GFP-­‐
fluorescence,	  cells	  of	  the	  second	  plate	  were	  permeabilized	  and	  subsequently	  exposed	  
to	   antibody	   staining.	   Since	   fixation	   may	   permeabilize	   cell	   membranes	   to	   a	   minor	  
extent	  resulting	  in	  signals	  of	  intracellular	  FGF2-­‐GFP	  proteins,	  cells	  expressing	  a	  FGF2-­‐
GFP	  mutant	  protein	  (K128,134Q	  R129Q)	  deficient	  in	  heparin-­‐binding	  were	  analyzed	  in	  
parallel.	   In	   order	   to	   rule	   out	   a	   signal	   due	   to	   unspecific	   binding	   of	   antibodies,	  
fluorescence	  derived	  from	  empty	  cells	  (MT)	  was	  subtracted.	  GFP-­‐derived	  signals	  were	  
normalized	  to	  the	  total	  cell	  number,	  which	  was	  determined	  by	  nuclear	  staining	  with	  
Syto-­‐60.	  As	   shown	   in	  Figure	  29,	  FGF2-­‐GFP	  cell	   surface-­‐signals	  of	  nocodazole	   treated	  
CHO	   and	   HeLa	   S3	   cells	   were	   reduced,	   however,	   the	   total	   cell	   number	   and	   thereby	  
total	   expression	   of	   FGF2-­‐GFP	  was	   increased	   under	  mock	   conditions.	   In	   the	   case	   of	  
HeLa	  S3	  cells,	  On-­‐Cell-­‐Western	  derived	  fluorescence	  of	  mock-­‐treated	  cells	  expressing	  
the	   heparin-­‐binding	   mutant	   protein	   was	   strongly	   reduced	   compared	   to	   wild	   type	  
expressing	   cells.	   By	   contrast,	   treating	   cells	   with	   nocodazole	   caused	   similar	   signal	  
intensities	  for	  both	  wild	  type	  and	  heparin-­‐binding	  mutant	  proteins,	  indicating	  that	  the	  
observed	  cell	  surface	  signal	  following	  nocodazole	  treatment	  was	  close	  to	  background	  
levels.	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Figure	  29:	  Analysis	  of	  nocodazole-­‐induced	  effects	  on	  FGF2	  export	  using	  On-­‐Cell-­‐Western.	  HeLa	  S3	  and	  
CHO	  cells	   expressing	  FGF2-­‐GFP	   (WT),	   FGF2-­‐GFP	  K128,134Q	  R129Q	  mutant	  protein	  deficient	   in	  HSPG-­‐
binding	  (Hepa	  Mut)	  or	  no	  fusion	  construct	  (MT)	  were	  grown	  in	  12-­‐well	  plates	  in	  two	  replicates,	  i.e.	  one	  
for	   In-­‐Cell-­‐Western,	   the	   other	   one	   for	   On-­‐Cell-­‐Western.	   Each	   sample	   was	   assayed	   in	   triplicates.	  
Expression	  was	  induced	  with	  doxycycline	  in	  the	  presence	  of	  either	  DMSO	  (mock)	  or	  2	  µM	  nocodazole.	  
Following	   20	   h,	   cells	   were	   fixed	   with	   PFA.	   Only	   cells	   prepared	   for	   In-­‐Cell-­‐Western	   analysis	   were	  
permeabilized	  with	  Triton	  X-­‐100	  and	  samples	  of	  both	  replicates	  were	  subjected	  to	  immunolabeling	  with	  
a	  primary	  antibody	  (rabbit	  anti-­‐GFP)	  followed	  by	  a	  mixture	  of	  secondary	  antibody	  (IR	  dye	  800	  CW	  goat	  
anti-­‐rabbit)	  and	  Syto-­‐60,	   a	  nuclear	   stain.	   Plates	  were	   scanned	  using	   LI-­‐COR	  Odyssey	   infrared	   imaging	  
system.	  
	  
Therefore,	  the	  obtained	  signal	  intensities	  were	  quantitatively	  evaluated	  as	  illustrated	  
in	  Figure	  30.	  While	  secretion	  of	  wild	  type	  FGF2-­‐GFP	  from	  nocodazole-­‐treated	  HeLa	  S3	  
cells	   was	   indeed	   near	   background	   being	   defined	   by	   fluorescence	   of	   the	   heparin-­‐
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increased	   nearly	   2.5-­‐fold.	   On	   the	   contrary,	   CHO	   cells	   showing	   increased	   secretion	  
efficiencies	  were	  not	  affected	  by	  nocodazole.	  
Figure	  30:	  Quantitative	  analysis	  of	  nocodazole-­‐induced	  effects	  on	  FGF2	  export.	  GFP-­‐derived	  antibody	  
signals	   were	   normalized	   to	   cell	   count	   determined	   by	   nuclear	   staining	   with	   Syto-­‐60.	   Signals	   of	   cells	  
expressing	  no	  construct	  were	  defined	  as	  background	  and	  subtracted	  from	  corresponding	  On-­‐Cell-­‐	  and	  
In-­‐Cell-­‐samples,	   respectively.	   Cell	   surface	   signals	   (On-­‐Cell-­‐Western)	   were	   divided	   by	   the	   total	  
GFP-­‐fluorescence	  derived	  from	  permeabilization	  (In-­‐Cell-­‐Western)	  to	  calculate	  the	  percentage	  of	  FGF2	  
on	   the	   surface.	   The	   chart	   represents	   the	   average	   of	   3	   independent	   experiments	   each	   of	   which	  was	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3 DISCUSSION	  
The	   vast	  majority	  of	   secretory	  proteins	  possess	   a	  hydrophobic	   signal	   sequence	   that	  
directs	  their	  entry	  into	  the	  ER/Golgi-­‐mediated	  conventional	  secretory	  pathway	  (Lee	  et	  
al.	   2004).	   However,	   a	   substantial	   number	   of	   extracellular	   proteins	   devoid	   of	  
hydrophobic	   N-­‐terminal	   signal	   peptides	   have	   been	   reported	   that	   are	   guided	   to	   the	  
plasma	   membrane	   by	   an	   ER/Golgi-­‐independent	   mechanism	   (Muesch	   et	   al.	   1990).	  
Therefore,	   neither	   BFA-­‐sensitive	   trafficking	   nor	   ER/Golgi	   typical	   modifications	   have	  
been	   observed	   for	   these	   proteins	   (Baldwin	   and	   Ostergaard	   2001;	   Baldwin	   and	  
Ostergaard	   2002).	   Since	   diverse	   export	   mechanisms	   have	   been	   proposed	   for	   the	  
growing	  number	  of	  unconventionally	  secreted	  proteins,	  they	  are	  broadly	  divided	  into	  
non-­‐vesicular	  and	  vesicular	  pathways	  (Rabouille	  et	  al.	  2012).	  	  
	  
FGF2	  represents	  a	  well-­‐studied	  example	  that	  directly	  traverses	  the	  plasma	  membrane	  
in	  a	  non-­‐vesicular	  way	  (Nickel	  2011).	  Regarding	  this,	  recruitment	  of	  FGF2	  to	  the	  inner	  
leaflet	   of	   the	   plasma	  membrane	   by	   PI(4,5)P2	   has	   been	   shown	   to	   be	   the	   initial	   step	  
(Temmerman	  et	  al.	  2008).	  Subsequent	  export	  neither	  depends	  on	  ATP	  hydrolysis	  nor	  a	  
membrane	   potential	   as	   driving	   force	   (Schafer	   et	   al.	   2004).	   In	   fact,	   PI(4,5)P2-­‐bound	  
FGF2	  directly	  crosses	  the	  plasma	  membrane	  in	  its	  folded	  state	  driven	  by	  the	  affinity	  to	  
extracellular	  HSPGs	   (Backhaus	   et	  al.	  2004;	  Zehe	   et	  al.	  2006;	  Torrado	   et	  al.	  2009).	   In	  
addition	  to	  PI(4,5)P2	  and	  HSPGs,	  phosphorylation	  of	  FGF2	  at	  position	  82	  by	  Tec	  kinase	  
has	  recently	  been	  found	  to	  be	  relevant	  for	  its	  secretion	  (Ebert	  et	  al.	  2010).	  	  
	  
Although	   many	   key	   features	   have	   been	   unraveled	   yet,	   little	   is	   known	   about	   the	  
physical	  mechanism	  of	  FGF2	  translocation	  and	  the	  cellular	  machinery	  involved	  in	  this	  
process.	   Since	   extracellular	   FGF2	   plays	   a	   role	   in	   various	   physiological	   but	   also	  
pathological	   processes,	   including	   tumor	   growth	   and	   invasion,	   interaction	   with	   or	  
modification	   by	   a	   further	   key	   component	   in	   the	   cellular	   export	  machinery,	   like	   Tec	  
kinase,	  represents	  a	  potential	  target	  for	  drug	  design	  and	  clinical	  therapeutic	  strategies.	  
Therefore,	  this	  thesis	  aimed	  to	  investigate	  the	  functional	  role	  of	  FGF2	  phosphorylation	  
on	  a	  molecular	  basis	  with	  respect	  to	  FGF2	  secretion.	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3.1 FGF2-­‐SECRETION-­‐INDUCED	   PROLIFERATION	   DEPENDS	   ON	   TEC	   KINASE	  
ACTIVITY	  
In	   order	   to	   investigate	   Tec	   kinase	   activity	   in	   FGF2	   secretion,	   proliferation	   as	   a	  well-­‐
known	   post-­‐secretion	   function	   was	   used	   as	   read-­‐out.	   The	   most	   direct	   means	   of	  
measuring	   proliferation	   is	   to	   count	   the	   number	   of	   cells	   present	   using,	   e.g.,	   a	   cell-­‐
counter	  or	  flow-­‐cytometry	  based	  methods.	  Therefore,	  cells	  have	  to	  be	  detached	  from	  
the	  surface	  of	  their	  cultivation	  device,	  which	  is	  barely	  possible	  in	  the	  case	  of	  starved	  
cells,	   as	   they	   are	   tightly	   attached.	  Due	   to	   this	   technical	   restriction,	   the	   calorimetric	  
MTT	   assay	   was	   used,	   which	   is	   considered	   to	   be	   an	   alternative	   for	   measuring	  
proliferation	  (Vega-­‐Avila	  and	  Pugsley	  2011).	  Here,	  metabolic	  activity	  of	  mitochondrial	  
dehydrogenases	   in	   living	   cells	   is	  determined	  as	  yellow	  MTT	   is	   reduced	   to	   formazan.	  
This	  purple	  product	  can	  be	  detected	  using	  a	  spectrophotometer.	  As	  a	  model	  system,	  
3T3	  fibroblasts	  cells	  were	  chosen	  since	  this	  cells	  are	  known	  to	  proliferate	  in	  response	  
to	   extracellular	   FGF2	   stimuli	   (Boilly	   et	   al.	   2000).	   For	   the	   purpose	   of	   linking	   FGF2	  
secretion	  and	  Tec	  activity	  in	  this	  experimental	  set-­‐up,	  proliferation	  in	  the	  presence	  of	  
LFM-­‐A13	   was	   measured.	   This	   compound	   specifically	   inhibits	   Tec	   kinase	   activity	   by	  
binding	  to	  the	  catalytic	  pocket	  of	  the	  kinase	  domain.	  LFM-­‐A13	  does	  not	  have	  an	  effect	  
on	  other	  tyrosine	  kinases	  as	  shown	  for	  epidermal	  growth	  factor	  receptor	  kinase,	  HCK,	  
Jak1	  (Janus	  kinase)	  or	  Jak3	  (Mahajan	  et	  al.	  1999).	  A	  first	  hint	  that	  LFM-­‐A13	  treatment	  
impairs	   FGF2-­‐GFP	   export	   form	   HeLa	   cells	   came	   from	   the	   observation	   that	   the	  
secretion	  efficiency	  is	  significantly	  reduced	  in	  the	  presence	  of	  this	  Tec	  inhibitor	  (Ebert	  
et	   al.	   2010).	   In	   order	   to	   further	   corroborate	   these	   findings	   by	   a	   second	   line	   of	  
evidence,	  both	  a	  different	  cell	  line	  and	  read	  out	  were	  used	  in	  this	  study.	  	  
	  
FGF2-­‐GFP-­‐induced	  proliferation	  depends	  on	  Tec	  kinase	  activity	  as	  metabolic	  activity	  of	  
doxycycline-­‐induced	  cells	   treated	  with	   LFM-­‐A13	  was	   significantly	   reduced	  compared	  
with	  mock	  conditions	  (Figure	  7).	  However,	  this	  observation	  does	  not	  reveal	  whether	  
secretion	  is	  affected	  or	  FGF2-­‐induced	  signaling.	  In	  the	  latter	  case,	  LFM-­‐A13	  treatment	  
possibly	  impairs	  components	  of	  either	  receptor	  stimulated	  signaling	  cascades	  or	  FGF2	  
internalization-­‐based	   signaling	   pathways.	   In	   order	   to	   address	   this	   issue,	   cells	   were	  
grown	   in	   presence	   of	   recombinant	   FGF2-­‐GFP	   (Figure	   7).	   Due	   to	   the	   fact	   that	   no	  
significant	  differences	  have	  been	  observed	  between	  mock	  and	  LFM-­‐A13	  treated	  cells,	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the	   kinase	   inhibitor	   does	   not	   impair	   post-­‐secretion	   features	   of	   FGF2	   or	   subsequent	  
intracellular	   signaling.	   Therefore,	   it	   can	   be	   concluded	   that	   FGF2-­‐secretion-­‐induced	  
proliferation	   of	   3T3	   fibroblasts	   depends	   on	   Tec	   kinase	   activity.	   This	   result	   clearly	  
supports	  the	   initial	   findings	  of	  Ebert	  et	  al.	   (2010)	  that	  Tec	  kinase	   is	   involved	   in	  FGF2	  
secretion.	  
	  
3.2 INTRACELLULAR	  LOCALIZATION	  OF	  PHOSPHORYLATED	  FGF2	  
The	   observation	   that	   Tec	   kinase	   activity	   is	   required	   for	   efficient	   secretion	   of	   FGF2	  
raised	   the	   question	   of	   how	   this	   is	   linked	   to	   its	   phosphorylation.	   So	   far,	   it	   has	   been	  
demonstrated	  that	  Tec	  phosphorylates	  FGF2	  on	  tyrosine	  82	  in	  vivo	  (Ebert	  et	  al.	  2010).	  
However,	  whether	   FGF2	   is	   transiently	   phosphorylated	   in	   the	   cytoplasm	   or	  whether	  
phosphorylation	  still	  remains	  in	  the	  extracellular	  space	  is	  currently	  unclear.	  In	  order	  to	  
address	   this	   issue,	   a	   site-­‐specific	   phospho-­‐antibody	   was	   generated	   that	   selectively	  
recognizes	  phosphorylated	  tyrosine	  82.	  This	  residue	  was	  first	  identified	  by	  an	  in	  vitro	  
kinase	  assay	   combined	  with	  mass	   spectrometric	   analysis	   and	   verified	  by	  mutational	  
analysis	  (Ebert	  et	  al.	  2010).	  
	  
Based	   on	   the	   tertiary	   structure	   and	   antigenicity	   predictions,	   a	   peptide	   including	  
tyrosine	  82	  was	  selected,	  synthesized	  and	  used	  for	   immunization	  (Table	  1).	   In	  ELISA,	  
both	  antiserums	  reacted	  with	  the	  ovalbumin-­‐coupled	  phosphopeptide	  indicating	  that	  
phosphopeptide-­‐immunization	  led	  to	  production	  of	  FGF2-­‐specific	  phospho-­‐antibodies	  
(α-­‐pY82;	   Figure	   10).	   Since	   the	   peptide	   antibody	   was	   intended	   to	   detect	   in	   vivo	  
phosphorylated	   FGF2,	   applying	   two-­‐step	   affinity	   purification	   reduced	   the	   risk	   of	  
contaminating	   proteins	   –	   and	   antibodies	   detecting	   non-­‐phosphorylated	   FGF2	   in	  
particular.	  The	  specificity	  of	  α-­‐pY82	  obtained	  after	  purification	  was	  determined	  by	  Dot	  
blot	   analysis	   (Figure	   11).	   Here,	   specific	   binding	   to	   the	   antigenic	   phosphopeptide	   as	  
observed	   for	   the	  corresponding	  serum	  was	  confirmed.	  Furthermore,	   cross	   reactivity	  
was	   examined	   by	   using	   a	   non-­‐phosphopeptide,	   a	   phosphomimetic	   peptide,	   a	   non-­‐
related	  phosphopeptide	   and	   recombinant	   FGF2.	  Although	   cross	   reactivity	   to	   certain	  
phosphorylated	   proteins	   as	   observed	   for	   Tec	   kinase	  might	   be	   possible,	   α-­‐pY82	  was	  
shown	   to	   be	   highly	   specific	   to	   discriminate	   between	   phosphorylated	   and	   non-­‐
phosphorylated	  FGF2	  (Figure	  11C	  and	  Figure	  12).	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Strikingly,	   the	   polyclonal	   antibody	   raised	   against	   the	   entire	   FGF2-­‐molecule	   did	   not	  
detect	   the	   phosphopeptide	   in	   Dot	   blot	   experiments	   indicating	   that	   this	   sequence	  
comprises	  a	   less-­‐preferred	  epitope	  (Figure	  11C).	  This	  might	  be	  explained	  by	  the	  fact	  
that	  two	  amino	  acids	  (L83	  and	  M85)	  in	  close	  proximity	  to	  tyrosine	  82	  are	  buried	  in	  the	  
protein	  interior	  (Figure	  9).	  Even	  though	  most	  suitable	  antigenic	  epitopes	  represent	  a	  
hydrophilic,	   flexible	   and	   surface	   oriented	   region,	   these	   buried	   residues	   were	  
unavoidable	   in	   the	   peptide	   sequence	   as	   modified	   residues	   of	   interest	   are	   highly	  
recommended	   to	   be	   in	   the	   middle	   of	   immunogenic	   peptides	   (Trier	   et	   al.	   2012).	  
Regarding	   this,	   an	   antibody	  was	   generated	  with	   a	   continuous	  but,	  most	   likely,	   less-­‐
preferred	  and	  linear	  epitope.	  The	  latter	  assumption	  might	  be	  supported	  by	  the	  finding	  
that	   phosphorylated	   full-­‐length	   FGF2-­‐GFP	   in	   its	   possibly	   folded	   conformation	   was	  
better	  detected	  by	  the	  commercial	  phosphotyrosine	  antibody	  than	  by	  α-­‐pY82	  (Figure	  
12).	   By	   contrast,	   due	   to	   the	   stronger	   immunoreactivity	   against	   His-­‐FGF2	   that	   was	  
incubated	   with	   Tec	   kinase,	   it	   could	   be	   concluded	   that	   α-­‐pY82	   has	   a	   much	   more	  
pronounced	  affinity	  to	  phosphorylated	  FGF2.	  Taken	  together,	  a	  site-­‐specific	  phospho-­‐	  
antibody	  was	  generated	   in	  this	  work	  proving	  Tec-­‐mediated	  phosphorylation	  of	  FGF2	  
as	  demonstrated	  by	  Ebert	  et	  al.	  (2010)	  using	  radiolabeling.	  
	  
Since	  a	  good	  accessibility,	  possibly	  as	  a	  linear	  epitope,	  was	  found	  to	  be	  a	  prerequisite,	  
phosphorylation	  of	  non-­‐GFP	  tagged	  FGF2	  in	  vivo	  was	  analyzed	  under	  denaturing	  SDS-­‐
PAGE	  conditions.	  Employing	  the	  well-­‐established	  biotinylation	  assay	  (Zehe	  et	  al.	  2006;	  
Seelenmeyer	   et	   al.	   2008),	   substantial	   amounts	   of	   FGF2	   were	   found	   in	   both	   the	  
intracellular	  and	  the	  extracellular	  fraction	  (Figure	  13).	  Even	  though	  α-­‐pY82	  was	  shown	  
to	   be	   highly	   valuable	   in	   the	   context	   of	   biochemical	   experiments	   investigating	  
considerable	  amounts	  of	  phosphorylated	  FGF2,	  α-­‐pY82	  was	  not	   sensitive	  enough	   to	  
detect	   phosphorylated	   FGF2	   in	   vivo.	   Due	   to	   the	   non-­‐inducible	   but	   constitutive	  
secretion	  characteristic	  of	  FGF2,	  only	  a	  small	  portion	  of	  FGF2	  might	  be	  phosphorylated	  
at	   a	   given	   time	   in	   living	   cells	   and,	   thus,	   none	   of	   both	   pools	   are	   homogenously	  
phosphorylated.	  	  
	  
However,	   Ebert	   et	   al.	   (2010)	   clearly	   demonstrated	   phosphorylation	   of	   FGF2	   on	  
tyrosine	  82	  in	  vivo	  using	  radioactive	  labeling.	  In	  order	  to	  still	  reveal	  the	  localization	  of	  
phosphorylated	   FGF2,	   the	   radiolabeling-­‐strategy	   was	   adopted;	   however	   in	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combination	   with	   separation	   of	   both	   intra-­‐	   and	   extracellular	   FGF2	   populations.	  
Extracellular	  FGF2-­‐GFP	  was	  captured	  after	  heparin	  elution.	  The	   remaining	  FGF2-­‐GFP	  
was	  defined	  as	   intracellular.	  After	  analyzing	  both	   fractions	  by	  phosphoimaging,	  only	  
intracellular	   FGF2-­‐GFP	   was	   found	   to	   be	   phosphorylated	   (Figure	   15).	   This	   pool	   of	  
intracellular	  FGF2-­‐GFP	  was	  much	  more	  pronounced	  than	  cell	  surface-­‐bound	  material	  
indicating	   a	   concentration-­‐dependent	   lack	   of	   phospho-­‐signals	   derived	   from	   cell-­‐
surface	   bound	   FGF2.	  However,	   in	   a	   previous	   attempt	   to	   quantify	   the	   proportion	   of	  
extracellular	   FGF2,	   it	   has	   been	   demonstrated	   that	   ≈10%	   of	   the	   total	   FGF2-­‐GFP	  
population	  is	  associated	  with	  cell	  surfaces	  (Zehe	  et	  al.	  2006).	  Assuming	  that	  exclusively	  
phosphorylated	   FGF2	   molecules	   accumulate	   in	   the	   extracellular	   space,	   it	   can	   be	  
strongly	   suggested	   that	  10%	  of	   the	  observed	   intracellular	  phospho-­‐signal	   is,	  at	   least	  
weakly,	  detectable.	  Therefore,	  it	  cannot	  be	  excluded	  that	  extracellular	  FGF2	  is	  partially	  
phosphorylated	  but	   a	   homogenous	  phosphorylation	  of	   cell-­‐surface	  bound	   FGF2	   can	  
virtually	  be	  ruled	  out.	  	  
	  
3.3 PHOSPHORYLATION	   IS	   NOT	   A	   PREREQUISITE	   FOR	   EXTRACELLULAR	  
PROPERTIES	  OF	  FGF2	  
In	  order	  to	  examine	  the	  impact	  of	  FGF2	  phosphorylation	  on	  the	  molecular	  mechanism	  
of	   FGF2	   secretion,	   a	   phosphotyrosine-­‐mimicking	   mutant	   protein	   was	   introduced.	  
Using	   an	   amber	   suppressor	   technology,	  p-­‐carboxylmethylphenylalanine	   (pCMF)	  was	  
incorporated	  in	  position	  82	  of	  FGF2	  (Xie	  et	  al.	  2007;	  Young	  et	  al.	  2010).	  This	  unnatural	  
amino	  acid	  is	  composed	  of	  a	  modified	  phenylalanine	  containing	  a	  carboxyl-­‐side	  chain	  
with	   a	   negative	   charge	   similar	   to	   that	   of	   phosphotyrosine.	   Since	   both	   carboxyl-­‐
oxygens	   spatially	   overlap	  with	   at	   least	   two	   oxygen	   atoms	   of	   the	   phosphate	   group,	  
pCMF	   substitution	   represents	   a	   better	   non-­‐hydrolyzable	   phosphotyrosine	   mimetic	  
than	  the	  commonly	  used	  glutamate.	  	  
Due	   to	   the	   fact	   that	   FGF2	   phosphorylation	   is	   not	   a	   prerequisite	   for	   extracellular	  
localization,	  the	  question	  was	  addressed	  whether	  dephosphorylation	  is	  a	  prerequisite	  
for	  extracellular	   features.	  When	  analyzing	  binding	  properties	   to	  HSPGs	  by	  FACS	  and	  
confocal	  microscopy,	   similar	  binding	  efficiencies	  of	  wild	   type	  FGF2	  and	  both	  mutant	  
proteins	   (Y82pCMF	   and	   Y82F)	   were	   observed	   (Figure	   16).	   Similar	   effects	   were	   also	  
found	  by	  monitoring	  the	  activation	  of	  intracellular	  signaling	  using	  metabolic	  activity	  as	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indicator	   for	   proliferation	   (Figure	   17).	   These	   findings	   led	   to	   the	   conclusion	   that	  
phosphorylation	   does	   not	   interfere	   with	   extracellular	   properties	   of	   FGF2.	  
Furthermore,	   the	   obtained	   results	   additionally	   provide	   information	   about	   the	  
structural	   integrity	   of	   FGF2.	   Mutations	   can,	   sometimes,	   change	   the	   structure	   of	  
proteins	  and	  these	  alterations	  can	  impair	  their	  biological	  characteristics.	  With	  regard	  
to	  heparin	  binding,	  it	  has	  been	  shown	  that	  the	  binding	  efficiency	  of	  urea-­‐treated	  and	  
thus	  unfolded	  FGF2	  was	  reduced	  in	  a	  dose-­‐dependent	  manner	  (Torrado	  et	  al.	  2009).	  
Since	  none	  of	  both	  mutant	  proteins	   tested	  showed	  an	   impaired	  binding	  behavior,	   it	  
can	   be	   assumed	   that	   FGF2	   containing	   the	   unnatural	   amino	   acid	   pCMF	   as	   well	   as	  
phenylalanine	  are	  properly	  folded.	  	  
Taken	   together,	   incorporation	   of	   pCMF	   does	   not	   affect	   the	   folding	   as	  well	   as	   post-­‐
secretion	  properties	  of	  FGF2.	  Therefore,	   it	  can	  be	  concluded	  that	  phosphorylation	   is	  
not	  a	  prerequisite	  for	  but	  also	  does	  not	  interfere	  with	  extracellular	  properties	  of	  FGF2.	  
	  
3.4 PI(4,5)P2-­‐DEPENDENT	  OLIGOMERIZATION	  AND	  MEMBRANE	  ACTIVITY	  OF	  FGF2	  
Previously,	  a	  FACS-­‐based	  assay	  has	  been	  established	  to	  characterize	  FGF2	  binding	  to	  
liposomes	   of	   different	   lipid	   composition.	   In	   this	   detailed	   study,	   it	   has	   been	  
demonstrated	  that	  recruitment	  by	  PI(4,5)P2	  to	  the	  inner	  leaflet	  of	  plasma	  membranes	  
is	   the	   initial	   step	   in	   unconventional	   secretion	   of	   FGF2	   (Temmerman	   et	   al.	   2008).	  
Therefore,	  a	  liposome-­‐based	  binding	  assay	  represents	  a	  powerful	  tool	  to	  analyze	  early	  
steps	  of	  export	  in	  an	  in	  vitro	  system.	  	  
	  
Using	   this	   quantitative	   FACS	   analysis,	   binding	   of	   FGF2-­‐GFP-­‐Y82pCMF	   to	   liposomes	  
containing	   PI(4,5)P2	   was	   shown	   to	   be	   reduced	   as	   compared	   to	  wild	   type	   FGF2-­‐GFP	  
(Figure	  19A).	  This	  was	  also	  confirmed	  by	  sedimentation	  of	   liposomes	  combined	  with	  
SDS-­‐PAGE	  analysis	  of	  the	  pelleted	  fraction	  and	  subsequent	  Coomassie	  staining	  (Figure	  
19B).	  In	  contrast	  to	  the	  reduced	  affinity	  shown	  by	  FACS	  and	  sedimentation,	  no	  striking	  
difference	   in	   terms	   of	   binding	   was	   obtained	   by	   flotation	   gradients	   followed	   by	  
SDS-­‐PAGE	   and	   Western	   blot	   analysis.	   Besides	   the	   read-­‐out,	   the	   major	   difference	  
between	   those	  PI(4,5)P2-­‐binding	   analyses	  was	   the	  use	  of	   FGF2	   variant	   forms.	  While	  
GFP-­‐fusion	   proteins	   were	   quantified	   by	   flow-­‐cytometry,	   the	   flotation	   assay	   was	  
performed	   with	   FGF2	   variants	   containing	   no	   GFP-­‐tag.	   Regarding	   secretion,	   a	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difference	   in	   export	   of	   FGF2-­‐GFP	   compared	   to	   non-­‐tagged	   proteins	   has	   also	   been	  
shown.	  Albeit	  both	  FGF2	  proteins	  were	  secreted	  in	  vivo,	  export	  efficiency	  was	  reduced	  
in	   cells	   expressing	   the	   FGF2-­‐GFP	   fusion	   protein	   (Julia	   P.	   Steringer,	   PhD	   thesis).	   This	  
observation	   suggests	   structural	   hindrance	   of	   the	  GFP-­‐tag,	  which	   probably	   results	   in	  
delayed	  processes	  occurring	  at	  the	  membrane.	  Thus,	  FGF2-­‐GFP	  fusion	  proteins	  seem	  
to	  be	  highly	   sensitive	   to	  detect	  differences	   in	  PI(4,5)P2-­‐binding	  between	  a	  wild	   type	  
and	  phosphomimetic	  variant	  form.	  
	  
In	  order	  to	  further	  investigate	  early	  events	  at	  the	  plasma	  membrane,	  liposome	  binding	  
of	  FGF2	  was	  assessed	  by	  flotation	  gradients	  followed	  by	  SDS-­‐PAGE	  under	  denaturing	  
conditions	  and	  Western	  blot	  analysis.	  When	  recruited	  to	  liposomes	  via	  PI(4,5)P2,	  FGF2	  
wild	  type	  was	  shown	  to	  form	  higher	  oligomers	  (Figure	  18).	  Formation	  of	  these	  higher	  
oligomers	  was	  also	  observed	   for	  both	  FGF2-­‐Y82pCMF	  and	  FGF2-­‐Y82A.	  As	  shown	   for	  
wild	   type	   FGF2,	   this	   was	   absolutely	   dependent	   on	   recruiting	   FGF2	   to	   PI(4,5)P2-­‐
containing	   liposomes	   since	   oligomerization	   in	   the	   absence	  of	   this	   lipid	  was	   virtually	  
non-­‐existent.	   Previous	   experimental	   evidence	   already	   exhibited	   PI(4,5)P2-­‐induced	  
oligomerization	   of	  wild	   type	   FGF2	   that	   required	   a	   liposome	  background	   resembling	  
plasma	  membranes	  (Julia	  P.	  Steringer,	  PhD	  thesis).	  In	  contrast	  to	  these	  data	  obtained	  
by	   sedimentation	   of	   FGF2-­‐tethered	   liposomes,	   flotation	   gradients	   as	   described	   by	  
Weber	   et	   al.	   (1998)	   were	   performed	   in	   this	   thesis.	   The	   advantage	   of	   flotation	  
gradients	   over	   previously	   shown	   sedimentation	   experiments	   is	   clear	   separation	   of	  
liposome-­‐bound	   proteins	   in	   the	   top	   fraction	   from	   unbound	   material	   and	   protein	  
aggregates	   in	   the	   bottom	   fraction.	   Therefore,	   oligomerization	   is	   not	   a	   result	   of	  
unspecific	  protein	  aggregation	  in	  the	  surrounding	  solution	  but	  rather	  a	  highly	  specific	  
process	  occurring	  at	  the	  plasma	  membrane.	  	  
Intriguingly,	   subsequent	   flotation	   studies	   using	   liposomes	   containing	   Ni-­‐NTA	   lipids	  
instead	   of	   PI(4,5)P2	   have	   shown	   that	   not	   only	  membrane	   proximity	   is	   required	   for	  
oligomerization.	   Although	   FGF2	   wild	   type	   and	   FGF2-­‐Y82pCMF	   were	   bound	   to	  
liposomes	  via	  this	  artificial	  membrane	  anchor,	  oligomerization	  was	  drastically	  reduced	  
(Steringer	  et	  al.	  2012).	  In	  conclusion,	  membrane-­‐proximity	  as	  well	  as	  PI(4,5)P2-­‐binding	  
are	  critically	  important	  requirements	  for	  oligomerization.	  Furthermore,	  using	  scanning	  
fluorescence	   cross-­‐correlation	   spectroscopy	   and	   cryo-­‐electron	  microscopy	   PI(4,5)P2-­‐
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observed	  (Steringer	  et	  al.	  2012;	   Julia	  P.	  Steringer,	  PhD	  thesis).	  Combining	  all	  data,	   it	  
has	   been	   hypothesized	   that	   recruitment	   via	   PI(4,5)P2	   forces	   oligomerization	   by	  
properly	  orienting	  FGF2	  in	  a	  specific	  way	  at	  the	  plasma	  membrane.	  	  
	  
It	  has	  been	  further	  speculated	  that	  oligomerization	  leads	  to	  membrane	  insertion	  and	  
formation	  of	  a	   lipidic	  pore	  (Nickel	  2011).	   In	  order	  to	  test	  this	  hypothesis,	  membrane	  
integrity	   in	   the	   presence	   of	   different	   FGF2	   variant	   proteins	   was	   analyzed	   using	   a	  
dequenching-­‐based	   leak-­‐out	   assay.	   Here,	  moderate	  membrane	   activity	   of	  wild	   type	  
FGF2	   was	   observed	   compared	   to	   the	   PI(4,5)P2	   binding-­‐deficient	   mutant	   protein	  
(Figure	   20).	   In	   contrast,	   the	   membrane	   activity	   exerted	   by	   the	   phosphomimetic	  
variant	  form	  of	  FGF2	  was	  drastically	   increased.	  Thus,	  phosphorylation	  of	  tyrosine	  82	  
triggers	   membrane	   insertion,	   which	   leads	   to	   release	   of	   the	   small	   tracer	   molecule	  
carboxyfluorescein.	  Again,	  this	  process	  was	  found	  to	  be	  highly	  dependent	  on	  PI(4,5)P2	  
reconstituted	  in	  plasma	  membrane-­‐like	  liposomes	  while	  recruitment	  by	  a	  Ni-­‐NTA	  lipid	  
in	  a	  phosphatidylcholine	  background	  was	  not	  sufficient	  to	  induce	  membrane	  activity.	  
In	   line,	   using	   a	   transbilayer	   diffusion	   assay,	   Steringer	   et	   al.	   (2012)	   demonstrated	  
PI(4,5)P2-­‐dependent	   redistribution	   of	   lipids	   between	   the	   two	   leaflets	   of	   artificial	  
membranes	  in	  the	  presence	  of	  FGF2.	  Along	  with	  the	  observation	  of	  PI(4,5)P2-­‐induced	  
oligomerization	  at	  plasma	  membranes	  (Figure	  18,	  Steringer	  et	  al.	  2012),	  the	  combined	  
data	  provide	  evidence	  that	  FGF2	  directly	   inserts	   into	  the	  plasma	  membrane	  with	  an	  
oligomer	  being	  the	  pore	  forming	  unit.	  	  
	  
3.5 MICROTUBULE-­‐DEPENDENT	  ACCUMULATION	  OF	  PHOSPHOMIMETIC	  FGF2	  
Absence	  of	  interference	  with	  extracellular	  properties	  but	  increased	  membrane	  activity	  
of	   phosphomimetic	   FGF2	   pointed	   towards	   an	   intracellular	   function	   of	  
phosphorylation.	  Using	  a	  cellular	  system	  based	  on	  HSPG-­‐deficient	  CHO	  745	  cells	  (Zehe	  
et	  al.	  2006)	  provided	  a	  favorable	  opportunity	  to	  exclusively	  examine	  phosphorylation-­‐
dependent	  processes	  of	  FGF2	  occurring	  inside	  cells	  prior	  to	  secretion.	  
When	  conducting	  microinjection	  experiments,	  Cy3-­‐labeled	  FGF2-­‐Y82pCMF	  was	  found	  
to	  accumulate	  near	  or	   at	   the	   inner	   leaflet	  of	   the	  plasma	  membrane	  as	  detected	  by	  
confocal	  microscopy	  and	  TIRF	  (Figure	  22	  and	  23).	  Furthermore,	  phosphomimetic	  FGF2	  
was	  found	  in	  defined	  local	  membrane	  areas	  mainly	  at	  the	  tips	  of	  the	  cell	  (Figure	  23).	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Intriguingly,	   the	   observed	   punctate	   pattern	   was	   not	   found	   to	   be	   a	   spontaneous	  
reaction	   at	   the	  plasma	  membrane	  but	   rather	   a	   time-­‐dependent	  process	   initiated	   in	  
the	  cytoplasm	  of	  the	  cell	  (Figure	  22).	  By	  contrast,	  this	  phenotype	  was	  not	  observed	  for	  
wild	  type	  FGF2	  or	  FGF2-­‐Y82F,	  which	  provided	  evidence	  for	  a	  unique	  phosphorylation-­‐
dependent	  process.	  	  
	  
In	   order	   to	   obtain	   higher	   resolution	   of	   the	   clustered	   structures,	   EM	   analyses	   were	  
employed.	  Since	  several	  protocols	  are	  available,	  an	  adapted	  protocol	  suitable	  for	  only	  
a	   few	   microinjected	   cells	   had	   to	   be	   established	   first.	   Here,	   high-­‐pressure	   freezing	  
followed	   by	   freeze	   substitution	  was	   shown	   to	   provide	   best	   structural	   preservations	  
compared	  to	  a	  progressive	  lowering	  of	  temperature	  technique	  (Figure	  24	  and	  25).	  As	  
microinjected	   cells	   were	   chemically	   prefixed	   in	   both	   approaches,	   rather	   the	  
temperature	  during	  dehydration	  and	  the	  infiltration	  time	  have	  a	  significant	  impact	  on	  
the	   structural	   integrity	   of	   organelles.	   Here,	   freeze-­‐substitution	   was	   carried	   out	   at	   -­‐
90°C.	   Therefore,	   samples	   were	   warmed-­‐up	   only	   after	   dehydration	   reducing	   the	  
occurrence	  of	  ice	  crystals	  within	  these	  samples.	  Moreover,	  it	  has	  been	  shown	  that	  plt-­‐
dehydration	   induces	   shrinkage	   of	   cells	   while	   this	   was	   not	   observed	   upon	   freeze-­‐
substitution	   (Oprins	   et	   al.	   1994).	   Therefore,	   it	   could	   be	   speculated	   whether	   this	  
caused	  such	  ultrastructural	  differences	  observed	  in	  this	  study.	  
Using	   freeze-­‐substitution	   and	   low-­‐temperature	   embedding,	   gold	   particles	   indicating	  
FGF2-­‐Y82pCMF	  were	  primarily	   found	  near	  the	  plasma	  membrane	  (Figure	  26A).	  Even	  
though	   little	   gold	   staining	   was	   observed,	   detection	   of	   FGF2-­‐Y82pCMF	   by	   the	  
polyclonal	   FGF2-­‐antibody	  was	  highly	   specific	   as	  no	   signal	  was	   found	   in	  non-­‐injected	  
cells	   (Figure	  26B).	  Remarkably,	  no	  membranous	  structures	  enclosing	  FGF2-­‐Y82pCMF	  
were	   observed	   indicating	   non-­‐vesicular	   clusters	   (Figure	   26A).	   Of	   note,	   freeze-­‐
substitution	  and	   low	  temperature	  embedding	   in	  Lowicryl	  HM20	  are	  also	  suitable	  for	  
preservation	   of	   lipidic	   structures	   (Voorhout	   et	   al.	   1991).	   However,	   evidence	   of	  
absence	   is	   no	   absence	   of	   evidence.	   For	   this	   reason,	   it	   cannot	   be	   excluded	   that	   the	  
observed	  punctate	  structures	  are	  vesicle-­‐enwrapped,	  even	  though	  the	  findings	  of	  the	  
current	  study	  pointed	  towards	  non-­‐vesicular	  clusters.	  	  
	  
Due	   to	   the	   observed	   time-­‐dependent	   accumulation	   primarily	   at	   defined	   local	  
membrane	   regions,	   it	  was	  assumed	   that	  phosphomimetic	  FGF2	  was	   targeted	   to	   the	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membrane	  by	  directed	  transport.	  In	  the	  present	  study,	  transport	  along	  microtubules	  
was	  indeed	  correlated	  with	  the	  peripheral	  accumulation	  at	  the	  plasma	  membrane	  as	  
examined	   by	   the	  microtubule	   disrupting	   drug	   nocodazole	   (Figure	   27	   and	   28).	   Even	  
though	   punctate	   structures	   were	   still	   observed	   under	   these	   conditions,	   they	   were	  
shifted	  to	  the	  perinuclear	  region	  being	  bigger	  in	  size.	  As	  mammalian	  MTOCs,	  the	  site	  
where	  microtubule	  formation	  begins,	  are	  most	  often	  located	  near	  the	  nucleus	  (Pereira	  
and	   Schiebel	   1997),	   it	   can	   be	   speculated	   that	   disruption	  of	  microtubules	   leads	   to	   a	  
block	   in	   intracellular	   trafficking	   resulting	   in	   oversized	   cluster	   formation	   of	  
phosphomimetic	  FGF2	  in	  the	  perinuclear	  region.	  However,	  as	  to	  whether	  FGF2	  forms	  
multi-­‐protein	   clusters	   or	   whether	   it	   is	   transported	   as	   a	   single	   molecule	   along	  
microtubules	   remains	   unclear.	   Since	   the	   obviously	   smaller	   punctate	   structures	   in	  
mock-­‐treated	  cells	  increase	  in	  the	  perinuclear	  region	  upon	  nocodazole-­‐treatment,	  an	  
alternating	   but	   continuous	   process	   of	   recruiting	   FGF2	   in	   the	   perinuclear	   region	  
followed	  by	  its	  transport	  towards	  the	  cell	  periphery	  could	  be	  assumed.	  	  
	  
Finally,	  the	  observed	  secretion	  defect	  of	  FGF2-­‐GFP	  in	  nocodazole-­‐treated	  HeLa	  S3	  cells	  
further	  corroborated	  the	  hypothesis	  of	  microtubule-­‐dependent	  intracellular	  trafficking	  
(Figure	  29	  and	  30).	  Using	  a	  quantitative	  secretion	  assay	  based	  on	  a	  combined	  In/On-­‐
Cell-­‐Western	   analysis	   (Ebert	   et	   al.	   2010,	   Julia	   P.	   Steringer	   PhD	   thesis),	   the	   export	  
efficiency	  of	  nocodazole-­‐treated	   cells	  was	   shown	   to	  be	   similar	   to	   that	  of	   a	  heparin-­‐
binding	  mutant,	  which	  was	  defined	  as	  background.	  Surprisingly,	  secretion	  of	  FGF2-­‐GFP	  
from	  CHO	  cells	  was	  not	   affected.	   Considering	   the	  dramatically	   increased	  expression	  
and	   secretion	   rate	  observed	   in	  doxycycline-­‐induced	  CHO	  cells	   compared	   to	  HeLa	  S3	  
cells,	   it	   could	   be	   speculated	   that	   the	   over-­‐proportional	   amount	   of	   FGF2	   causes	  
secretion.	  Assuming	  that	  phosphorylation	  initiates	  the	  formation	  of	  FGF2-­‐recruitment-­‐
complexes	  and	  its	  subsequent	  transport	  towards	  the	  cell	  periphery,	  this	  might	  not	  be	  
required	  in	  CHO	  cells	  strongly	  expressing	  FGF2	  fusion	  proteins,	  which	  are	  distributed	  
throughout	  the	  whole	  cytoplasm.	  	  
Taken	   together,	   the	   combined	   data	   provide	   evidence	   that	   phosphorylation	   initiates	  
the	   formation	   of	   recruitment-­‐complexes	   in	   the	   perinuclear	   region	   followed	   by	  
microtubule-­‐based	   transport	   into	   the	   cell	   periphery.	   These	   findings	   thus	   stress	   the	  
importance	   of	   phosphorylation	   as	   a	   regulatory	   element	   within	   the	   secretory	  
machinery	  of	  FGF2.	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3.6 THE	  ROLE	  OF	  PHOSPHORYLATION	  IN	  UNCONVENTIONAL	  SECRETION	  OF	  FGF2	  
FGF2	   refers	   to	   the	   group	   of	   non-­‐vesicular	   exported,	   cytoplasmic	   proteins,	   which	  
directly	   traverse	   the	   plasma	  membrane	   (Rabouille	   et	   al.	   2012).	   Even	   though	  many	  
fundamental	   aspects	   concerning	   a	   direct	  membrane	   translocation	  mechanism	  were	  
elucidated,	   the	   role	   of	   FGF2	   phosphorylation	   within	   the	   secretory	   machinery	   still	  
needs	  to	  be	  unraveled.	  The	  findings	  observed	  in	  this	  study	  as	  well	  as	  previous	  results	  
(Steringer	  et	  al.	  2012)	  provide	  evidence	  that	  phosphorylation	  represents	  a	  regulatory	  
signal	   involved	   in	   intracellular	   trafficking	   and	   subsequent	   insertion	   into	   the	   plasma	  
membrane.	  	  	  
	  
The	   present	   study	   suggests	   that	   phosphorylated	   FGF2	   is	   transported	   along	   the	  
microtubule	  cytoskeleton	  from	  the	  perinuclear	  region	  towards	  the	  cell	  membrane.	  In	  
this	   scenario,	   FGF2	  might	  be	  phosphorylated	   in	   the	  cytoplasm	  by	  Tec.	  Alternatively,	  
FGF2	  phosphorylation	  might	  occur	  at	   the	  plasma	  membrane,	  where	  Tec	  kinases	  are	  
recruited	   via	   the	   PH-­‐domain	   for	   activation	   (Takesono	   et	   al.	   2002).	   Intriguingly,	  
membranes	  are	  at	  least	  not	  a	  prerequisite	  for	  Tec-­‐mediated	  FGF2	  phosphorylation	  as	  
shown	  by	  the	  kinase	  assay	  in	  vitro	  (Figure	  12).	  Since	  ATP	  is	  distributed	  throughout	  the	  
whole	   cytosol	   (Imamura	   et	   al.	   2009),	   it	   can	   be	   speculated	   that	   Tec	   phosphorylates	  
FGF2	  in	  the	  perinuclear	  region	  prior	  to	  its	  transport.	  	  
	  
According	   to	   these	   results,	   phosphorylation	   might	   be	   a	   switch	   enabling	   the	  
microtubule-­‐based	   transport	   of	   FGF2,	  which	   potentially	   involves	   complex-­‐formation	  
with	   translokin	   (Bossard	  et	  al.	  2003;	  Meunier	  et	  al.	  2009).	  This	  protein	   represents	  a	  
linker	  that	  directly	  interacts	  with	  FGF2	  and	  indirectly	  with	  microtubules	  via	  the	  kinesin	  
KIF3A	  (Meunier	  et	  al.	  2009).	  Of	  note,	  these	  direct	  interactions	  would	  further	  reinforce	  
a	  non-­‐vesicular	   transport	   towards	   the	  plasma	  membrane	   (Figure	  26).	   In	   addition	   to	  
anterograde	  trafficking,	  direct	   interactions	  and	  complex	  formation	  of	  translokin	  with	  
FGF2,	  SNX6	  and	  RanBPM	  has	  been	  linked	  to	  nuclear	  translocation	  of	  FGF2.	  Therefore,	  
it	   has	   been	   proposed	   that	   translokin	   is	   an	   adaptor	   protein	   involved	   in	   bidirectional	  
transport	  of	  FGF2	  along	  microtubules	  (Meunier	  et	  al.	  2009).	  So	  far,	  it	  remained	  elusive	  
how	  translokin	  is	  able	  to	  discriminate	  between	  intracellular	  and	  formerly	  extracellular,	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re-­‐cycled	  FGF2.	  Thus,	  phosphorylation	  on	  tyrosine	  82	  might	  be	  a	  recognition	  motif	  for	  
translokin	  resulting	  in	  anterograde	  transport	  and	  subsequent	  secretion	  of	  FGF2.	  
	  
Beside	   this	   promising	   hints	   pointing	   to	   phosphorylation-­‐regulated	   trafficking,	   first	  
experimental	   evidence	   of	   the	   formation	   of	   an	   oligomeric	   structure	   and	   its	  
phosphorylation-­‐stimulated	   membrane	   insertion	   was	   shown	   here.	   Subsequently,	  
detailed	   analysis	   of	   pore	   formation,	   including	   GUV-­‐based	   leak-­‐in	   and	   transbilayer	  
diffusion	   assays,	   confirmed	   this	   observations	   (Steringer	   et	   al.	   2012).	   It	   has	   been	  
suggested	   that	   PI(4,5)P2-­‐induced	   oligomerization	   leads	   to	   formation	   of	   toroidal	  
membrane	  pores	  a	  process	  that	  was	  strongly	  increased	  by	  tyrosine	  phosphorylation	  of	  
FGF2.	  	  
	  
Once	   inserted,	   FGF2	   molecules	   are	   extracted	   from	   the	   membrane	   by	   cell	   surface-­‐
proximal	   HSPGs,	   which	   might	   result	   in	   disassembly	   of	   the	   pore	   (Zehe	   et	   al.	   2006;	  
Steringer	   et	  al.	   2012).	  Regarding	   this,	   a	   reduced	  PI(4,5)P2	  affinity	  of	  phosphorylated	  
FGF2	  observed	  in	  this	  study	  might	  facilitate	  the	  translocation	  triggered	  by	  cell-­‐surface	  
bound	   HSPGs.	   On	   the	   other	   hand,	   assuming	   that	   constitutive	   secretion	   represents	  
only	   a	   basal	   level	   of	   FGF2	   export,	   phosphorylation	   might	   be	   a	   regulatory	   element	  
crucial	  for	  up-­‐regulating	  its	  secretion	  in	  response	  to	  e.g.	  proangiogenic	  signals	  (Nickel	  
2010).	   Even	   though	   PI(4,5)P2	   binding	   was	   reduced,	   phosphorylation	   was	   shown	   to	  
strongly	   increase	   membrane	   insertion	   (Figure	   19,	   Figure	   20).	   Therefore,	   a	   reduced	  
PI(4,5)P2	   affinity	   might	   provide	   evidence	   for	   an	   intrinsic	   protection	   mechanism	   to	  
avoid	   lethal	  perturbance	  of	  the	  membrane	  integrity	  by	  massive	  membrane	   insertion	  
upon	  receiving	  potential	  stimulation	  signals.	  
	  
Since	  FGF2	  in	  the	  extracellular	  space	  is	  at	  least	  not	  homogenously	  phosphorylated	  but	  
membrane	   insertion	   is	   strongly	   increased	  upon	   tyrosine	  phosphorylation,	   a	  puzzling	  
problem	  concerns	   the	  question	  whether	  exclusively	  phosphorylated	  FGF2	  molecules	  
physically	   traverse	   the	   plasma	  membrane.	   In	   a	   first	   scenario,	   phosphorylated	   FGF2	  
might	   exit	   the	   plasma	   membrane	   followed	   by	   its	   dephosphorylation	   in	   the	  
extracellular	   space.	   As	   the	   affinity	   to	   HSPGs	   of	   both	   non-­‐phosphorylated	   and	  
phosphomimetic	  FGF2	  was	  shown	  to	  be	  similar,	  dephosphorylation	  could	  occur	  while	  
bound	   to	   HSPGs.	   Secondly,	   it	   could	   be	   assumed	   that	   membrane	   insertion	   of	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phosphorylated	   FGF2	   molecules	   forming	   a	   pore	   allows	   for	   passing	   of	   non-­‐
phosphorylated	  proteins.	  However,	  as	  shown	  by	  Steringer	  et	  al.	   (2012),	   the	   toroidal	  
pore	   has	   a	   defined	   size	   cutoff	   below	   the	  molecular	   weight	   of	   FGF2	   disproving	   this	  
hypothesis.	   Finally,	   a	   further	   alternative	   could	   be	   pore	   formation	   and	   direct	  
translocation	  of	  phosphorylated	  FGF2	  in	  complex	  with	  non-­‐phosphorylated	  molecules.	  
This	   finally	   would	   also	   result	   in	   release	   and	   extracellular	   accumulation	   of	   a	   non-­‐
homogenously	  phosphorylated	  FGF2	  population.	  	  
	  
Taken	  together,	  the	  current	  study	  provides	  first	  evidence	  for	  microtubule-­‐dependent	  
intracellular	   trafficking	   towards	   the	   cell	   periphery	   induced	   by	   tyrosine	  
phosphorylation	   of	   FGF2.	   At	   the	   plasma	  membrane,	   PI(4,5)P2	   induced	   formation	   of	  
oligomers	   at	   the	   inner	   leaflet	   is	   followed	   by	   their	   membrane	   insertion,	   which	   is	  
strongly	   up-­‐regulated	   by	   phosphorylation	   on	   tyrosine	   82.	   Combining	   all	   data,	   Tec-­‐
mediated	   phosphorylation	   of	   FGF2	   seems	   to	   be	   a	   fundamental	   regulatory	   element	  
involved	   in	   intracellular	   processes,	   thereby	   offering	   an	   excellent	   opportunity	   for	  
modifying	  unconventional	  secretion	  of	  FGF2.	  	  
	  
3.7 FUTURE	  PERSPECTIVES	  
In	   this	   work,	   phosphorylation	   as	   a	   regulatory	   signal	   for	   intracellular	   trafficking	   is	  
proposed.	   In	   order	   to	   confirm	   this	   first	   hint	   by	   a	   second	   line	   of	   evidence,	   live	   cell	  
imaging	   of	   phosphomimetic	   FGF2	   would	   elucidate	   the	   mode	   of	   trafficking	   within	  
HSPG-­‐deficient	  cells.	  So	  far,	  all	  experiments	  were	  performed	  with	  proteins	  coupled	  to	  
Cy3,	   which	   caused	   problems	   with	   laser-­‐induced	   cross-­‐linking	   in	   live-­‐cell	   analysis.	  
Therefore,	   a	   different	   labeling	   dye	   would	   be	   beneficial.	   Furthermore,	   a	   different	  
labeling	   approach	   avoiding	   cysteine	   labeling	   would	   also	   be	   reasonable,	   since	  
preliminary	   data	   point	   to	   oligomerization	   based	   on	   intermolecular	   disulfide-­‐bond	  
formation.	  	  
Such	   a	   labeled	   protein	   would	   then	   allow	   for	   investigations	   on	   secretion	   upon	  
intracellular	  trafficking.	  For	  that	  reason,	  co-­‐cultivation	  of	  microinjected	  CHO-­‐745	  cells	  
with	  a	  wild	  type	  CHO	  cell	  line	  as	  HSPG-­‐donor	  would	  examine	  differences	  in	  secretion	  
efficiencies	   between	   the	   various	   FGF2	   mutant	   proteins.	   Instead	   of	   co-­‐cultivation,	  
heparin	  coated	  cultivation-­‐plates	  would	  also	  mimic	  the	  molecular	  trap	  important	  for	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FGF2	  translocation	  from	  HSPG-­‐deficient	  CHO-­‐745	  cells.	  A	  follow	  up	  analysis	  using	  this	  
system	  could	  aim	   for	  a	  more	  detailed	  understanding	  of	  membrane	   translocation	  by	  
investigating	  microinjected	  FGF2	  variant	   forms	  coupled	  to	  pH	  sensitive	   fluorophores	  
and	   photoactivation	   of	   caged	   PI(4,5)P2	   derivatives	   for	   synchronization	   purposes.	   A	  
second	  alternative	  for	  synchronization	  could	  be	  provided	  by	  the	  “hook	  system”.	  The	  
principal	  of	  this	  method	  is	  that	  microinjected	  FGF2,	  coupled	  to	  a	  streptavidin-­‐binding	  
peptide,	   is	   immobilized	   at	   mitochondria	   by	   a	   biotin-­‐coupled	   mitochondrial	   target	  
protein,	   e.g.	   TOM20.	   Addition	   of	   biotin	   to	   the	   medium	   will	   result	   in	   synchronized	  
transport	  and	  membrane	  translocation.	  
In	  order	  to	  examine	  whether	  phosphorylation	  of	  FGF2	  is	  linked	  to	  translokin-­‐mediated	  
intracellular	  trafficking	  along	  microtubules	  colocalization	  studies	  could	  be	  performed.	  
Moreover,	  transport	  of	  microinjected	  FGF2	  mutant	  proteins	  upon	  down-­‐regulation	  by	  
small	  interfering	  RNAs	  directed	  against	  KiF3A	  as	  well	  as	  translokin	  could	  be	  analyzed.	  
Furthermore,	  pull-­‐down	  experiments	  would	  reveal	  binding	  efficiencies	  of	  FGF2	  variant	  
forms	  and	  translokin.	  
Moreover,	   the	   effect	   of	   phosphorylation	   on	   the	   oligomeric	   state	   and	   membrane	  
insertion	   on	   a	   molecular	   basis	   still	   remain	   elusive.	   This	   could	   be	   investigated	  
employing	   model	   membranes	   such	   as	   GUVs,	   lipidic	   bilayer	   and	   nano	   disks	   using	  
atomic	   force	  microscopy,	  nuclear	  magnetic	   resonance	   spectroscopy,	  EM	  or	   cryo-­‐EM	  
and	   confocal	   microscopy	   as	   read	   out.	   Since	   cysteines	   possibly	   play	   a	   role	   in	  
oligomerization,	   these	   approaches	   could	   be	   combined	   with	   stably	   cross-­‐linking	   the	  
oligomeric	   interface	  of	  FGF2	  variant	   forms.	  Finally,	  a	   liposome-­‐based	   in	  vitro-­‐system	  
could	  give	   crucial	   information	  whether	  phosphorylation	  of	   FGF2	  by	  Tec	  depends	  on	  
their	   recruitment	   to	   the	   plasma	   membrane.	   Replacement	   of	   buffer-­‐enclosing	  
liposomes	   by	   heparin-­‐filled	   model	   membranes	   could	   provide	   a	   minimal	   system	  
allowing	  for	  further	  analysis	  of	  direct	  membrane	  translocation	  of	  FGF2.	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4 MATERIAL	  AND	  METHODS	  
4.1 MATERIAL	  
4.1.1 Chemicals	  and	  consumables	  
Material	   Provider	  
Acetic	  acid	  (CH3COOH)	   Sigma	  Aldrich	  
Acetone	   Zentrallager	  Neuenheimer	  Feld	  
Agar	   Life	  Technologies	  
Agarose	   Life	  Technologies	  
Albumin	  standard	   Pierce,	  Thermo	  Scientific	  
Ammoium	  persulfate	  (APS)	   Carl	  Roth	  
Ampicillin	   Gerbu	  Biotechnik	  
Aqua	  ad	  iniectabilia	   Braun	  
AvantGuard	  Barrier	  Tips	   Light	  Labs	  
Benzamidine	   Sigma	  Aldrich	  
Bovine	  serum	  albumin,	  fatty	  acid	  free	   Roche	  
Bovine	  serum	  albumin,	  fraction	  V	   Carl	  Roth	  
Brilliant	  blue	  G250	   Carl	  Roth	  
Bromphenol	  blue	   Serva	  Electrophoresis	  
Calcium	  Chloride	  (CaCl2)	   J.	  T.	  Baker	  
Calf	  serum	   Biochrom	  
Carrier	   Martin	  Wohlwend	  GmbH	  
Cell	  culture	  dishes	  and	  plates	  
(6-­‐well,	  12-­‐well,	  96-­‐well)	  
Corning	  
Cell	  culture	  plates	  (10	  cm)	   Sarstedt	  
Cell	  culture	  plates	  (15	  cm)	   Nunc	  
Cell	  Dissociation	  Buffer	   Life	  Technologies	  
Centrifugal	  filter	  units	  (Amicon	  ultra)	   Millipore	  
Centrifugal	  filter	  units	  (Vivaspin	  500)	   Satorius	  stedim	  biotech	  
Centrifuge	  bottles	   Beckman	  Instruments	  
Centrifuge	  tubes	   Beckman	  Instruments	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Chloramphenicol	   Carl	  Roth	  
Chloroform	   Sigma	  Aldrich	  
Complete	  (Protease	  Inhibitor	  Cocktail)	   Roche	  
Complete,	  EDTA-­‐free	  (Protease	  Inhibitor	  Cocktail)	   Roche	  
Coomassie	  brilliant	  blue	  R250	   Serva	  Electrophoresis	  
CryoBox	   Nalgene	  
CryoTubes	  Cryo	  S	   Greiner	  bio-­‐one	  
Cuvettes	  (10	  x	  4	  x	  45	  mm)	   Sarstedt	  
Cy3	  Maleimide	  Mono-­‐Reactive	  Dye	   GE	  Healthcare	  
D(+)-­‐Glucose	   Merck	  
D(+)-­‐Sucrose	  p.A.	   Applichem	  
Di-­‐potassium	  hydrogen	  phosphate	  (K2HPO4)	   Grüssing	  
Di-­‐sodiumhydrogenphosphate	  (Na2HPO4)	   J.	  T.	  Baker	  
Dimethyl	  sulfoxide	  (DMSO)	   J.	  T.	  Baker	  
Dithiothreitol	  (DTT)	   Gerbu	  Biotechnik	  
DMEM	   Life	  Technologies	  
DMEM	  without	  phenol	  red	   Life	  Technologies	  
DMEM	  without	  phosphate	   c.c.	  pro	  
DNA	  ladder	  (1kb	  and	  100	  bp)	   New	  England	  Biolabs	  
dNTP-­‐Mix	   Fermentas	  
Doxycycline	   Clontech	  
DPBS	   Life	  Technologies	  
Drain	  disc	  filter	  (10	  mm)	   Whatman	  
EGTA	   Carl	  Roth	  
Ethanol	   Zentrallager	  Neuenheimer	  Feld	  
Ethanol	  p.A.	   Sigma	  Aldrich	  
Ethidium	  bromide	   Carl	  Roth	  
Ethylene	  diamine	  tetraacetate	  (EDTA)	   Applichem	  
FACS	  Clean	  fluid	   Becton	  Dickinson	  
FACS	  Rinse	  fluid	   Becton	  Dickinson	  
Femtotips	  II	   Eppendorf	  
Fetal	  calf	  serum	   Biochrom	  AG	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Fish	  skin	  gelatin	   Sigma	  Aldrich	  
Formvar	   Plano	  
Glass	  distilled	  acetone	   Electron	  Microscopy	  Sciences	  
Glutaraldehyde	   Electron	  Microscopy	  Sciences	  
Glycerol	   Applichem	  
Glycine	   Applichem	  
Glycine	   Sigma	  Aldrich	  
Grids	  (100	  mesh)	   Plano	  
Guanidine	  hydrochloride	   Sigma	  Aldrich	  
Ham´s	  F12	  medium	   Biochrom	  
Heparin	   Sigma-­‐Aldrich	  
Heparin	  Sepharose	  Fast	  Flow	   GE	  Healthcare	  
Heparin	   sodium	   salt	   from	   porcine	   intestinal	  
mucosa	  
Sigma	  Aldrich	  
HEPES	   Carl	  Roth	  
Hexadecen	   Merck	  
HiPrep	  16/10	  Heparin	  FF	  Column	   GE	  Healthcare	  	  
HisTrap	  Fast	  Flow	   GE	  Healthcare	  
HisTrap	  FF	  Column	  5	  ml	   GE	  Healthcare	  	  
Hydrochloric	  acid	   VWR	  Prolabo	  
Imidazole	   Merck	  
Isopropyl-­‐β-­‐D-­‐thiogalactopyranoside	  (IPTG)	   Gerbu	  Biotechnik	  
KOH	   Applichem	  
L-­‐(+)-­‐Arabinose	   Sigma	  Aldrich	  
L-­‐Glutamine	   Biochrom	  AG	  
Lead	  citrate	   Electron	  Microscopy	  Sciences	  
LFM	  A-­‐13	   Calbiochem,	  Millipore	  
Lowicryl	  HM20	   Polysciences	  
Magnesium	  chloride	  (MgCl2)	   Sigma	  Aldrich	  
Methanol	   Zentrallager	  Neuenheimer	  Feld	  
Methanol	  p.A.	   Applichem	  
Microloader	   Eppendorf	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Milk	  powder	   Carl	  Roth	  
MOPS	  SDS	  running	  buffer	   Life	  Technologies	  
Mycoplasma	  removal	  agent	   MP	  Biomedicals	  
Mycoplasma	  removal	  agent	  (MRA)	   MP	  Biomedicals	  
N,N,N´,N´-­‐Tetramethylethylenediamine	  (TEMED)	   Carl	  Roth	  
Needles	   Becton	  Dickinson	  
Nickelsulfate	  hexahydrate	   Applichem	  
Nitrocellulose	  filter	  membrane	  (0.2	  µM)	   Millipore	  
Nitrocellulose	  membrane	  (0.2	  µM)	   Whatman	  
Nocodazole	   Applichem	  
Nonidet	  P40	  (NP-­‐40)	   Roche	  
Nuclepore	  Track-­‐Etch	  Membrane	  (1000nm)	   Whatman	  
NuPAGE	  antioxidant	   Invitrogen	  
Nycodenz	   Nycodenz	  
Odyssey	  blocking	  buffer	   LI-­‐COR	  Biosciences	  
p-­‐Carboxymethyl-­‐L-­‐phenylalanine	  (pCMF)	   ENAMINE	  
PAGE	  ruler	  prestained	  protein	  ladder	   Fermentas	  
Parafilm	  M	   Brand	  
Paraformaldehyde	   Sigma	  Aldrich	  
Paraformaldehyde,	  EM	  Grade	   Electron	  Microscopy	  Sciences	  
PCR	  tubes	   Biozym	  Scientific	  
PD10	  desalting	  column	   GE	  Healthcare	  
Penicillin-­‐Streptomycin	   Biochrom	  
pH	  indicator	  stripes	   Merck	  
Phenylmethylsulfonyl	  fluoride	  (PMSF)	   Roche	  
PhosSTOP	  (Phosphatase	  Inhibitor	  Cocktail)	   Roche	  
PIPES	   Carl	  Roth	  
Pipet	  tips	   Greiner	  bio-­‐one	  
Pipets	  (5	  ml,	  10	  ml,	  25	  ml)	   Sarstedt	  
Poly-­‐prep-­‐chromatography	  columns	   Biorad	  
Potassium	  chloride	  (KCl)	   Applichem	  
Potassium	  dihydrogen	  phosphate	  (KH2PO4)	   Applichem	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Potassium	  hydroxide	  (KOH)	   J.	  T.	  Baker	  
Protein	  A	  Sepharose	  4	  Fast	  Flow	   GE	  Healthcare	  
Protein	  A-­‐gold	  (10	  nm)	   CMC	  Utrecht,	  the	  Netherlands	  
PVDF	  Immobilon-­‐FL	  transfer	  membrane	  (0.45	  µM)	   Millipore	  
Razor	  blade	   Wilkinson	  
Reaction	  tube	  (0.5	  ml,	  1.5	  ml	  and	  2	  ml	  safe	  lock)	   Sarstedt	  
Reaction	  tube	  (1.5	  ml	  safe	  lock)	   Eppendorf	  
Reaction	  tube	  (15	  ml	  and	  50	  ml)	   Greiner	  bio-­‐one	  
Sapphire	  disks	   Martin	  Wohlwend	  GmbH	  
Sheath	  fluid	  for	  FACS	   Becton	  Dickinson	  
Sodium	  azide	   Carl	  Roth	  
Sodium	  chloride	  (NaCl)	   Applichem	  
Sodium	  dodecyl	  sulfate	  (SDS)	   Sigma	  Aldrich	  
Sodium	  hydroxide	  (NaOH)	   Sigma	  Aldrich	  
Spectra/Por	  Dialysis	  Membrane	  (MWCO	  6-­‐8	  kDa)	   Spectrum	  Laboratories	  
Syringe	  filters	  (0.2	  and	  0.4	  µM)	   Carl	  Roth	  
Syringes	  (1	  ml,	  5	  ml,	  10	  ml	  and	  50	  ml)	   Becton	  Dickinson	  
Syto-­‐60	  nuclear	  stain	   Life	  Technologies	  
Tec	  kinase	   Millipore	  
Trichloro	  acetic	  acid	  (TCA)	   Applichem	  
Triethanolamine	   Merck	  
Tris	   (2-­‐carboxyethyl)phosphine	   hydrochloride	  
(TCEP)	  
Sigma	  Aldrich	  
Tris[hydroxymethyl]aminoethane	   Carl	  Roth	  
Triton	  X-­‐100	   Merck	  
Trypan	  blue	   Biochrom	  
Trypsin/EDTA	   Biochrom	  
Trytone	   Carl	  Roth	  
Tween-­‐20	   Carl	  Roth	  
UC	  adaptors	   Gilson	  
Uranyl	  acetate	   Serva	  
UV-­‐Cuvette	  micro	   Brand	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Whatman	  3	  MM	  Paper	   Whatman	  
Xylencyanol	  FF	   Serva	  Electrophoresis	  
Yeast	  extract	   Carl	  Roth	  
α-­‐MEM	   Life	  Technologies	  
α-­‐MEM	  without	  phenol	  red	   Life	  Technologies	  
β-­‐Mercaptoethanol	   Merck	  
µ-­‐dish	  35mm,	  high	  glass	  bottom	  	   ibidi	  
[32P]	  Phosphoric	  acid	   Hartmann	  Analytic	  GmbH	  
2-­‐Propanol	   Zentrallager	  Neuenheimer	  Feld	  
2-­‐Propanol	  p.A.	   Merck	  
3-­‐(4,5-­‐Dimethyl-­‐2-­‐thiazolyl)-­‐2,5-­‐diphenyl-­‐2H-­‐
tetrazolium	  bromide	  (MTT)	  
Sigma	  Aldrich	  
30%	  acrylamide	  4K	  solution	  37.5:1	   Dg-­‐pharma	  
5,6-­‐Carboxyflurescein	   Sigma	  Aldrich	  




Enzyme	   Provider	  
Pfu	  TURBO	  Polymerase	   Agilent	  
Dpn	  I	   New	  England	  Biolabs	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4.1.3 Technical	  devices	  
Device	   Provider	  
AFS2	   Leica	  
ÄKTAprime	   GE	  Healthcare	  	  
ÄKTApurifier	   GE	  Healthcare	  	  
Analytical	  balance	  CP64	   Sartorius	  
Bacterial	  incubator	  	   Infors	  AG	  
Balance	  Kern	  474	   Kern	  
Centrifuge	  5415	  C	  	   Eppendorf,	  
Centrifuge	  5417	  C	  	   Eppendorf	  
Centrifuge	  5417	  R	  	   Eppendorf	  
Centrifuge	  5804	  R	  	   Eppendorf	  
Centrifuge	  Megafuge	  16R	   Eppendorf	  
Centrifuge	  Megafuge	  40R	   Eppendorf	  
Centrifuge	  Sorvall	  RC	  12BP	   Thermo	  Scientific	  
Confocal	  Microscope	  LSM	  510	   Zeiss	  
Diatome	  ultra	  Diamond	  knife	   Electron	  Microscopy	  Sciences	  
Electron	  microscope	  EM900	   Zeiss	  
Exmire	  microsyringes	  (25	  µl,	  100	  µl,	  250	  µl,	  
500	  µl)	  
ITO	  Corporation	  
FACSCalibur	  	   Becton	  Dickinson	  
FemtoJet	   Eppendorf	  
Freezer	  -­‐20°C	   Bosch	  or	  Liebherr	  
Freezer	  -­‐86°C	  	   Thermo	  Electron	  Cooperation	  
Gas	  tight	  syringes	  (250	  µl,	  1000	  µl)	   Hamilton	  
Gel-­‐Doc	  2000	  System	   Biorad	  	  
High	  Pressure	  Freezing	  Machine	  HPM	  010	   ABRA	  FLUID	  AG	  
High	  pressure	  homogenizer	   Microfluidics	  
Ice	  machine	   Ziegra	  Eismaschinen	  
Incubation	  shaker	  Innova	  4200	   New	  Brunswick	  Scientific	  
Incubation	  shaker	  Innova	  4330	   New	  Brunswick	  Scientific	  
Incubator	  Function	  Line	  T6	  	   Heraeus	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InjectMan	  N12	   Eppendorf	  
JENWAY	  6310	  Spectrophotometer	   Jenway	  
Laboport	  vacuum	  pump	   KNFLab	  
Magnetic	  stirrer	  MR	  Hei-­‐Mix	  L	   Heidolph	  
Megafuge	  16R	   Heraeus,	  Thermo	  Scientific	  
Microcentrifuge	   Neolab	  
Microscope	  Axiovert	  35	  	   Zeiss	  
Microscope	  Axiovert	  40	  C	   Zeiss	  
Microwave	   Panasonic	  or	  Severin	  
Mini	  Extruder	   Avanti	  Polar	  Lipids	  
Mini	  Trans-­‐Blot	  blotting	  system	  	   Biorad	  	  
Mini-­‐Protean	  III	  gel	  system	  	   Biorad	  	  
Modular	   high	   vacuum	   coating	   system	  
(MED020),	  Monitor	  (QSG100),	  Electron	  beam	  
evaporation	  control	  (EVM	  030)	  
Leica	  	  
Multi-­‐pipette	  12-­‐channel	   Gilson	  
Multi-­‐pipette	  8-­‐channel	   Gilson	  
Multitron	  2	  Incubator	   Infors	  HT	  
Nanodrop	  ND-­‐1000	  spectrophotometer	  	   Peqlab,	  Erlangen	  
Neubauer	  chamber	   W.Schreck	  
Novex	  Mini	  gel	  system	   Life	  technologies	  
Odyssey	  Infrared	  Imaging	  System	  	   LI-­‐COR	  Biosciences	  
Osmometer	  Osmomat	  030	   Gonotech	  
PCR	  Thermocycler	  primus	  96	   Peqlab	  
Peristaltic	  pump	   Gilson	  
pH-­‐meter	  766	  Calimatic	  	   Knick	  
Phospho	  imaging	  plate	  BAS-­‐MS	  2040	   Fujifilm	  
phosphor	  imager	  FLA-­‐7000	   Fujifilm	  
Pipetboy	  acu	  	   Integra	  biosciences	  
Pipetman	  P10,	  P20,	  P200,	  P1000	   Gilson	  
Plasma	  cleaner	   Solarus	  
Power	  Pac	  200	  and	  300	   Biorad	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Reax	  top	  vortex	   Heidolph	  
Refrigerator	   Liebherr	  
Resys	  Anthos	  2001	  microplate	  reader	   Anthos	  
Roto-­‐Shake	  Genie	  Rotator	  	   Scientific	  Industries	  
Rotor	  50.2	  Ti	   Beckman	  Coulter	  
Rotor	  SW60	  Ti	   Beckman	  Coulter	  
Rotor	  TFT	  50.38	   Beckman	  Coulter	  
Scanner	  EPSON	  Perfection	  4870	  Photo	   EPSON	  
Shaker	  St5	   Cat	  
Sonication	  bath	  Sonorex	  super	   Bandelin	  Electronic	  
Spectramax	  GEMINI	  XS	  microplate	  reader	   Molecular	  Devices	  
Steri-­‐Cycle	  CO2	  Incubator	   Thermo	  Scientific	  
Sterile	  hood	  HeraSafe	  KS12	   Thermo	  Scientific	  
Thermoblock	   Grant	  Instruments	  
Thermomixer	  comfort	  	   Eppendorf,	  Hamburg	  
TIRF	  MC	  Microscope	  AF7000	   Leica	  
Ultracentrifuge	  Optima	  L-­‐90K	   Beckmann	  Coulter	  
Ultracentrifuge	  Optima	  LE-­‐80K	   Beckmann	  Coulter	  
Ultramicrotome,	  Reichert	  Ultracut	  S	   Leica	  
Ultrapure	  water	  system	  TKA	  xCAD	   TKA	  
Vacuum	  exsiccator	   Duran	  
Water	  bath	  Typ	  1003	   Gesellschaft	  für	  Labortechnik	  
Wide	  Mini-­‐Sub	  Cell	  GT	  System	   Biorad	  
Zetasizer	  1000HS	   Malvern	  Instruments	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4.1.4 Molecular	  biological	  and	  biochemical	  kits	  
Kit	   Provider	  
BCA	  Protein	  Assay	  Kit	   Pierce,	  Thermo	  Scientific	  
EZ-­‐Link	  Sulfo-­‐NHS	  Biotinylation	  Kit	   Pierce,	  Thermo	  Scientific	  
NucleoBond	  PC	  100	  (Midi)	   Machery-­‐Nagel	  
NucleoSpin	  Plasmid	  (Mini)	   Machery-­‐Nagel	  




Primary	  antibody	   Source	   Provider	  
anti-­‐FGF2,	  monoclonal	   mouse	   Sigma-­‐Aldrich,	  clone	  FB-­‐8	  
anti-­‐FGF2,	  polyclonal	   rabbit	   AG	  Nickel,	  BZH,	  Heidelberg	  
anti-­‐GAPDH,	  monoclonal	   mouse	   Ambion,	  clone	  6C5	  
anti-­‐GFP,	  polyclonal	   rabbit	   AG	  Nickel,	  BZH,	  Heidelberg	  




Secondary	  antibody	   Dye	   Source	   Provider	  
anti-­‐rabbit	   Alexa	  Fluor	  488	   goat	   Life	  technologies	  
	   Alexa	  Fluor	  680	   goat	   Life	  technologies	  
	   Allophycocyanin	   goat	   Life	  technologies	  
	   IRDye	  800CW	   goat	   LICOR	  Biosciences	  
anti-­‐mouse	  	   Alexa	  Fluor	  680	   goat	   Life	  technologies	  
	   IRDye	  800CW	   goat	   LICOR	  Biosciences	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4.1.6 Lipids	  
Lipid	   MW	  (Da)	   Source	  
Phosphatidylcholine	   786.64	   Liver,	  bovine	  
Phosphatidylethanolamine	   756.34	   Liver,	  bovine	  
Phosphatidylserine	   824.97	   Brain,	  porcine	  
Phosphatidylinositol	   902.13	   Liver,	  bovine	  
Phosphatidylinositol-­‐4,5-­‐bisphospate	   1096,39	   Brain,	  porcine	  
Sphingomyelin	   710.97	   Egg,	  chicken	  
Cholesterol	   386.36	   Ovine	  wool	  
Rhodamine-­‐PE	  	  
(lissmaine	  rhodamine	  B	  sulfonyl)	  
1249.64	   synthetic	  




Primer	   Sequence	   Created	  by	   Tm	  
FGF2_mut_Y82F-­‐for	   5´GAGTGTGTGCTAACCGTTTCC
TGGCTATGAAG	  ´3	  
Created	  in	  this	  thesis	   66,8	  
FGF2_mut_Y82F-­‐rev	   5´CTTCATAGCCAGGAAACGGTT
AGCACACACTC	  ´3	  
Created	  in	  this	  thesis	   66,8	  
Y-­‐82-­‐A-­‐For	   5´AGTGTGTGCTAACCGTGCCCT
GGCTATGAAGGAAG	  3	  
Andre	  Engling	   78,8	  
Y-­‐82-­‐A-­‐Rev	   5´CTTCCTTCATAGCCAGGGCAC
GGTTAGCACACACT´3	  
Andre	  Engling	   78,8	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4.1.8 Plasmids	  
Plasmid	   Resistance	   Created	  by	  
pQE30-­‐His6-­‐FGF2	  wt	   Ampicillin	   Hans-­‐Michael	  Müller	  
pQE30-­‐His6-­‐FGF2	  Y82F	   Ampicillin	   Created	  in	  this	  thesis	  
pQE30-­‐His6-­‐FGF2	  Y82A	   Ampicillin	   Created	  in	  this	  thesis	  
pQE30-­‐His6-­‐FGF2	  K128Q,	  R129Q	   Ampicillin	   Julia	  P.	  Steringer	  
pET-­‐15b-­‐His6-­‐FGF2-­‐Y82pCMF	   Ampicillin	   Hans-­‐Michael	  Müller	  
pET-­‐15b-­‐His6-­‐FGF2-­‐GFP	  wt	   Ampicillin	   Hans-­‐Michael	  Müller	  
pET-­‐15b-­‐His6-­‐FGF2-­‐GFP-­‐Y82pCMF	   Ampicillin	   Hans-­‐Michael	  Müller	  
pEVOL-­‐pCMF	   Chloramphenicol	   Young	  et	  al.,	  2010	  
	  
	  
4.1.9 	  Bacteria	  and	  media	  
	  
	  
All	   constructs	   coded	   on	   pQE	   vectors	   were	   expressed	   in	   W3110Z1	   cells	   whereas	  
pET-­‐15b-­‐His6-­‐FGF2-­‐GFP	  wt	  was	   expressed	   using	   BL21	   (DE3)	   RIL	   cells.	   BL21	   star	   cells	  
were	   used	   to	   express	   pCMF-­‐incorporated	   proteins.	   For	   DNA	   purification,	   plasmids	  
were	  transformed	  into	  DH5α	  cells.	  
	  
	   	  
Bacterial	  strain	   Genotype	  
DH5α	   E.	   coli	   K12	   F-­‐	   φ80dlacZΔM15	   Δ(lacZYA-­‐argF)	   U169	   recA1	   endA1	  
hsdR17	  (rk-­‐,	  mk+)	  phoA	  supE44	  λ-­‐	  thi-­‐1	  gyrA96	  relA1	  
BL21	  (DE3)	  RIL	   E.	  coli	  B	  F-­‐	  ompT	  hsdS(rB-­‐mB-­‐)	  dcm+	  Tetr	  gal	  λ	   (DE3)	  endA	   I	   [argU	  
ileY	  leuW	  Camr]	  
W3110Z1	   E.	  coli	  K12	  F-­‐	  λ-­‐	  rph-­‐1	  IN(rrnD,	  rrnE)1	  lacIq	  tetR	  Spr	  
BL21	  star	   E.	  coli	  B	  F-­‐	  ompT	  hsdS(rB-­‐mB-­‐)	  gal	  dcm	  rne131	  (DE3)	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Lysogeny	  broth	  (LB)-­‐medium	  	   Tryptone	   10	  g/l	  
Yeast	  extract	  	   10	  g/l	  	   	  
NaCl	   5	  g/l	  
Rich	  LB-­‐medium	  	   Tryptone	   10	  g/l	  
Yeast	  extract	  	   10	  g/l	  	   	  
NaCl	   5	  g/l	  
2x	  YT	  medium	   Tryptone	   16	  g/l	  
Yeast	  extract	  	   10	  g/l	  	   	  
NaCl	   5	  g/l	  
Terrific	  broth	  (TB)-­‐medium	   Tryptone	   12	  g/l	  
Yeast	  extract	  	   24	  g/l	  	   	  
NaCl	   5	  g/l	  
10x	  P-­‐stock	   KH2PO4	   23,1	  g/l	  
K2HPO4	  *	  3	  H2O	   164,3	  g/l	  
	  
	  
All	   frequently	   used	   media	   and	   P-­‐stock	   were	   prepared	   with	   deionized	   water	   and	  
sterilized	  by	  autoclaving	  at	  120°C	  for	  30	  min.	  P-­‐stock	  was	  mixed	  with	  TB-­‐medium	  after	  
autoclaving.	  Medium	  was	   supplied	   with	   Ampicillin	   (100	   µg/ml)	   or	   Chloramphenicol	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4.1.10 Mammalian	  cell	  lines	  and	  media	  
	  
	  
HeLa	  cells	  (ATCC	  Ref	  No.:	  CCL-­‐2.1)	  
HeLa-­‐S3	  cells	  (ATCC	  Ref	  No.:	  CCL-­‐2.2)	  
CHO	  K1	  cells	  (ATCC	  Ref	  No.:	  CCL-­‐61)	  
3T3-­‐Swiss	  albino	  cells	  (ATCC	  Ref	  No.:	  CCL-­‐92)	  
	   	  
Cell	  line	   Expressed	  protein	   Provider	  
HeLaMCAT-­‐TAM2	  	   -­‐	   AG	  Nickel,	  BZH,	  Heidelberg	  
HeLaFGF2-­‐GFP	   FGF2-­‐GFP	   AG	  Nickel,	  BZH,	  Heidelberg	  
HeLa-­‐S3MCAT-­‐TAM2	   -­‐	   AG	  Nickel,	  BZH,	  Heidelberg	  
HeLa-­‐S3FGF2-­‐IRES-­‐GFP	   FGF2	  and	  GFP	   AG	  Nickel,	  BZH,	  Heidelberg	  
HeLa-­‐S3FGF2-­‐GFP	   FGF2-­‐GFP	   AG	  Nickel,	  BZH,	  Heidelberg	  
HeLa-­‐S3FGF2-­‐GFP	  K129Q	  R130Q	  K134Q	   FGF2-­‐GFP-­‐K128,134Q	  
R129Q	  
AG	  Nickel,	  BZH,	  Heidelberg	  
CHO-­‐K1-­‐pgsA-­‐745	   -­‐	   AG	  Nickel,	  BZH,	  Heidelberg	  
CHO-­‐K1MCAT-­‐TAM2	   -­‐	   AG	  Nickel,	  BZH,	  Heidelberg	  
CHO-­‐K1FGF2-­‐GFP	   FGF2-­‐GFP	   AG	  Nickel,	  BZH,	  Heidelberg	  
CHO-­‐K1FGF2-­‐GFP	  K129Q	  R130Q	  K134Q	   FGF2-­‐GFP-­‐K128,134Q	  
R129Q	  
AG	  Nickel,	  BZH,	  Heidelberg	  
Swiss	  3T3	  FGF2-­‐GFP	   FGF2-­‐GFP	   AG	  Nickel,	  BZH,	  Heidelberg	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FCS	  (10%	  v/v)	  
Glutamine	  (2	  mM)	  
Penicillin-­‐Streptomycin	  (0.1	  mg/ml)	  
CHO	   α-­‐MEM:	  
FCS	  (10%	  v/v)	  
Glutamine	  (2	  mM)	  
Penicillin-­‐Streptomycin	  (0.1	  mg/ml)	  
Swiss	  3T3	   D-­‐MEM:	  
CS	  (10%	  v/v)	  
	   Glutamine	  (2	  mM)	  
	   Penicillin-­‐Streptomycin	  (0.1	  mg/ml)	  
	  
	  
4.2 MOLECULAR	  BIOLOGY	  METHODS	  
4.2.1 Site-­‐directed	  mutagenensis	  
Amplification	   reactions	  were	   performed	   in	   a	   PCR	   Thermocycler	   primus	   96	   (Peqlab).	  
Pfu	   polymerase	   was	   used	   for	   high-­‐fidelity	   amplifications	   due	   to	   having	   3’→5’	  
exonuclease	   proofreading	   activity.	   The	   reaction	   mixture	   components	   used	   and	   the	  
amplification	  program	  are	  detailed	  in	  following	  tables:	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In	  order	  to	  cleave	  the	  bacterial	  plasmid	  template,	  PCR-­‐reaction	  mixes	  were	  subjected	  
to	  DpnI	  digestion	  after	  amplification.	  DpnI	  cleaves	  only	  when	  its	  DNA	  restriction	  site	  is	  
methylated.	  
	  
PCR	  product	   18	  µl	  
NEB-­‐buffer	  4	   2	  µl	  
DpnI	   1	  µl	  
	  
	  
4.2.2 Agarose	  gel	  electrophoresis	  
Gels	  containing	  1-­‐1.5%	  (w/v)	  of	  agarose	  in	  1	  x	  TAE	  buffer	  were	  prepared	  according	  to	  
the	   size	   range	   of	   DNA	   fragments.	   Agarose	   was	   solved	   by	   boiling	   the	   mixture	   in	   a	  
microwave	  before	  cooling	  down	  to	  40°C.	  Then,	  ethidium	  bromide	  was	  added	  to	  a	  final	  
Component	   Volume	  per	  reaction	  	  
10x	  reaction	  buffer	   5	  µl	  
dNTP´s	  (10	  mM,	  each	  dNTP)	   1	  µl	  
DNA	  template	   100	  ng	  
Primer	  #1	  (10	  pmol/µl)	   1.3	  µl	  
Primer	  #2	  (10	  pmol/µl)	   1.3	  µl	  
DNA	  polymerase	  	   1	  µl	  
ddH2O	   Ad	  50	  µl	  	  
Total	  reaction	  volume	   50	  µl	  
Number	  of	  Cycles	   Temperature	   Duration	  
1	   95°C	   2	  min	  
	  
20	  
95°C	   30	  sec	  
Primer	  Tm	  -­‐5°C	   30	  sec	  
72°C	   1	  min	  per	  kb	  
1	   72°C	   10	  min	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concentration	  of	   0.5	  mg/ml.	  Before	   loading,	   samples	  were	  mixed	  with	  ¼	   volume	  of	  
5x	  gel-­‐loading	  buffer.	   In	  order	   to	  determine	   the	   fragment	   size,	  10	  µl	  of	  1:10	  diluted	  
molecular	  weight	  markers	   (100	  bp	  and	  1	  kb)	  were	  also	   loaded.	  Electrophoresis	  was	  
performed	   in	  1x	  TAE	  buffer.	  DNA-­‐fragments	  were	   separated	  by	  applying	  a	   constant	  
voltage	  of	  120	  V	  for	  15-­‐25	  min	  according	  to	  the	  fragment	  size.	  Since	  ethidium	  bromide	  
is	  a	  DNA	  intercalator	  with	  UV	  absorbance	  maxima	  at	  300	  and	  360	  nm	  and	  an	  emission	  
maximum	  at	  590	  nm,	  DNA	  was	  finally	  visualized	  by	  exposing	  the	  gel	  to	  UV	  light	  using	  a	  
Gel-­‐Doc	  2000	  imaging	  system	  (BioRad).	  
	  
50x	  TAE	  buffer:	  	   	   242	  g	  	   Tris	  base	  
	   	   	   57.1	  ml	   glacial	  acetic	  acid	  
	   	   	   100	  ml	  	   EDTA	  (0.5	  M,	  pH	  8.0)	  
	   	   	   ad	  1l	   ddH2O	   	  
	  
5	  x	  gel-­‐loading	  buffer	   	   0.25%	  (w/v)	   Bromphenol	  blue	  
	   	   	   0.25%	  (w/v)	   Xylencyanol	  FF	   	  
	   	   	   30%	  (w/v)	   Glycerol	  
	  
	  
4.2.3 Preparation	  of	  calcium	  competent	  E.coli	  cells	  
A	  single	  colony	  of	  a	  suitable	  E.coli	  host	  strain	  was	  grown	  in	  10	  ml	  LB	  over	  night	  in	  an	  
incubation	  shaker	  (37°C,	  180	  rpm).	  Then,	  a	  100	  ml	  culture	  was	  inoculated	  (OD600nm	  =	  
0.05)	  and	  grown	  at	  37	  °C	  with	  shaking.	  The	  OD600nm	  was	  measured	  at	  regular	  intervals.	  
When	  the	  OD600nm	  reached	  0.5,	  cells	  were	  transferred	  into	  an	  ice-­‐bath	  for	  15	  min.	  The	  
following	  steps	  were	  performed	  on	  ice/at	  4°C.	  Cells	  were	  collected	  by	  centrifugation	  
for	  10	  min	  at	  4000xg	  in	  50	  ml	  reaction	  tubes.	  Supernatants	  were	  decanted	  and	  cells	  
were	   gently	   resuspended	   in	   10	   ml	   ice-­‐cold	   CaCl2	   (0.1	  M).	   Following	   a	   second	  
centrifugation	   step	   (10	  min,	  4000xg),	   each	  pellet	  was	   carefully	   resuspended	   in	  2	  ml	  
ice-­‐cold	   storage-­‐buffer	   (0.1	   M	   CaCl2,	   15%	   (w/v)	   glycerol).	   Cells	   were	   dispensed	  
(100	  µl),	  snap	  frozen	  in	  liquid	  nitrogen	  and	  stored	  at	  -­‐80°C.	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4.2.4 Heat-­‐shock	  transformation	  protocol	  of	  competent	  E.	  coli	  cells	  	  
For	  transformation,	  50	  μl	  of	  competent	  cells	  were	  thawed	  on	  ice	  and	  mixed	  with	  50	  ng	  
of	   DNA	   or	   8	   μl	   of	   site	   directed	  mutagenesis-­‐mixture	   after	   DpnI	   digest.	   Tubes	  were	  
incubated	  on	  ice	  for	  30	  min.	  After	  incubation,	  cells	  were	  heat-­‐shocked	  in	  a	  42°C	  water	  
bath	   for	   30	   sec	   and	   immediately	   transferred	  back	   to	   ice	   for	   3	  min.	   Then,	   950	  µl	   of	  
LB-­‐medium	   was	   added	   and	   cells	   were	   incubated	   at	   37°C	   for	   1	   h	   with	   shaking	   at	  
750	  rpm.	  Cells	  were	  centrifuged	  at	  5000xg	  for	  2	  min,	  resuspended	  in	  50	  µl	  LB	  medium,	  
plated	  on	  LB	  agar	  plates	  containing	  the	  appropriate	  antibiotic	  and	  incubated	  at	  37°C.	  
	  
	  
4.2.5 Freezing	  of	  bacterial	  cells	  
For	  long-­‐term	  storage	  900	  µl	  of	  an	  overnight	  culture	  were	  carefully	  mixed	  with	  600	  µl	  




6	  ml	   (Mini)	   or	   100	  ml	   (Midi)	   of	   LB	  medium	   containing	   appropriate	   antibiotics	  were	  
inoculated	  with	  a	  single	  colony	  and	  grown	  overnight	  at	  37°C	  while	  shaking	  (180	  rpm).	  
Cells	  were	  harvested	  by	  centrifugation	  at	  4500xg	  for	  10	  min.	  DNA	  was	  isolated	  using	  
the	   NucleoSpin	   Plasmid	   (Mini)-­‐kit	   according	   to	   the	   manufacture´s	   instructions	   and	  
eluted	  with	  40	  µl	  ddH2O.	  
	  
	  
4.2.7 Determination	  of	  DNA	  concentration	  
To	   determine	   DNA	   concentrations	   the	   NanoDrop	   ND-­‐1000	   Spectrophotometer	  
(NanoDrop	  Technologies)	  was	  used.	  DNA	  absorbance	  was	  measured	  at	  260	  nm	  and	  
protein	  absorbance	  at	  280	  nm.	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4.3 	  BIOCHEMICAL	  METHODS	  
4.3.1 Antibody	  generation	  and	  purification	  
Peptide	  predictions	  
The	  primordial	  approach	  to	  locating	  potentially	  exposed	  protein	  sequences	  comprised	  
hydrophilic	  predictions.	  Here,	  Kyte-­‐Doolittle	  scales	  were	  used	  to	  determine	  the	  degree	  
of	   hydrophobicity	   of	   the	   amino	   acid	   side	   chains.	   Therefore,	   every	   amino	   acid	   was	  
assigned	  a	  hydropathy	  value	  between	  4,5	  and	  -­‐4,5	  (Kyte	  and	  Doolittle	  1982).	  Then,	  a	  
window	   size	   of	   7	   residues	   was	   set,	   which	   determined	   the	   number	   of	   amino	   acids	  
whose	  hydropathy	  scores	  were	  averaged	  and	  assigned	  to	  the	  first	  amino	  acid	   in	  the	  
window.	   Higher	   positive	   values	   correspond	   to	   more	   hydrophobic	   residues,	   while	  
lower	  negative	  values	  represent	  more	  hydrophilic	  peptide	  sequence.	  	  
Surface	   probability	   was	   calculated	   according	   to	   the	   formula	   of	   Emini	   et	   al.	   (1985).	  
Here,	   surface	  accessibility	  values	  at	  position	  n	   in	  a	  given	  amino	  acid	  sequence	  were	  
obtained	  for	  a	  sequential	  hexapeptide	  (n	  -­‐2	  to	  n	  +	  3)	  considering	  the	  fractional	  surface	  
probability	   described	   by	   Janin	   and	   Wodak	   (1978).	   A	   value	   greater	   than	   1	   for	   a	  
hexapeptide	  indicates	  an	  increased	  probability	  for	  being	  found	  on	  the	  surface	  (Emini	  
et	  al.	  1985).	  	  
For	   the	   purpose	   of	   flexibility	   prediction,	   Karplus	   and	   Schulz	   (1985)	   determined	  
flexibility	   indices	   for	   each	   amino	   acid	   on	   the	   basis	   of	   normalized	   B-­‐factors,	   which	  
were	  calculated	  by	  the	  analysis	  of	  Cα-­‐atoms	  of	  31	  known	  protein	  structures.	  In	  order	  
to	  compute	  the	  mobility	  of	  every	  amino	  acid	  at	  position	  n	  within	  the	  FGF2-­‐sequence	  
considering	   neighboring	   amino	   acids,	   the	   defined	   B-­‐values	   were	   used	   in	   a	   sliding-­‐
window	  prediction.	  The	  window	  was	  composed	  of	  a	  stretch	  of	  7	  amino	  acids	  (n	  -­‐3	  to	  
n	  +3),	  which	  was	  shifted	  by	  one	  residue	  at	  a	  time.	  Additionally,	  residues	  were	  assigned	  
with	  coefficients	  dependent	  on	  the	  position	  in	  the	  window.	  Thus,	  the	  weighting	  of	  an	  
amino	  acid	  depends	  on	  its	  distance	  from	  the	  middle	  of	  the	  window.	  Based	  on	  these	  
calculations,	  each	  flexibility	  value	  below	  1	  describes	  a	  rigid	  residue,	  while	  every	  value	  
above	  1	  reflects	  a	  flexible	  residue.	  	  
The	  algorithm	  of	  Jameson	  and	  Wolf	  (1988)	  for	  predicting	  antigenicity	  was	  designed	  
to	  combine	  surface	  probability	  (Emini	  et	  al.	  1985)	  and	  flexibility	  parameters	  (Karplus	  
and	  Schulz	  1985),	  as	  described	  before.	   In	  addition,	  hydropathy	  values	  according	  to	  
Hopp	  and	  Woods	  (1981)	  and	  secondary	  structure	  predictions	  were	  also	  considered	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(Chou	  and	  Fasman	  1978;	  Garnier	  et	  al.	  1978).	  Depending	  on	  its	  value,	  each	  of	  these	  
parameters	  was	  assigned	  to	  defined	  subgroups,	  revalued	  and	  finally	  included	  in	  the	  
antigenicity	  calculation	  on	  a	  proportional	  basis	  according	  Jameson	  and	  Wolf	  (1988).	  	  
Hydropathy	   scores	  were	  determined	  with	   the	  help	  of	  an	  online-­‐tool	   from	  ExPASy	  –	  
SIB	   Bioinformatics	   Resource	   Portal	   (http://web.expasy.org/protscale/).	   All	   other	  
calculations	   were	   performed	   using	   software	   provided	   by	   Peptide	   Specialty	  
Laboratories	   (Heidelberg).	   In	   order	   to	   limit	   the	   cross-­‐reactivity,	   the	   peptide	   was	  
compared	   to	   sequences	   of	   all	   species	   listed	   in	   the	   NCBI-­‐database:	  
http://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE=Proteins.	  
	  
Purification	  of	  phospho-­‐specific	  α-­‐pY82	  
Peptide	   synthesis	   and	   its	   HPLC-­‐purification	   (both	   a	   phospho-­‐	   and	   a	   non-­‐
phosphopeptide),	   immunization	   of	   two	   New	   Zealand	   White	   rabbits	   and	   column	  
preparation	   (1	   ml	   column	   matrix	   coupled	   to	   2	   mg	   peptide	   via	   its	   additional,	  
C-­‐terminally	   attached	   cysteine	   amino	   acid)	   were	   performed	   by	   Peptide	   Specialty	  
Laboratories	  (Heidelberg).	  In	  order	  to	  generate	  a	  phospho-­‐specific	  antibody	  that	  does	  
not	   cross-­‐react	  with	  non-­‐phosphorylated	   forms	  of	   the	  protein,	   two-­‐step	  purification	  
was	   applied.	   A	   non-­‐phosphopeptide	   column	   was	   used	   first	   to	   remove	   antibodies	  
detecting	   the	  non-­‐phospho	  epitope.	  The	  phospho-­‐specific	  antibodies	  were	  collected	  
in	   the	   flow-­‐through.	   This	   fraction	  was	   then	   loaded	   onto	   a	   phosphopeptide-­‐coupled	  
column	  to	  purify	  the	  phosphospecific	  antibodies	  from	  all	  other	  immunoglobulins.	  	  
	  
Antibodies	   were	   purified	   by	   gravity	   flow	   using	   0.5	   ml	   packed	   beads.	   The	   non-­‐
phosphopeptide	   column	   was	   equilibrated	   by	   adding	   4	   x	   5	   ml	   1x	   PBS	   at	   room	  
temperature.	   Then,	   the	   resin	   was	   suspended	   in	   3	   ml	   phosphopeptide	   serum	   and	  
incubated	  for	  90	  min	  at	  room	  temperature	  rotating	  on	  a	  head-­‐over-­‐head	  shaker.	  After	  
beads	   settled	   down,	   serum	   was	   released	   by	   gravity	   flow.	   The	   flow-­‐through	   was	  
collected	   and	   subjected	   to	   a	   pre-­‐equilibrated	   (1x	   PBS)	   column	   filled	   with	  
phosphopeptide-­‐conjugated	   beads	   (0.5	  ml)	   and	   incubated	   for	   15	  min	   rotating	   on	   a	  
head-­‐over-­‐head	   shaker.	   When	   beads	   were	   settled	   down,	   the	   flow	   through	   was	  
collected	   and	   again	   applied	   to	   the	   column.	   The	   procedure	  was	   repeated	   two	  more	  
times.	   After	   washing	   the	   column	   with	   5	   ml,	   10	  ml	   and	   5	   ml	   PBS,	   antibodies	   were	  
eluted	   with	   glycine	   buffer	   (100	   mM	   Glycine	   pH	   2.8,	   adjusted	   with	   HCl).	   For	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neutralization,	  1.5	  ml	  reaction	  tubes	  filled	  with	  8	  µl	  Tris-­‐HCl	  (1.5	  M	  pH	  8.8)	  were	  used	  
to	  collect	  elution	  fractions.	  	  
	  
1x	  PBS	   	   	   140	  mM	   NaCl	  
	   	   	   2.7	  mM	   KCl	  
	   	   	   10	  mM	   Na2HPO4	  
	   	   	   1.8	  mM	   KH2PO4	  
	   	   	   pH	  7.4	   adjust	  with	  HCl	  
	  
	  
4.3.2 Protein	  synthesis	  in	  bacteria	  
30	  ml	  LB	  supplemented	  with	  antibiotics	  were	   inoculated	  with	  20	  µl	  of	  E.coli	  glycerol	  
stocks	   containing	   the	   appropriate	   plasmid.	   Cells	   were	   grown	   at	   37°C	   while	   shaking	  
overnight	  (180	  rpm).	  In	  the	  morning,	  pre-­‐cultures	  were	  diluted	  in	  0.6-­‐1.2	  l	  LB	  medium	  
(OD600nm	  0.2)	  and	  grown	  to	  OD600nm	  of	  2.	  Finally,	  cells	  were	  diluted	  1:10	  in	  6-­‐12	  L	  rich	  
LB	  medium	  (pQE-­‐derived	  plasmids)	  or	  2x	  TY	  (pET-­‐15b-­‐derived	  plasmids).	  The	  OD600nm	  
was	   measured	   at	   regular	   intervals.	   When	   the	   OD600nm	   reached	   1.2-­‐1.5,	   protein	  
synthesis	   was	   induced	   with	   0.5	   mM	   isopropyl	   β-­‐D-­‐1-­‐thiolgalactopyranoside	   (IPTG)	  
final	  concentration.	  Cells	  were	  grown	  overnight	  at	  25°C	  at	  a	  speed	  of	  180	  rpm.	  Finally,	  
cells	  were	  collected	  by	  centrifugation	  for	  20	  min	  at	  4000xg.	  
	  
	  
4.3.3 Protein	  synthesis	  of	  pCMF-­‐incorporated	  proteins	  
pCMF-­‐containing	   proteins	   were	   expressed	   using	   E.coli	   BL21	   star	   cells	   transformed	  
with	   both	   the	   pET-­‐15b	   plasmid	   coding	   for	   pCMF-­‐incorporated	   proteins	   and	   the	  
pEVOL-­‐pCMF	   plasmid	   coding	   for	   pCMF	   specific	   aminoacyl-­‐tRNA	  
synthetase/suppressor	   tRNAopt	   CUA.	  Pre-­‐cultures	  were	  prepared	  as	  described	  before.	  
The	  main	  culture	  was	  grown	   in	  6	   l	  2x	  YT	  medium	  supplemented	  with	  Ampicillin	  and	  
Chloramphenicol.	   For	   production	   of	   pCMF	   incorporated	   proteins,	   0.1%	   (w/v)	  
Arabinose,	  1	  mM	  pCMF	  and	  1	  mM	  IPTG	  were	  added	  to	  the	  medium.	  The	  main	  culture	  
was	  grown	  and	  harvested	  as	  described	  before.	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4.3.4 Protein	  purification	  
All	  recombinant	  FGF2	  variant	  forms	  were	  N-­‐terminally	  fused	  to	  a	  His-­‐tag.	  Therefore,	  
these	  proteins	  were	  purified	  using	  nickel-­‐sepharose	  affinity	   chromatography.	  Owing	  
to	   the	  high	  affinity	  of	  FGF2	   to	  heparin,	   columns	  containing	  heparin-­‐Sepharose	  were	  
subsequently	   used	   to	   improve	   protein	   purity.	   Both	   columns	   were	   connected	   to	   a	  
ÄKTAprime,	  ÄKTApurifier	  system	  or	  a	  peristaltic	  pump.	  
Cell	   pellets	   were	   resuspended	   in	   lysis	   buffer	   (15	   ml/l	   culture).	   Cell	   lysates	   were	  
subsequently	   disrupted	   by	   passing	   them	   5	   times	   through	   a	   high-­‐pressure	  
microfluidizer	   system.	   In	  order	   to	   separate	  soluble	  proteins	   from	  cell	  debris,	   lysates	  
were	   centrifuged	   for	   1	   h	   at	   33,000	   rpm	   (ultracentrifuge	  Optima,	   rotor	   50.2	   Ti)	   and	  
cleared	  lysates	  were	  collected.	  For	  equilibration	  purpose,	  the	  HisTrapFF	  5	  ml	  column	  
was	   first	   rinsed	  with	   25	  ml	   ddH2O	   followed	   by	   25	  ml	   binding	   buffer	   I.	   The	   cleared	  
lysate	  was	  then	   loaded	  onto	  the	  column	  and	  washed	  with	  75	  ml	  binding	  buffer	   I.	   In	  
order	   to	   achieve	   a	   higher	   protein	   purity	   grade,	   the	   column	  was	   additionally	   rinsed	  
with	  50	  ml	  binding	  buffer	  I	  containing	  40	  mM	  Imidazole.	  Finally,	  proteins	  were	  eluted	  
with	  elution	  buffer	  I	  in	  2	  ml	  fractions.	  Next,	  elution	  fractions	  containing	  the	  protein	  of	  
interest	   were	   pooled	   and	   cleared	   from	   remnant	   impurities	   using	   a	   25	   ml	   Heparin	  
column.	  Therefore,	  the	  column	  was	  washed	  with	  80	  ml	  ddH2O	  and	  equilibrated	  with	  
the	  same	  amount	  of	  binding	  buffer	   II.	  After	   loading	   the	  protein-­‐pool,	   columns	  were	  
rinsed	  with	  100	  ml	  binding	  buffer	   II	   and	   finally	  eluted	   in	  2	  ml	   fractions.	  Afterwards,	  
best	   fractions	  were	   pooled	   and	   concentrated	   using	   Amicon	   ultra	   centrifugal	   filters.	  
Finally,	   buffer	   exchange	   to	   storage	   buffer	   was	   performed	   (PD10	   desalting	   colums,	  
according	  to	  manufacture´s	  manual)	  and	  proteins	  were	  snap	  frozen	  in	  liquid	  nitrogen	  
for	  long-­‐term	  storage	  at	  -­‐80°C.	  
	  
Lysis	  buffer:	   	  	   25	  mM	  	   HEPES	  pH	  7.4	  
300	  mM	  	   NaCl	  
2%	  (v/v)	  	   Glycerol	  	  
0.1%	  (w/v)	  	   Triton	  X-­‐100	  
20	  mM	  	   Imidazole,	  	  
1	  mM	  	   PMSF	  
1	  mM	  	   Benzamidine	  
Complete	  EDTA-­‐free	  protease	  inhibitors	  were	  
added	  freshly.	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Binding	  buffer	  I:	   	  	   25	  mM	  	   HEPES	  pH	  7.4	  	  
300	  mM	  	   NaCl	  
2%	  (v/v)	  	   Glycerol	  
20	  mM	  	   Imidazole	  
	  
Elution	  buffer	  I:	   	  	   25	  mM	  	   HEPES	  pH	  7.4	  
300	  mM	  	   NaCl	  
2%	  (v/v)	  	   Glycerol	  	  
300	  mM	   Imidazole	  
	  
Binding	  buffer	  II:	   	   25	  mM	  	   HEPES	  pH	  7.4	  	  
300	  mM	   NaCl	  
2%	  (v/v)	  	   Glycerol	  
	  
Elution	  buffer	  II:	   	   25	  mM	  	   HEPES	  pH	  7.4	  	  
2	  M	  	   NaCl	  
2%	  (v/v)	   Glycerol	  
	  
Storage	  buffer	   	   25	  mM	  	   HEPES	  pH	  7.4	  
150	  mM	  	   KCl	  
2%	  (v/v)	  	   Glycerol	  
	  
	  
4.3.5 Determination	  of	  protein	  concentration	  
NanoDrop	  
In	   order	   to	   determine	   protein	   concentrations	   a	   NanoDrop	   ND-­‐1000	  
Spectrophotometer	   (NanoDrop	   Technologies)	   was	   used.	   Protein	   absorbance	   was	  
measured	   at	   280	   nm.	   Calculations	   are	   based	   upon	   Lambert	   Beers	   Law.	   Molecular	  
weights	  and	  molar	  extinction	  coefficients	  of	  the	  proteins	  were	  estimated	  with	  the	  help	  




Protein	   concentrations	  were	  determined	  using	   the	   colorimetric	   BCA	   assay.	   2.5	  µl	   of	  
each	   sample	   were	   mixed	   with	   47.5	   µl	   ddH2O	   in	   1.5	   ml	   reaction	   tubes.	   Highly	  
concentrated	  samples	  were	  diluted	  1:5	  or	  1:10	  with	  ddH2O.	  Each	  measurement	  was	  
carried	  out	  in	  triplicates.	  The	  working	  solution	  was	  then	  prepared	  using	  a	  ratio	  of	  1:50	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(reagent	  A:	  reagent	  B).	  200	  µl	  of	  this	  solution	  were	  added	  to	  the	  sample	  and	  incubated	  
for	  30	  min	  at	  60	  °C.	  Samples	  were	  cooled	  down	  to	  room	  temperature	  and	  subjected	  to	  
96-­‐well	  plates.	  Subsequently,	  absorbance	  of	  each	  well	  was	  read	  at	  562	  nm	  using	  an	  
ELISA	   reader	   (Resys	   Analytical	   ELISA-­‐Reader).	   In	   order	   to	   determine	   the	   protein	  
amount,	  different	  concentrations	  of	  BSA	  ranging	  from	  0	  to	  20	  ng/µl	  were	  measured	  in	  
parallel.	  By	  plotting	  a	  BSA-­‐standard	  curve	  using	  a	  linear	  fit,	  the	  protein	  amount	  of	  each	  
sample	  was	  estimated.	  	  
	  
	  
4.3.6 Preparation	  of	  labeled	  protein	  probes	  
Proteins	  were	   dissolved	   at	   0.5	  mg/ml	   in	   degassed	   HK	   buffer.	   Following	   addition	   of	  
100	  molar	   excess	   of	   TCEP,	   vials	   were	   flushed	   with	   nitrogen	   gas	   and	   incubated	   for	  
15	  min	  on	  ice.	  In	  the	  meantime,	  one	  pack	  of	  dried	  dye	  (Cy3	  maleimide)	  was	  dissolved	  
in	  50	  µl	  degassed	  HK	  buffer.	  1	  mg	  of	  reduced	  protein	  was	  mixed	  with	  the	  dye	  solution	  
and	   covered	   with	   nitrogen	   gas.	   The	   reaction	   was	   incubated	   at	   4°C	   for	   2	   h	   while	  
rotating	   on	   a	   wheel.	   The	   unconjugated	   dye	   was	   removed	   by	   repeated	   washing	   of	  




Proteins	   were	   separated	   by	   molecular	   weight	   (MW)	   using	   polyacrylamide	   gels	  
containing	  SDS	  as	  denaturing	  agent	  as	  is	  described	  (Laemmli,	  1970).	  The	  composition	  
of	  the	  solutions	  and	  gels	  used	  is	  detailed	  in	  the	  table	  below:	  
	  
Stock	  solution	   10%	  Resolving	  gel	   13%	  Resolving	  gel	   5%	  Stacking	  gel	  
Gel	  buffer	  A	   6.8	  ml	   6.8	  ml	   -­‐	  
Gel	  buffer	  B	   -­‐	   -­‐	   1	  ml	  
Acrylamide/Bis	  30%	  (w/v)	   6.8	  ml	   8.7	  ml	   1.7	  ml	  
10%	  APS	   120	  µl	   120	  µl	   50	  µl	  
TEMED	   20	  µl	   20	  µl	   18	  µl	  
ddH2O	   6.3	  ml	   4.5	  ml	   7.3	  ml	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After	  casting	  the	  resolving	  gel,	  the	  layer	  was	  covered	  with	  2-­‐propanol	  to	  level	  the	  gels	  
top.	  2-­‐propanol	  was	  removed	  from	  the	  polymerized	  resolving	  gel	  before	  the	  stacking	  
gel	   was	   poured	   on	   top.	   Gels	   were	   used	   freshly	   or	   stored	   for	   several	   days	   at	   4°C,	  
wrapped	  with	  wet	  tissues	  (ddH2O)	  to	  avoid	  drying.	  
1x	   SDS	   sample	   buffer	   was	   added	   to	   each	   sample,	   which	   were	   then	   incubated	   for	  
10	  min	   at	   95°C.	   Electrophoresis	   was	   carried	   out	   at	   200	   V,	   using	   a	   Mini-­‐protean-­‐II	  
electrophoresis	   cell	   (Biorad)	   filled	   with	   running	   buffer.	   The	   molecular	   weight	   of	  
proteins	  was	  calculated	  by	  comparison	  of	  their	  migration	  in	  SDS-­‐PAGE	  gels	  with	  that	  
of	  a	  pre-­‐stained	  MW	  marker	  (10-­‐170	  kDa;).	  Once	  proteins	  were	  separated,	  gels	  were	  
stained	  with	  Coomassie	  solution	  or	  applied	  to	  Western	  blotting.	  
	  
	  
Gel	  buffer	  A	  (pH	  8.8)	   	   34.1	  g	   Tris	  base	  
	   	   	   7.5	  ml	   SDS	  (10%	  (w/v))	  
	   	   	   6	  ml	   concentrated	  HCl	  
	   	   	   ad	  250	  ml	  	   ddH2O	  
	  
Gel	  buffer	  B	  (pH	  6.8)	   	   7.6	  g	   Tris	  base	  
	   	   	   5	  ml	   SDS	  (10%	  (w/v))	  
	   	   	   5	  ml	   concentrated	  HCl	  
	   	   	   ad	  30	  ml	  	   ddH2O	  
	  
10x	  Running	  buffer	   	   30.3	  g	   Tris-­‐HCl,	  pH	  8.3	  
	   	   	   144.1	  g	  	   Glycine	  
	   	   	   10	  g	   SDS	  
	   	   	   ad	  1	  l	  	   ddH2O	  
	  
4x	  SDS	  Sample	  buffer	   	   24	  ml	   0.5	  M	  Tris-­‐HCl,	  pH	  6.8	  
	   	   	   4	  g	   SDS	  
	   	   	   12.5	  ml	   Glycerol	  
	   	   	   2.5	  ml	   β-­‐Mercaptoethanol	  
	   	   	   2	  ml	   Bromphenol	  blue	  (1%	  (w/v))	  
	   	   	   ad	  50	  ml	  	   ddH2O	  
	  
	  
4.3.8 Bis-­‐Tis	  gels	  (NuPAGE	  gels)	  
Samples	  were	  prepared	  as	  described	  before	  and	  loaded	  onto	  pre-­‐cast	  4-­‐12%	  gradient	  
gels	  (NuPAGE,	  Life	  Technologies).	  Samples	  were	  separated	  using	  1x	  MOPS	  buffer	  for	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50	  min	   applying	   200	   V.	   Before	   starting	   the	   run,	   deoxidant	  was	   added	   to	   the	   inner	  
chamber.	  
	  
1x	  MOPS	  buffer	   	   50	  mM	   MOPS	  pH	  7.7	  
	   	   	   50	  mM	   Tris	  base	  
	   	   	   0.1%	  (w/v)	  	   SDS	  
	   	   	   1	  mM	  	   EDTA	  
	  
	  
4.3.9 Coomassie	  blue	  staining	  
After	  separation	  in	  a	  polyacrylamide	  gel,	  proteins	  were	  detected	  using	  Coomassie	  blue	  
staining.	  Gels	  were	  incubated	  in	  Coomassie	  staining	  solution	  at	  room	  temperature	  for	  
45-­‐60	  min	  (for	  a	  high	  contrast	  over	  night)	  with	  gentle	  shaking.	  Then,	  gels	  were	  briefly	  
rinsed	  with	  ddH2O	  and	  subjected	  to	  the	  destaining	  solution	  for	  at	  least	  30	  min	  or	  until	  
the	  background	  was	  virtually	  clear.	  
	  
Coomassie-­‐staining	  solution:	  	   50%	  (v/v)	   2-­‐Propanol	  
	   	   	   10%	  (v/v)	   Acetic	  acid	  
0.25%	  (v/v)	   Coomassie	  brilliant	  blue	  R-­‐250	  
	   	   	   0.025%	  (v/v)	   Coomassie	  brilliant	  blue	  G-­‐250	  
	  
Destaining	  solution:	  	   	   30%	  (v/v)	   2-­‐Propanol	  
	   	   	   10%	  (v/v)	   Acetic	  acid	  
	  
	  
4.3.10 Western	  blot	  analysis	  
In	  order	  to	  specifically	  detect	  proteins,	  SDS-­‐PAGE	  separated	  proteins	  were	  transferred	  
to	  PVDF	  membranes	  and	  subsequently	  subjected	  to	  immunostaining.	  
Therefore,	  a	  polivinylidene	  fluoride	  (PVDF)	  membrane	  was	  activated	  with	  100%	  (v/v)	  
Methanol	   for	   1	  min	   and	  placed	   together	  with	   the	  protein-­‐containing	   SDS-­‐gel	   into	   a	  
Mini-­‐Protean	   Cell	   according	   to	   the	   manufacturer’s	   specifications.	   Proteins	   were	  
transferred	   to	   the	   membrane	   in	   Blot-­‐buffer	   at	   100	   V	   for	   70	   min.	   For	  
immunodetection,	   membranes	   were	   first	   blocked	   with	   blocking	   solution	   at	   room	  
temperature	   for	   1	   h	   or	   overnight	   at	   4°C.	   Next,	   proteins	   were	   exposed	   to	   primary	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antibodies	  for	  1	  h	  at	  room	  temperature.	  Primary	  antibody-­‐dilutions	  are	  listed	  below.	  
Following	   four	   washing	   steps	   with	   PBS-­‐T,	   membranes	   were	   incubated	   with	  
appropriate	   secondary	   antibodies	   (1:10,000)	   in	   the	   dark	   for	   30	   min	   at	   room	  
temperature.	  After	  washing	  the	  membrane	  three	  times	  with	  PBS-­‐T	  and	  once	  with	  PBS,	  
signals	  were	  finally	  visualized	  using	  an	  Odyssey	  imaging	  system	  (LI-­‐COR	  biosciences).	  
	  
Specificity	   Source	   Dilution	  
anti-­‐FGF2,	  polyclonal	   rabbit	   1:200	  
anti-­‐GFP	   rabbit	   1:500	  
anti-­‐FGF2,	  monoclonal	   mouse	   1:1000	  
anti-­‐GAPDH,	  monoclonal	   mouse	   1:10,000	  
	  
Blot	  buffer	   	   	   40	  mM	  	   Glycine	  
	   	   	   25	  mM	  	   Tris-­‐HCl	  pH8.4	  
	   	   	   20%	  (v/v)	   Methanol	  
	  
Blocking	  solution	   	   5%	  (w/v)	  	   Milk	  powder	  
	   	   	   1x	  	   PBS	  
	  
PBS-­‐T	   	   	   0.05%	  (w/v)	   Tween	  20	  
	   	   	   1	  x	  	   PBS	  
	  
Primary	  antibody	  solution	   	   3%	  (w/v)	   BSA	  
	   	   	   0.05%	  (w/v)	   Tween-­‐20	  
	   	   	   	   in	  1x	  PBS	  
	  
Secondary	  antibody	  solution	   3%	  (w/v)	   BSA	  
	   	   	   0.05%	  (w/v)	   Tween-­‐20	  
	   	   	   0.01%	  (w/v)	   SDS	  
	   	   	   	   in	  1x	  PBS	  
	  
	  
4.3.11 Dot	  blot	  analysis	  
A	  nitrocellulose	  membrane	  was	  placed	  on	  a	  Whatman	  filter	  paper	  of	  same	  size.	  10	  µl	  
of	   each	   sample	   (diluted	   to	   a	   final	   concentration	   of	   8.2	   µM	  or	   4.1	   µM	  as	   indicated)	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were	   pipetted	   on	   the	  membrane.	  When	   completely	   dried,	  membrane	  was	   blocked	  
and	  stained	  with	  antibodies	  as	  described	  in	  section	  4.3.10.	  	  
	  
	  
4.3.12 Phosphorylation	  of	  FGF2	  in	  vitro	  using	  a	  kinase	  assay	  kit	  
For	   phosphorylation	   purposes,	   a	   Signa	   TECT	   PTK	   Assay	   System	   kit	   was	   used.	   As	  
indicated,	  recombinant	  FGF2-­‐GFP,	  His6-­‐FGF2	  or	  GFP	  were	  diluted	  in	  PTK	  assay	  buffer	  
(55	  µM	  final	  concentration)	  supplemented	  with	  0.1	  mM	  sodium	  vanadate.	  Following	  
incubation	   of	   recombinant	   proteins	   with	   0.1	   µg	   of	   recombinant	   Tec	   Kinase	   in	   the	  
presence	  of	   absence	  of	  20	  µM	  ATP	   for	  30	  min	  at	  30	   °C,	   reactions	  were	   stopped	  by	  
boiling	  samples	   for	  10	  min	  at	  95°C	   in	  SDS	  sample	  buffer.	  Samples	  were	  analyzed	  by	  
SDS-­‐PAGE	  and	  Western	  blot	  analysis	  as	  described	  before.	  
	  
	  
4.3.13 Liposome	  preparation	  
In	  order	  to	  obtain	  a	  stock	  mixture	  of	  3	  mM,	  chloroform	  dissolved	  lipids	  were	  mixed	  in	  
a	  ratio	  listed	  below:	  
	  
Lipid	   PM	  
(mol%)	  
PM	  +	  PIP2	  
(mol%)	  
PC	  +	  Ni	  
(mol%)	  
Phosphatidylcholine	   17.5	   15.5	   97	  
Phosphatidylethanolamine	   9	   9	   -­‐	  
Phosphatidylserine	   5	   5	   -­‐	  
Phosphatidylinositol	   5	   5	   -­‐	  
Sphingomyelin	   12.5	   12.5	   -­‐	  
Cholesterol	   50	   50	   -­‐	  
Rhodamine-­‐PE	   1	   1	   1	  
PI(4,5)P2	  	   -­‐	   2	   -­‐	  
DGS-­‐NTA	  (Ni)	   -­‐	   -­‐	   2	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All	  steps	  were	  performed	  on	  ice.	   Immediately	  after	  taking	  out	  appropriate	  amounts,	  
lipid	  stocks	  were	  covered	  with	  Argon	  in	  order	  to	  prevent	  lipid	  oxidation,	  wrapped	  with	  
parafilm	  and	  stored	  at	  -­‐20°C.	  The	  obtained	  plasma	  membrane	  stock	  mixture	  was	  used	  
freshly	   or	   stored	   at	   -­‐20°C	   also	   covered	   with	   argon	   and	   carefully	   wrapped	   with	  
parafilm.	  
For	   liposome	   preparation,	   round-­‐bottom	   flasks	   were	   washed	   with	   detergent	   and	  
rinsed	   25	   times	  with	  water	   followed	   by	  washing	  with	  methanol	   and	   chloroform	   to	  
remove	  water	  and	  remaining	  detergent.	  Then,	   the	  plasma	  membrane	  stock	  mixture	  
was	   transferred	   and	   dried	   under	   a	   gentle	   nitrogen	   stream	  while	  manually	   rotating	  
flasks.	  Following	  vacuum	  drying	  for	  1.5	  h	   in	  an	  exsiccator,	   lipids	  were	  hydrated	  with	  
filtered	  reconstitution	  buffer	  to	  a	  final	  concentration	  of	  4	  mM	  for	  binding	  experiments	  
and	   8	   mM	   for	   dequenching	   experiments.	   Lipids	   were	   completely	   dissolved	   by	  
alternating	   vortexing	   and	   heating	   in	   a	   water	   bath	   to	   45°C.	   In	   order	   to	   disrupt	   and	  
homogenize	   obtained	   large,	   multilamellar	   vesicles,	   10	   freeze	   (dry-­‐ice-­‐2-­‐
propanol)/thaw	   (45°C	   water	   bath)	   cycles	   were	   applied.	   Following	   21	   size-­‐extrusion	  
steps	   (mini-­‐extruder;	  Avanti	  Polar	  Lipids)	  using	  1000	  nm	  polycarbonate	  membranes,	  
large,	   unilamellar	   vesicles	   were	   analyzed	   by	   dynamic	   light	   scattering	   (Malvern	  
Zetasizer	   Nono	   Series	   Instrument)	   to	   prove	   a	   mean	   diameter	   of	   200-­‐400	   nm.	  
Liposome	  were	  used	  freshly	  or	  stored	  snap	  frozen	  in	  liquid	  nitrogen	  by	  -­‐80°C.	  
	  
Reconstitution	  buffer	   	   25	  mM	  	   HEPES-­‐KOH	  pH	  7.4	  
	   	   	   150	  mM	  	   KCl	  
	   	   	   10%	  (w/v)	   Sucrose	  
	  
	  
4.3.14 Analysis	  of	  protein	  binding	  to	  liposomes	  using	  flow	  cytometry	  
Liposome-­‐binding	   assays	   were	   performed	   as	   described	   by	   Temmerman	   and	   Nickel	  
(2009).	  Therefore,	  25	  µl	  plasma	  membrane	   like	   liposomes	  containing	  PI(4,5)P2	  were	  
blocked	  with	  75	  µl	  1%	  (w/v)	  fatty	  acid	  free	  BSA	  in	  HK	  buffer	  for	  1	  h	  at	  25	  °C.	  Liposomes	  
were	  then	  washed	  with	  1	  ml	  HK-­‐	  buffer	  (8000xg,	  10	  min,	  25	  °C)	  and	  both	  100	  µl	  FGF2-­‐
GFP	   wild	   type	   and	   FGF2-­‐GFP-­‐Y82pCMF	   fusion	   proteins	   at	   different	   protein	  
concentrations	  were	  added.	   Following	   incubation	   for	  1.5	  h	  at	  25°C,	   liposomes	  were	  
again	  washed	  with	  1	  ml	  HK	  buffer,	  resuspended	  in	  300	  µl	  HK	  buffer	  and	  analyzed	  by	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flow	  cytometry.	  Liposomes	  incubate	  with	  equimolar	  amounts	  of	  GFP	  were	  analyzed	  in	  
parallel	  and	  served	  for	  background	  compensation.	  	  
	  
HK	  buffer	   	   	   25	  mM	  	   HEPES-­‐KOH	  pH	  7.4	  
150	  mM	  	   KCl	  
	  
	  
4.3.15 Analysis	  of	  protein	  binding	  to	  liposomes	  by	  sedimentation	  
Liposomes	   resembling	   plasma	   membranes	   were	   prepared	   and	   incubated	   with	  
proteins	   as	   described	   in	   section	   4.3.14.	   After	   incubation,	   liposomes	   were	   washed	  
twice	  with	  HK	   buffer	   (8000xg,	   10	  min,	   25	   °C),	   resuspended	   in	   50	   µl	   1x	   SDS	   sample	  
buffer	  and	  analyzed	  by	  SDS-­‐PAGE	  in	  combination	  with	  Coomassie-­‐staining.	  
	  
	  
4.3.16 Analysis	  of	  protein	  binding	  to	  liposomes	  using	  a	  density	  gradient	  
Liposomes	   resembling	  plasma	  membranes	  were	  prepared	  either	   in	   the	  presence	  or	  
absence	  of	  PI(4,5)P2.	  25	  µl	  liposome-­‐mix	  was	  blocked	  with	  75	  µl	  of	  1%	  (w/v)	  fat-­‐free	  
BSA	  in	  HK	  buffer	  (see	  section	  4.3.14)	  for	  1	  h.	  After	  addition	  of	  1	  ml	  HK	  buffer,	  pelleted	  
liposomes	   (15,000xg,	   10	  min,	   25	   °C)	  were	   resuspended	   in	   100	   µl	   HK	   buffer-­‐diluted	  
proteins	  indicated	  (5	  µM	  final	  concentration).	  Following	  incubation	  for	  90	  min	  at	  25°C,	  
liposomes	   were	   subjected	   to	   a	   Nycodenz	   density	   gradient	   (40:30:0%	   (w/v))	   as	  
described	  in	  Weber	  et	  al.	  (1998).	  Therefore,	  the	  complete	  sample	  (100	  µl)	  were	  mixed	  
with	  100	  µl	  80%	  (w/v)	  Nycodenz	   in	  HK	  buffer	   in	  a	  centrifuge	  tube	  (5	  x	  41	  mm).	  The	  
bottom	  fraction	  was	  covered	  with	  350	  µl	  30	  %	  (w/v)	  Nycodenz	  in	  HK	  buffer	  followed	  
by	  50	  µl	  HK	  buffer.	  For	  separation,	  samples	  were	  centrifuged	  at	  200,000xg	  at	  4°C	  for	  
4	  h	  in	  a	  SW55	  Ti	  rotor	  using	  split	  adapters.	  Finally	  four	  fractions	  (á	  150	  µl)	  were	  taken	  
form	  the	  top	  and	  analyzed	  by	  SDS-­‐PAGE	  and	  subsequent	  Western	  blot	  analysis.	  
	  
	  
4.3.17 Analysis	  of	  membrane	  activity	  using	  a	  dequenching	  assay	  
Liposomes	  were	   reconstituted	   in	  HKC	  buffer	   containing	   the	  membrane-­‐impermeant	  
molecule	   carboxyfluorescein	   to	   a	   final	   concentration	   of	   8	  mM.	   In	   order	   to	   remove	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extraluminal	   dye-­‐excess,	   75	   µl	   liposomes	   were	   washed	   with	   1.4	   ml	   HK	   buffer	   (see	  
section	   4.3.14)	   and	   centrifuged	   at	   15,000xg	   for	   10	   min	   at	   25°C.	   The	   pellet	   was	  
resuspended	  in	  50	  µl	  HK	  buffer	  and	  subjected	  to	  a	  pre-­‐equilibrated	  (HKG	  buffer)	  PD10	  
desalting	   column.	   This	   buffer	   was	   titrated	   with	   glucose	   to	   reach	   iso-­‐osmolality	  
(820	  mOsmol/kg)	   with	   HKC-­‐buffer,	   which	   was	   proved	   with	   a	   freezing	   point	  
osmometer	   (OSMOMAT	   030,	   Gonotec).	   Collected	   PD10-­‐fractions	   (á	   500	  µl)	   of	  
different	   liposome	  preparations	  were	   diluted	   in	  HKG	  buffer	   to	   adapt	   rhodamine-­‐PE	  
signals	  (50	  RFU).	  Rhodamine	  fluorescence	  was	  determined	  using	  a	  fluorescence	  plate	  
reader	  (Gemine	  XS,	  Molecular	  Devices).	  180	  µl	  of	  diluted	  liposomes	  were	  transferred	  
to	  a	  96-­‐well	  plate	  and	  mixed	  with	  20	  µl	  of	  diluted	  protein	   (in	  HK	  buffer,	   1	  µM	   final	  
protein	  concentration)	  using	  a	  multi-­‐channel	  pipette.	  Fluorescence	  was	  measured	  for	  
90	  min	   in	   regular	   intervals	   (2	  min).	  Subsequently,	  Triton	  X-­‐100	  was	  added	   to	  a	   final	  
concentration	   of	   0.2%	   (w/v)	   to	   achieve	   complete	   lysis	   of	   all	   liposomes.	   These	   end-­‐
point	  values	  were	  used	  to	  normalize	  data.	  Liposomes	  incubated	  with	  HK	  buffer	  were	  
analyzed	  in	  parallel	  to	  determine	  background	  signals	  that	  were	  subtracted.	  	  	  
	  
HKC	   	   	   25	  mM	  	   HEPES-­‐KOH	  pH	  7.4	  
100	  mM	  	   KCl	  	  
10%	  (w/v)	  	   Sucrose	  
100	  µM	  	   Carboxyfluorescein	  
	  
HKG	   	   	   25	  mM	  	   HEPES-­‐KOH	  pH	  7.4	  	  
100	  mM	  	   KCl	  
10%	  (w/v)	  	   Sucrose	  
2%	  (w/v)	  	   Glucose	  
	  
	  
4.4 CELL	  BIOLOGICAL	  METHODS	  
4.4.1 Cultivation	  of	  eukaryotic	  cells	  	  
Mammalian	   cells	  were	   plated	   in	   10	   cm	   culture	   plates	   in	   appropriate	  medium.	   Cells	  
were	  incubated	  at	  37°C	  in	  an	  atmosphere	  containing	  5%	  CO2	  and	  at	  96%	  humidity.	  To	  
passage	   adherent	   cell	   lines,	   cells	  were	  washed	  with	   sterile	   PBS	   and	   incubated	  with	  
trypsin	   until	   cells	   were	   detached	   from	   the	   bottom	   of	   the	   plate.	   Finally,	   cells	   were	  
resuspended	  in	  culture	  medium	  and	  seeded	  at	  the	  appropriate	  density.	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4.4.2 Freezing	  of	  eukaryotic	  cells	  
For	  long-­‐term	  storage,	  cells	  were	  detached	  with	  trypsin,	  pelleted	  by	  centrifugation	  at	  
200xg	  for	  3	  min	  and	  resuspended	  in	  10%	  (v/v)	  DMSO	  in	  appropriate	  culture	  medium	  
supplement	   with	   20%	   (v/v)	   FCS.	   In	   order	   to	   allow	   slow	   freezing,	   cryo-­‐tubes	   were	  
stored	  at	  -­‐80°C	  for	  2	  days	  and	  finally	  transferred	  to	  liquid	  nitrogen.	  
	  
	  
4.4.3 Thawing	  of	  eukaryotic	  cells	  
For	   fast	   thawing	  of	   cells,	   cryo-­‐tubes	  were	  heated	   in	  a	  water	  bath.	  When	   frozen	  cell	  
suspension	  became	  liquid,	  it	  was	  transferred	  into	  a	  15	  ml	  reaction	  tube	  containing	  the	  
adequate	   medium.	   Following	   pelleting	   of	   cells	   at	   200xg	   for	   3	   min,	   cells	   were	  
resuspended	  in	  10	  ml	  culture	  medium	  and	  seeded	  in	  6-­‐well	  plates.	  In	  order	  to	  reduce	  
probable	  contaminations	  with	  mycoplasma,	   cells	  were	   incubated	   in	   the	  presence	  of	  
MRA	  (mycoplasma	  removal	  agent)	  at	  a	  concentration	  of	  0.05	  µg/ml	  for	  one	  week.	  
	  
	  
4.4.4 MTT	  assay	  
Stably	   transfected	   swiss	   3T3	   albino	   mouse	   fibroblasts	   were	   seeded	   at	   2-­‐3x104	  
cells/well	   (96-­‐well	  plate)	   in	  DMEM	  medium	  containing	  10%	   (v/v)	  CS.	  After	  5	  h,	   cells	  
were	  starved	  in	  ½	  DMEM	  ½	  F12	  medium	  containing	  0.1%	  (v/v)	  CS	  in	  the	  presence	  or	  
absence	   of	   LFM-­‐A13,	   10%	   (v/v)	   CS,	   3	   µg/ml	  Doxycycline	   or	   FGF2-­‐GFP	   variant	   forms	  
(3	  nM	   final	   concentration)	   as	   indicated.	   Proliferation	   was	   assayed	   following	   a	   48	   h	  
culture	  by	   staining	  with	  100	  µl	  MTT-­‐reagent,	  dissolved	   in	  phenol	   red-­‐free	  DMEM	  at	  
1	  mg/ml.	  After	  2	  h	  of	   incubation,	   formazan	  crystals	  were	  dispersed	   in	  100	  µl	  DMSO	  
and	  absorbance	  was	  measured	  at	  570	  nm.	  Signal	  intensities	  obtained	  from	  a	  reference	  
wavelength	  (630	  nm)	  were	  subtracted.	  	  
	  
4.4.5 Biotinylation	  assay	  
HeLa	  S3	  cells	  expressing	  FGF2	   in	  a	  doxycycline	  dependent	  manner	  were	  grown	  to	  a	  
confluency	   of	   about	   80%	   in	   a	   10	  cm	   plate	   for	   16	   h	   in	   the	   presence	   of	   doxycycline	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(2	  µg/ml).	  Then,	  cells	  were	  washed	  twice	  with	  PBS	  Ca/Mg	  (1x	  PBS,	  0.1	  mM	  CaCl2	  and	  
1	  mM	  MgCl2).	  Following	  incubation	  with	  4	  ml	  Biotin	  buffer	  for	  30	  min	  at	  4°C,	  residual	  
biotin-­‐reagent	  was	  quenched	  by	  washing	  cells	  with	  buffer	  Q	   (PBS	  Ca/Mg	  containing	  
100	  mM	  glycine).	  After	  another	   incubation	   for	  20	  min	   in	  buffer	  Q	  at	  4°C,	  cells	  were	  
washed	  twice	  with	  PBS.	  For	  the	  purpose	  of	  cell	  lysis,	  buffer	  was	  removed	  completely	  
and	   cells	  were	   scraped	   in	   the	   remaining	   fluid.	  Cell	   suspension	  was	   then	   transferred	  
into	  a	  1	  ml	  reaction	  tube	  and	  diluted	  with	  2x	  lysis	  buffer	  in	  a	  ratio	  of	  1:1	  (~150	  µl	  in	  
total).	  Cells	  were	  lysed	  by	  3	  min	  sonication	  in	  a	  sonication	  bath	  followed	  by	  incubation	  
for	  15	  min	  at	  RT,	  vortexing	  every	  5	  min.	  Cell	  debris	  was	  removed	  by	  centrifugation	  at	  
20,000xg	  for	  10	  min	  and	  the	  supernatant	  was	  collected.	  An	  aliquot	  of	  10%	  was	  stored	  
as	   input	  material.	   The	   remaining	   cleared	   lysate	  was	   then	   subjected	   to	   Streptavidin	  
beads,	   using	   30	   µl	   of	   packed	   beads,	   equilibrated	  with	   lysis	   buffer.	   Following	   1	   h	   of	  
incubation	   at	   RT	   under	   constant	   head-­‐over-­‐head	   rolling,	   beads	   were	   pellet	   by	  
centrifugation	  at	  3000xg	  for	  1	  min.	  Supernatant	  was	  collected	  and	  beads	  were	  washed	  
once	  with	  buffer	  W1	  and	  twice	  with	  buffer	  W2.	  After	  the	  last	  washing	  step,	  buffer	  was	  
removed	   carefully	   and	   biotinylated	   proteins	   bound	   to	   the	   streptavidin	   beads	   were	  
eluted	  with	  50	  µl	  2x	  SDS	  sample	  buffer.	  
	  
Biotin	  buffer	   	   	   150	  mM	  	   NaCl	  
10	  mM	  	   Triethanolamine	  
2	  mM	  	   CaCl2	  
0.5	  mg/ml	  Biotin	  was	  added	  freshly	  
	  
2x	  lysis	  buffer	   	   125	  mM	  	   EDTA	  pH	  8	  	  
100	  mM	  	   Tris-­‐HCl	  pH	  7.5	  
0.8%	  (w/v)	  	   Deoxycholat	  
2%	  (w/v)	   NP-­‐40	  
protease	  and	  	  
phosphatase	  inhibitors	  were	  added	  freshly	  
	  
Buffer	  W1	   	   	   62.5	  mM	  	   EDTA	  pH	  8	  
50	  mM	  	   Tris-­‐HCl	  pH	  7.5	  
0.4%	  (w/v)	   Deoxycholat	  
1%	  (w/v)	   NP-­‐40	  
0.5	  M	  	   NaCl	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Buffer	  W2	   	   	   same	  as	  W1,	  except:	  
0.1%	  (w/v)	   NP-­‐40	  
	  
	  
4.4.6 Heparin	  elution	  of	  cell	  surface-­‐bound	  FGF2	  	  
Cells	  were	   grown	   as	   described	   in	   section	   4.4.5.	   Cells	  were	  washed	   twice	  with	   5	  ml	  
HEPES	   buffer.	   Following	   incubation	   with	   10	  ml	   HEPES	   buffer	   containing	   0.5	  mg/ml	  
heparin	  for	  30	  min	  at	  4°C	  with	  gentle	  shaking,	  supernatant	  was	  collected.	  Remaining	  
cells	  were	  washed	  twice	  with	  5	  ml	  HEPES	  buffer	  and	  lysed	  as	  described	  before	  (section	  
4.4.5).	   Extracellular	   FGF2	   in	   the	   collected	   supernatant	   (10	  ml)	  was	   concentrated	   by	  
immunoprecipitation	  (50	  µl	  antibody-­‐coupled	  beads)	  as	  described	  in	  the	  next	  section.	  
	  
HEPES	  buffer	  	   	   25	  mM	   HEPES	  
	   	   	   125	  mM	  	   NaCl	  
	   	   	   5	  mM	   KCl	  
	   	   	   1	  mM	  	   MgCl2	  




For	   immunoprecipitation	   of	   FGF2-­‐GFP,	   anti-­‐GFP	   antibody	   was	   added	   to	   Protein	  A-­‐
Sepharose	   beads	   (ratio	   1:1)	   and	   incubated	   for	   18	   h	   at	   4°C	   on	   a	   rotating	   wheel.	  
Following	   centrifugation	   (800xg,	   3	  min),	   supernatant	  was	   removed	   and	   beads	  were	  
washed	  three	  times	  with	  1	  ml	  of	  IP	  buffer	  I.	  Lysates	  were	  added	  and	  incubated	  for	  2	  h	  
at	   4°C	   under	   constant	   head-­‐over-­‐head	   rolling.	   Following	   two	   washing	   steps	   with	  
IP	  buffer	   I,	  beads	  were	  washed	  once	  with	   IP	  buffer	   II.	  4x	  SDS	   sample	  buffer	   (4x	  SDS	  
sample	   buffer:bead	   volume	   1:4)	   was	   added	   to	   the	   beads	   and	   boiled	   at	   95°C	   for	  
10	  min.	  Finally,	  supernatants	  were	  loaded	  on	  a	  15-­‐well	  4-­‐12%	  Bis-­‐Tris-­‐gel.	  
	  
IP	  buffer	  I	   	   	   25	  mM	   HEPES	  pH	  7.4	  
	   	   	   150	  mM	   NaCl	  
	   	   	   0.5%	  (w/v)	   NP-­‐40	  
	   	   	   1	  mM	   EDTA	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IP	  buffer	  II	   	   	   IP	  buffer	  I	  without	  NP-­‐40	  
	  
	  
4.4.8 Analysis	  of	  FGF2	  phosphorylation	  in	  a	  cellular	  system	  
In	   order	   to	   analyze	   the	   localization	   of	   phosphorylated	   FGF2-­‐GFP,	   proteins	   were	  
labeled	   with	   32[P]	   phosphoric	   acid.	   Phosphorylation	   state	   of	   heparin-­‐extracted	   cell	  
surface-­‐bound	   FGF2-­‐GFP	   as	   well	   as	   intracellular	   FGF2	   was	   monitored	   by	  
phosphorimaging.	  
For	   this	   purpose,	   2.5x106	   HeLa	   cells	   were	   seeded	   on	   15	   cm	   plates	   in	   medium	  
containing	   10%	   (v/v)	   FCS.	   Following	   24	   h,	   cells	   were	   washed	   twice	   and	   starved	   in	  
20	  ml	  phosphate-­‐free	  DMEM	  containing	  0.1%	  (v/v)	  dialyzed	  FCS	  (6-­‐8	  kDa	  MWCO)	  and	  
5	  µg/ml	  Doxycycline	  for	  48	  h.	  Medium	  was	  then	  reduced	  to	  15	  ml	  and	  supplemented	  
with	   10%	  (v/v)	   dialyzed	   FCS,	   150	   µCi/ml	   32[P]	   phosphoric	   acid	   and	   again	   5	   µg/ml	  
Doxycycline.	  
After	   another	   incubation	   for	   18	   h,	   cells	  were	  washed	   twice	  with	   cold	  HEPES	   buffer	  
(see	  section	  4.4.6)	  and	  incubated	  with	  12	  ml	  heparin-­‐buffer	  (HEPES	  buffer,	  0.5	  mg/ml	  
heparin)	  for	  30	  min	  on	  ice	  with	  gentle	  shaking.	  Thereby,	  cell	  surface-­‐bound	  FGF2-­‐GFP	  
molecules	   were	   separated	   from	   intracellular	   proteins	   and	   finally	   concentrated	   by	  
immunoprecipitation	   (section	   4.4.7,	   60	   µl	   antibody-­‐coupled	   beads)	   as	   described	  
before.	  	  
Intracellular	  FGF2-­‐GFP	  was	   released	  during	  cell	   lysis.	   Therefore,	  adherent	   cells	  were	  
washed	   twice	   with	   HEPES	   buffer.	   After	   the	   last	   wash	   step,	   buffer	   was	   removed	  
completely	   and	   cells	  were	   scraped	   in	   the	   remaining	   fluid	   (~400	  µl).	   Cell	   suspension	  
was	  then	  transferred	  into	  2	  ml	  tubes	  and	  diluted	  with	  2x	  lysis	  buffer	  in	  a	  ratio	  of	  1:1.	  
Cells	  were	  lysed	  by	  sonication	  in	  a	  sonication	  bath	  for	  3	  min	  following	  incubation	  for	  
15	  min	   at	   RT,	   vortexing	   every	   5	  min.	   Cell	   debris	  was	   removed	   by	   centrifugation	   at	  
20,000xg	   for	   10	   min	   and	   supernatants	   were	   collected.	   FGF2-­‐GFP	   was	   then	  
precipitated	  on	  anti-­‐GFP	  coupled	  Protein	  A-­‐beads	  as	  described	  before	  (section	  4.4.7,	  
60	  µl	  antibody-­‐coupled	  beads).	  	  
After	   separation	   by	   SDS-­‐gel	   electrophoresis	   (4-­‐12%	   Bis-­‐Tris	   gels,	   NuPAGE),	  Western	  
blotting	  and	  immunostaining,	  proteins	  were	  detected	  by	  an	  Odyssey	  imaging	  system	  
(LI-­‐COR	  biosciences).	  In	  order	  to	  visualize	  phosphorylated	  proteins,	  membranes	  were	  
Material	  and	  Methods	  
	   113	  
exposed	   on	   a	   phosphor	   screen	   imaging	   plate	   (BAS-­‐MS	   2040,	   Fujifilm;	   time	   as	  
indicated)	  and	  imaged	  on	  a	  phosphor	  imager	  (Fujifilm	  FLA-­‐7000).	  
	  
Dialyzed	  FCS	  (50	  ml)	   	   2	  l	  	   TBS	   	   16	  h	  
	   	   	   2	  l	   TBS	   	   8	  h	  
	   	   	   2	  l	   TBS	   	   16	  h	  
	   	   	   0.3	  l	   phosphate	  free	  DMEM	   10	   h
	   	   	   0.3	  l	   phosphate	  free	  DMEM	   24	  h	  
	  
TBS	   	   	   50	  mM	   Tris-­‐HCl	  pH	  7.4	  
	   	   	   150	  mM	   NaCl	  
	  
	  
4.4.9 Analysis	  of	  HSPG	  binding	  using	  flow	  cytometry	  
For	   removal	   of	   endogenous	   FGF2	  bound	   to	  HSPG	  on	   the	   cell	   surface,	  HeLaMCAT-­‐TAM2	  
cells	  were	  washed	  twice	  with	  1x	  PBS	  and	  incubated	  with	  0.5	  mg/ml	  heparin	  dissolved	  
in	   DMEM	   for	   30	   min.	   Following	   detaching	   cells	   with	   cell	   dissociation	   buffer,	  
2.5x105	  cells	  were	  pelleted	  (250xg,	  3	  min,	  4°C)	  and	  resuspended	  with	  both	  wild	  type	  
and	  FGF2	  mutant	  proteins	  at	  concentrations	  as	   indicated.	  Following	  1	  h	  at	  4°C,	  cells	  
were	  washed	  with	  1	  ml	  DMEM	  containing	  10%	  (v/v)	  FCS	  (250xg,	  3	  min)	  and	  incubated	  
with	  a	  rabbit	  anti-­‐FGF2	  antibody-­‐dilution	  (1:100).	  Cells	  were	  incubated	  for	  1	  h	  before	  
remaining	  antibody	  was	  removed	  by	  washing	  with	  1	  ml	  complete	  medium.	  Cells	  were	  
then	   incubated	   with	   secondary	   allophycocyanin	   goat	   anti-­‐rabbit	   IgG	   (1:1000)	   for	  
30	  min.	   Finally,	   samples	   were	   washed	   with	   DMEM	   supplemented	   with	   10%	   (v/v)	  
serum,	   resuspended	   in	   sorting	   medium	   (5%	   (v/v)	   0.5	   mM	   EDTA/PBS	   in	   FCS-­‐free	  
DMEM)	  and	  cell	  surface	  signal	  was	  subsequently	  quantified	  by	  flow	  cytometry	  using	  a	  
FACSCalibur	   flow	   cytometer.	   This	   device	   is	   equipped	   with	   a	   633	   nm	   Diode	   laser.	  
APC-­‐derived	   fluorescence	  was	  analyzed	  using	   the	   FL-­‐4	   (661/16	  nm)	   channel.	  A	   gate	  
around	   the	  major	   cell	  population	  was	   set	  on	   the	  SSC	   (side	   scatter)	   vs.	   FSC	   (forward	  
scatter)	  plot	  for	  data	  analysis.	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4.4.10 Analysis	  of	  HSPG	  binding	  using	  confocal	  microscopy	  
HeLaMCAT	   TAM2	   cells	  were	   plated	   on	   cover	   slips	   and	   grown	   for	   48	   h	   in	   DMEM.	   FGF2	  
variant	   forms	  were	  diluted	   in	  DMEM	  to	  a	   final	  concentration	  of	  3	  nM	  and	  added	  to	  
adherent	   cells.	   After	   3	   h,	   cells	   were	   fixed	   and	   subjected	   to	   immunofluorescence.	  
Therefore,	   cells	   were	   washed	   twice	   with	   1x	   PBS	   and	   fixed	   with	   3%	   (w/v)	  
paraformaldehyde	  (PFA)	  for	  20	  min	  on	  ice.	  All	  further	  incubations	  were	  carried	  out	  at	  
room	  temperature.	  Samples	  were	  washed	  twice	  with	  1x	  PBS	  followed	  by	   incubation	  
with	   blocking	   solution	   (1%	   (w/v)	   BSA	   in	   1x	  PBS)	   for	   1	   h.	   Cells	   were	   subsequently	  
labeled	  with	  primary	  antibodies	  diluted	  in	  blocking	  buffer	  (rabbit	  anti-­‐FGF2,	  1:100)	  for	  
1	   h,	   washed	   three	   times	   with	   1x	   PBS	   and	   incubated	   with	   appropriate	   secondary	  
antibodies	   diluted	   in	   blocking	   solution	   (goat	   anti-­‐rabbit	   antibody	   coupled	   to	   Alexa	  
Fluor	  488,	  1:1000)	  for	  30	  min.	  Finally,	  cells	  were	  washed	  three	  times	  and	  covered	  with	  
1	  ml	  1x	  PBS	  for	  imaging	  and	  storage.	  	  
Confocal	   fluorescent	   images	  were	  obtained	  by	   a	   Zeiss	   LSM510	   confocal	  microscope	  
with	  40x	  oil	  immersion	  objective.	  Excitation	  at	  488	  nm	  (emission	  filter	  BP500-­‐550)	  was	  
provided	  by	  an	  argon	  laser.	  Images	  were	  analyzed	  using	  the	  open-­‐source	  software	  Fiji.	  
	  
	  
4.4.11 Preparation	  and	  microscopic	  analysis	  of	  microinjected	  cells	  
Localization	  studies	  of	  phosphomimetic	  FGF2	  were	  performed	  by	  microinjecting	  FGF2	  
mutant	   proteins	   and	   subsequent	   microscopic	   analysis.	   Therefore,	   HSPG	   deficient	  
CHO-­‐745	  cells	  were	  plated	  on	  3.5	  cm	  glass	  bottom	  dishes	  (3.5x104	  cells)	  and	  grown	  for	  
48	   h.	   Each	   dish	  was	  marked	  with	   a	   diamond	   knife	   for	   location	   purposes.	   Complete	  
medium	   was	   replaced	   with	   α-­‐MEM	   containing	   1%	   (v/v)	   serum	   directly	   before	  
injection.	   Each	   sample	  was	   centrifuged	   shortly	   before	   use	   (20,000xg,	   15	  min	   10°C).	  
Cy3	  labeled	  proteins	  were	  then	  injected	  into	  cells	  cytoplasm	  by	  using	  a	  microinjection	  
system	   (injection	   pressure:	  80	   hPa;	   injection	   time:	   0.1	   sec;	   compensation	  
pressure:	  50	  hPa).	   After	   injection,	   low	   serum	   medium	   was	   aspirated	   and	   medium	  
supplemented	  with	  10%	   (v/v)	   FCS	  was	  added.	   In	   the	   case	  of	   analyzing	   the	  effect	  of	  
nocodazole,	   either	   2	  µM	   nocodazole	   (in	   DMSO)	   or	   appropriate	   amounts	   of	   DMSO	  
(0.1%	   (v/v)	   final	   concentration)	   were	   added	   to	   the	   incubation	   medium.	   Following	  
incubation,	  cells	  were	  washed	  twice	  with	  1x	  PBS	  and	  fixed	  with	  300	  µl	  3%	  (w/v)	  PFA	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(in	  1x	  PBS)	   for	  20	  min	  on	   ice.	  Cells	  were	  washed	  three	  times	  and	  covered	  with	  1	  ml	  
1x	  PBS	   for	   imaging	   and	   storage.	   Intracellular	   localization	   of	   FGF2	   variant	   forms	  was	  




Confocal	   fluorescent	   images	  were	  obtained	  by	   a	   Zeiss	   LSM510	   confocal	  microscope	  
with	   63x	   oil	   immersion	   objective.	   Excitation	   at	   543	   nm	   (emission	   filter	   LP560)	   was	  





For	   live-­‐cell	   imaging,	   injection	   medium	   (α-­‐MEM,	   1%	   (v/v)	   FCS)	   was	   replaced	   by	  
imaging	   medium	   (α-­‐MEM,	   without	   phenol	   red,	   10%	   (v/v)	   FCS).	   Microinjected	   cells	  
were	   then	   placed	   in	   a	   CO2	   incubator	   for	   3	   h.	   After	   subjecting	   cells	   to	   a	   live-­‐cell	  
chamber	  (37	  °C,	  5%	  CO2,	  50%	  humidity)	  connected	  to	  a	  TIRF	  microscope	  (Leica	  AF7000	  
TIRF	  MC)	  epifluorescence	  and	  TIRF	  images	  were	  obtained	  using	  a	  100x	  oil	  immersion	  
objective.	  Excitation	  at	  560	  nm	  was	  provided	  by	  a	  DPSS	  laser.	  Images	  were	  analyzed	  
using	  the	  open-­‐source	  software	  Fiji.	  
	  
	  
4.4.12 Immunofluorescence	  analysis	  of	  microinjected	  cells	  	  
After	   incubation	   of	   microinjected	   cells	   for	   1.5	   h	   in	   the	   presence	   of	   either	   2	  µM	  
nocodazole	   (in	   DMSO)	   or	   appropriate	   amounts	   of	   DMSO	   (0.1%	   (v/v)	   final	  
concentration),	   cells	  were	   fixed	   for	   1	   h	   at	   room	   temperature	  with	   fixation	   solution	  
directly	   added	   to	   the	   medium	   (1:1,	   final	   ratio).	   Following	   two	   times	   washing	   with	  
1x	  PBS,	  cells	  were	  blocked	  with	  300	  µl	  blocking	  solution	  (1%	  (w/v)	  BSA	  in	  1x	  PBS)	  for	  
1	  h.	  Cells	  were	  subsequently	  labeled	  with	  300	  µl	  mouse	  anti-­‐tubulin	  antibody	  coupled	  
to	  Alexa	  Fluor	  488	  (1:250,	  diluted	  in	  blocking	  buffer)	  for	  1	  h.	  Finally,	  cells	  were	  washed	  
three	  times	  with	  and	  imaged/stored	  in	  1	  ml	  1x	  PBS.	  	  
Confocal	   fluorescent	   images	  were	  obtained	  by	   a	   Zeiss	   LSM510	   confocal	  microscope	  
with	  63x	  oil	   immersions	  objectives.	  Excitation	  at	  488	  nm	  (emission	  filter	  BP500-­‐550)	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and	  543	  nm	   (emission	   filter	   LP560)	  was	  provided	  by	   argon	   and	  helium-­‐neon	   lasers,	  
respectively.	  Images	  were	  analyzed	  using	  the	  open-­‐source	  software	  Fiji.	  
	  
2x	  fixation	  solution	   	   8%	  (w/v)	  	   PFA	  
0.2%	  (w/v)	  	   Glutaraldehyde	  
in	  1x	  PBS	  
	  
	  
4.4.13 Sample	  preparation	  and	  analysis	  using	  electron	  microscopy	  
Microinjection	  
For	  microinjection,	  cells	  were	  grown	  on	  carbon	  coated	  (8	  nm),	  plasma	  cleaned	  (15	  sec)	  
and	  sterile	  (UV	  for	  1h)	  sapphire	  disks	  (diameter	  3	  mm,	  thickness	  0.16	  mm).	  After	  24	  h,	  
most	   cells	  were	   scraped	  off.	  Remaining	   cells	   (200-­‐400	  cells)	  were	  grown	   for	   further	  




Cells	  were	  fixed	  with	  2x	  fixation	  solution	  directly	  added	  to	  the	  medium	  in	  a	  ratio	  1:1	  
for	  1	  h	  at	  room	  temperature.	  Then,	  cells	  were	  washed	  3	  times	  with	  wash	  buffer.	  Cells	  
subjected	  to	  high	  pressure	   freezing	  were	  stored	  over	  night	  at	  4°C	   in	  1x	  PHEM	  while	  
cells	  prepared	  for	  plt-­‐substitution	  were	  stored	  in	  contrasting	  solution.	  
	  
4x	  PHEM	  buffer	   	   240	  mM	  	   PIPES	   	  
	   	   	   100	  mM	  	   HEPES	  
8	  mM	  	   MgCl2	  
40	  mM	  	   EGTA	  
pH	  6.9	   	  
	  
2x	  fixation	  solution	   	   8%	  (w/v)	  	   PFA	  
0.2%	  (w/v)	  	   Glutaraldehyde	  
in	  PBS	  
	  
Wash	  buffer	   	   	   0.1	  M	  	   PHEM	  
20	  mM	  	   Glycine	  
	  
Contrasting	  solution	   	   25%	  (v/v)	   EtOH	  
0.2%	  (w/v)	   Uranyl	  acetate	  (UAC)	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High	  pressure	  freezing	  
For	  rapid	  freezing	  by	  means	  of	  hpf,	  sapphire	  disks	  were	  dipped	  into	  hexadecen,	  placed	  
in	   an	   appropriate	   holder	   and	   covered	   with	   a	   hexadecen-­‐wetted	   aluminum	   carrier	  
(thickness	   0.84	  mm).	   Cells	  were	   frozen	  under	   2300-­‐2600	  bar	   of	   liquid	  nitrogen	   in	   a	  
high	  pressure-­‐freezing	  machine.	  Using	  pre-­‐cooled	  tweezers,	  samples	  were	  transferred	  
in	  a	  tube	  for	  storage	  in	  liquid	  nitrogen	  until	  samples	  were	  further	  processed.	  	  
	  
Progressive	  lowering	  of	  temperature	  
Samples	   were	   transferred	   from	   contrasting	   solution	   to	   a	   cryo-­‐tube	   cap	   filled	   with	  
25%	  (v/v)	  ethanol	  (EtOH),	  which	  was	  precooled	  to	  0°C	  in	  a	  freeze	  substitution	  machine	  
(AFS	  2,	  LEICA).	  All	  steps	  were	  performed	  this	  machine	  and	  are	  listed	  below.	  
All	   solutions	   were	   precooled	   to	   the	   appropriate	   temperature	   and	   replaced	   using	   a	  
Pasteur	  pipette.	  For	  embedding,	  sapphire	  disks	  were	  transferred	  into	  a	  0.5	  ml	  reaction	  
tube	  as	  deeply	  as	  possible	  before	  Lowicryl	  HM20	  was	  added.	  
	  




Time	  (h)	   UV	  
Substitution	   25	  %	  (v/v)	  EtOH	   0	   -­‐15	   1	   -­‐	  
	   50	  %	  (v/v)	  EtOH	   -­‐15	   -­‐35	   1	   -­‐	  
	   75	  %	  (v/v)	  EtOH	   -­‐35	   -­‐35	   1	   -­‐	  
	   95	  %	  (v/v)	  EtOH	   -­‐35	   -­‐40	   1	   -­‐	  
	   100	  %	  (v/v)	  EtOH	   -­‐40	   -­‐40	   1	   -­‐	  
	   100	  %	  (v/v)	  EtOH	   -­‐40	   -­‐40	   1	   -­‐	  
Infiltration	   1:2	  (HM20:EtOH)	   -­‐40	   -­‐40	   1	   -­‐	  
	   2:1	  (HM20:EtOH)	   -­‐40	   -­‐40	   1	   -­‐	  
	   HM20	   -­‐40	   -­‐40	   16	   -­‐	  
	   HM20	   -­‐40	   -­‐40	   6	   -­‐	  
Embedding	   HM20	   -­‐40	   -­‐40	   48	   +	  
	   HM20	   -­‐40	   20	   2	   +	  
	  
Samples	  were	  exposed	  to	  UV	  irradiation	  for	  at	  least	  2	  days	  at	  room	  temperature	  and	  
further	  7	  days	  to	  daylight	  until	  Lowicryl	  HM20	  was	  sufficiently	  polymerized.	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Lowicryl	  HM20	   	   35.29	  g	   Crosslinker	  D	  
	   	   	   	  6.26	  g	   Crosslinker	  E	  
	   	   	   	   15	  min	  on	  a	  rotating	  wheel	  
	   	   	   0.21	  g	   Initiator	  C	  
	   	   	   	   15	  min	  on	  a	  rotating	  wheel	  
	  
Freeze-­‐substitution	  
Samples	  were	  transferred	  very	  rapidly	  with	  precooled	  tweezers	   from	  liquid	  nitrogen	  
to	  a	  cryo-­‐tube	  cap	  filled	  with	  freeze	  substitution	  medium	  (FSM),	  which	  was	  precooled	  
to	  -­‐90°C	  in	  a	  freeze	  substitution	  machine	  (AFS	  2,	  LEICA).	  All	  steps	  were	  performed	  in	  
this	  machine	  and	  are	  listed	  below.	  
Glass	  distilled	  acetone	  was	  used	  for	  all	  washing	  steps	  and	  dilutions.	  All	  solutions	  were	  
precooled	  to	  the	  appropriate	  temperature	  and	  replaced	  using	  a	  Pasteur	  pipette.	  For	  
embedding,	  sapphire	  disks	  were	  transferred	  into	  a	  0.5	  ml	  reaction	  tube	  as	  deeply	  as	  
possible	  before	  Lowicryl	  HM20	  was	  added.	  
	  




Time	  (h)	   UV	  
Substitution	   FSM	   -­‐90	   -­‐90	   2	   -­‐	  
	   FSM	   -­‐90	   -­‐50	   3	   -­‐	  
Wash	   100	  %	  (v/v)	  acetone	   -­‐50	   -­‐50	   0.25	   -­‐	  
	   100	  %	  (v/v)	  acetone	   -­‐50	   -­‐50	   0.25	   -­‐	  
	   100	  %	  (v/v)	  acetone	   -­‐50	   -­‐50	   0.25	   -­‐	  
Infiltration	   1:4	  (HM20:	  acetone)	   -­‐50	   -­‐50	   1	   -­‐	  
	   1:2	  (HM20:	  acetone)	   -­‐50	   -­‐50	   1	   -­‐	  
	   4:1	  (HM20:	  acetone)	   -­‐50	   -­‐50	   1	   -­‐	  
	   HM20	   -­‐50	   -­‐50	   1	   -­‐	  
Embedding	   HM20	   -­‐50	   -­‐50	   19	   -­‐	  
	   HM20	   -­‐50	   -­‐50	   48	   +	  
	   HM20	   -­‐50	   20	   2	   +	  
	  
Samples	  were	  exposed	  to	  UV	  irradiation	  for	  at	  least	  2	  days	  at	  room	  temperature	  and	  
further	  3	  days	  to	  daylight	  until	  Lowicryl	  HM20	  was	  sufficiently	  polymerized.	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FSM	   	   	   0.1%	  (w/v)	   UAC	  
	   	   	   3%	  (v/v)	   H2O	  
	   	   	   	   in	  glass	  distilled	  acetone	  
	  
Serial	  sectioning	  
Polymerized	   sample	   were	   manually	   trimmed	   with	   an	   acetone-­‐cleaned	   razor	   blade.	  
Subsequently,	  serial	   thin	  sections	  (60	  nm)	  were	  cut	  with	  a	  diamond	  knife	  on	  a	  Leica	  
Ultracut	   microtome.	   Sections	   were	   collected	   on	   formvar-­‐coated	   grids	   (100	   mesh),	  
which	  were	  stabilized	  with	  an	  evaporated	  carbon	  film	  (2.6	  nm).	  	  
	  
Antibody	  labeling	  
For	  antibody	   labeling,	  each	   solution	  was	   spotted	  on	  parafilm	  and	  grids	  were	  placed	  
upside	  down.	  All	  steps	  were	  performed	  at	  room	  temperature.	  First,	  thin	  sections	  were	  
blocked	   for	   25	   min	   with	   50	   µl	   blocking	   buffer.	   For	   immunolabeling,	   samples	   were	  
incubated	   for	   90	   min	   in	   20	   µl	   blocking	   buffer	   containing	   the	   first	   antibody	   (rabbit	  
anti-­‐FGF2,	   1:20)	   followed	   by	   washing	   samples	   five	   times	   with	   blocking	   buffer	   for	  
2	  min.	   Then,	   samples	   were	   incubated	   with	   protein	   A-­‐gold	   (10	   nm,	   1:60)	   diluted	   in	  
blocking	   buffer	   for	   20	   min.	   After	   washing	   5	   times	   with	   blocking	   buffer	   for	   5	   min,	  
samples	   were	   washed	   with	   PBS	   (5	   x	   2	   min).	   Samples	   were	   fixed	   with	   1%	   (w/v)	  
glutaraldehyde	   and	   washed	   ten	   times	   with	   H2O	   for	   2	   min.	   Sections	   were	   first	  
contrasted	   in	   an	   aqueous	   solution	   of	   uranyl	   acetate	   for	   10	   min	   in	   a	   chamber	  
containing	   KOH	  pellets.	   After	  washing	   ten	   times	  with	  H2O,	   samples	  were	   incubated	  
with	  lead	  citrate	  for	  1	  min	  followed	  by	  washing	  five	  times	  with	  H2O.	  Finally,	  grids	  were	  
dried	  using	  a	  filter	  paper	  and	  stored	  at	  room	  temperature	  until	  samples	  were	  analyzed	  
using	  an	  electron	  microscope	  EM900.	  
The	   number	   of	   gold	   particles	   per	   µm2	   in	   CHO-­‐745	   wild	   type	   cells	   and	   His6FGF2-­‐
Y82pCMF	  injected	  cells	  was	  quantified	  using	  iTEM	  software	  (Olympus	  SYS).	  
	  
Blocking	  buffer	   	   0.1%	  (w/v)	   FSG	  
	   	   	   1.5%	  (w/v)	   BSA	  
	   	   	   	   in	  1x	  PBS	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4.4.14 In/On-­‐Cell-­‐Western	  
1x104	  cells	  were	  grown	   in	  12-­‐well	  plates	   in	   the	  presence	  or	  absence	  of	  either	  2	  µM	  
nocodazole	   or	   appropriate	   amounts	   of	   DMSO	   (0.01%	   (v/v)	   final	   concentration).	  
Following	  20	  h	  the	  medium	  was	  aspirated	  and	  cells	  were	  fixed	  with	  3%	  (w/v)	  PFA	  in	  
1x	  PBS	   for	  20	  min	  on	   ice.	  All	   following	  steps	  were	  performed	  at	   room	  temperature.	  
While	  cells	  of	  one	  plate	  were	  stored	  in	  1x	  PBS	  (surface	  staining),	  200	  µl	  of	  0.1%	  (w/v)	  
Triton	  X-­‐100	  was	  added	   to	   the	   second	  plate	   (total	   signal)	   and	   incubated	   for	  10	  min	  
before	  replaced	  with	  the	  same	  solution.	  After	  5	  min,	  cells	  were	  washed	  once	  with	  1	  ml	  
1x	  PBS	   and	   incubated	  with	  200	  µl	   LICOR	  blocking	   solution	   for	   90	  min.	   The	  blocking	  
solution	   was	   directly	   replaced	   by	   200	   µl	   primary	   antibody	   solution	   (1%	   (w/v)	   BSA,	  
rabbit	  anti-­‐GFP	  1:500).	  After	  another	  incubation	  for	  2	  h,	  cells	  were	  washed	  twice	  with	  
1	   ml	   1x	  PBS.	   Then,	   200	   µl	   of	   the	   secondary	   antibody	   dilution	   (1%	   (w/v)	   BSA,	  
IRDye	  800	  CW	  goat	  anti-­‐rabbit	  1:1000,	  Syto-­‐60	  nuclear	  stain	  1:5000)	  was	  added	  and	  
incubated	   for	  1	  h	   in	   the	  dark.	  After	  aspirating	   the	   secondary	  antibody	  dilution,	   cells	  
were	  washed	   twice	   and	   covered	  with	   1	  ml	   1x	   PBS.	   Finally,	   cells	  were	   imaged	   on	   a	  
LICOR	  Biosciences	  Odyssey	  Infrared	  Imaging	  System.	  The	  obtained	  signal	  intensities	  (I)	  
were	  normalized	  as	  follows:	  
	  
1.	  Cell	  count	  correction	  (individual	  well)	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  𝑥!   = !!""(!"#$%&'(  !"#$%&)!!""  (!"#$  !") ×  1000	  
	  
2.	  Averaging	  triplicates	  (xave;	  for	  surface	  and	  Triton-­‐treated	  samples,	  respectively).	  	  
	  
3.	  Background	  correction	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  𝑥 = 𝑥!"# − 𝑥!"#  !"#$!!"#!	  
	  
4.	  Percentage	  on	  cell	  surface	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  %  𝑜𝑛  𝑠𝑢𝑟𝑓𝑎𝑐𝑒 = !!"#$%&'!!"#$%& ×100	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5 LIST	  OF	  ABBREVIATIONS	  
Acb	   Acyl-­‐CoA	  binding	  protein	  
APS	   Ammoium	  peroxo	  disulfate	  
ATP	   adenosine	  triphosphate	  
BCA	   bicinchoninic	  acid	  
BFA	   Brefeldin	  A	  
BH	   Btk	  homology	  
Bmx	   bone	  marrow	  kinase	  gene	  on	  chromosome	  X	  
BSA	   bovine	  serum	  albumin	  
Btk	   Brutons´s	  tyrosine	  kinase	  
c.F.U.	   corrected	  fluorescence	  units	  
CCR5	   C-­‐C	  chemokine	  receptor	  type	  5	  
CF	   carboxyfluorescein	  
CFTR	   cystic	  fibrosis	  tansmembrane	  conductance	  regulator	  
COP	   coat	  protein	  complex	  
COPII	  CV	   coat	  protein	  complex	  II-­‐coated	  vesicle	  
CS	   calf	  serum	  
CUPS	   compartment	  for	  unconventional	  protein	  secretion	  
CXCR4	   C-­‐X-­‐C	  chemokine	  receptor	  type	  4	  
dd	   double-­‐distilled	  
DHFR	   dihydrofolate	  reductase	  
DISC	   disrupted	  in	  schizophrenia	  
DMEM	   Dulbeccos´s	  modiefied	  eagle	  medium	  
DMSO	   Dimethyl	  sulphoxide	  
DOL	   degree	  of	  labeling	  
Dox	   Doxicycline	  
DTT	   Dithiothreitol	  
E.	  coli	   Escherichia	  coli	  
e.g.	   exempli	  gratia	  (for	  example)	  
EDEM	   ER	  degradation-­‐enhancing	  mannosidase-­‐like	  
EDTA	   Ethylene	  diamine	  tetraacetate	  
ELISA	   enzyme-­‐linked	  immunosorbent	  assays	  
EM	   electron	  microscopy	  
ER	   endoplasmic	  reticulum	  
ERAD	   ER-­‐associated	  degradation	  




et	  alli	  (and	  others)	  
FACS	   fluorescence	  activated	  cell	  sorting	  
FCS	   fetal	  calf	  serum	  
FGF	   fibroblast	  growth	  factor	  
FGFR	   fibroblast	  growth	  factor-­‐receptor	  
FRS	   FGFR	  substrate	  	  
FSM	   freeze	  substitution	  medium	  
GAPDH	   glyceraldehyde	  3-­‐phosphate	  dehydrogenase	  
GFP	   green	  fluorescent	  protein	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GRASP	   Golgi	  re-­‐assembly	  and	  stacking	  protein	  
GrpA	   Golgi	  re-­‐assembly	  stacking	  protein	  
GTP	   guanosine	  triphosphate	  
HIV-­‐Tat	   human	  immunodeficiency	  virus-­‐trans-­‐activator	  of	  transcription	  
HMW	   high	  molecular	  weight	  
hpf	   high-­‐pressure	  freezing	  
HSP150	   heat-­‐shock	  protein	  150	  
HSPG	   heparan	  sulfate	  proteoglycans	  
i.e.	   id	  est	  (that	  is)	  
IgG	   immunoglobulin	  G	  
IL-­‐1β	   interleukin-­‐1β	  
IP	   immunoprecipitation	  
IPTG	   Isopropyl-­‐β-­‐D-­‐thiogalactopyranoside	  
Itk	   interleukin-­‐2	  inducible	  T	  cell	  kinase	  
JAK	   Janus	  kinase	  
kb	   kilobase	  
KD	   dissociation	  constant	  
kDa	   Kilodalton	  
KIF	   kinesin	  superfamily	  
LAT	   linker	  for	  activation	  of	  T	  cells	  
LB	   lysogeny	  broth	  
LFM-­‐A13	   leflunomide	  metabolite	  analog	  
LIS	   lisencephaly	  
LMW	   low	  molecular	  weight	  
LSM	   laser	  scanning	  microscope	  
MAPK	   mitogen-­‐activated	  protein	  kinase	  
Mcat	   murine	  cationic	  tranporter	  
Mr	   molecular	  weight	  marker	  
MRA	   Mycoplasma	  removal	  agent	  
mRNA	   messenger-­‐RNA	  
MT	   Mcat-­‐Tam2	  
MTOC	   microtuble	  organizing	  center	  
MTT	   3-­‐(4,5-­‐Dimethylthiazol-­‐2-­‐yl)-­‐2,5-­‐diphenyltetrazolium	  bromide	  
MUT	   mutant	  
MVB	   multi-­‐vesicular	  bodies	  
MW	   molecular	  weight	  
NLS	   nuclear	  localization	  sequence	  
NP-­‐40	   Nonidet	  P40	  
nr-­‐pY	   Non-­‐related	  phosphotyrosine-­‐peptide	  
ns	   not	  significant	  
NSF	   N-­‐ethylmaleimide-­‐sensitive	  factor	  
nudel	   NudE-­‐like	  
OD600nm	   optical	  density	  at	  600nm	  
ova	   ovalbumin	  
PAGE	   polyacrylamide	  gel	  electrophoresis	  
PBS	   phosphate	  buffered	  saline	  
PC	   Phosphatidylcholine	  
pCMF	   p-­‐carboxylmethylphenylalanine	  
PCR	   polymerase	  chain	  reaction	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pep	   peptide	  
PFA	   paraformaldehyde	  
PH	   pleckstrin	  homology	  
PI(4,5)P2	   Phosphatidylinositol-­‐4,5-­‐bisphosphate	  
PI3K	   phosphoinositide	  3	  kinase	  
PIP2	   Phosphatidylinositol-­‐4,5-­‐bisphosphate	  
PLC-­‐	  γ	   phospholipase	  C	  (PLC)-­‐γ	  
plt	   progressive	  lowering	  of	  temperature	  
PM	   plasma	  membrane	  
PMSF	   Phenylmethylsulfonyl	  fluoride	  
PR	   proline-­‐rich	  
PS	   Phosphatidylserine	  
PTEN	   phosphatase	  and	  tensin	  homolog	  
PVDF	   polivinylidene	  fluoride	  
pY	   Phosphotyrosine	  
RanBPM	   Ran-­‐binding	  protein	  M	  
Rb	   rabbit	  
Rlk	   resting	  lymphocyte	  kinase	  
RNA	   ribonucleic	  acid	  
rpm	   rounds	  per	  minute	  
SDF2	   spore	  differentiation	  factor-­‐2	  
SDS	   sodium	  dodecyl	  sulfate	  
SH	   Src-­‐homolgy	  
SHIP	   SH2-­‐containing	  inositol	  5´-­‐phosphatase	  
SLP-­‐76	   SH2-­‐domain-­‐containing	  leukocyte	  protein	  of	  76	  kDa	  
SNARE	   soluble	   N-­‐ethylmaleimide	   sensitive	   factor	   attachment	   protein	  
receptors	  
SNX	   sorting	  nexin	  
Src	   sarcoma	  
SRP	   signal	  recognition	  particle	  
Syt	   Synaptotagmin	  
TB	   terrific	  broth	  
TCA	   Trichloro	  acetic	  acid	  
TCEP	   Tris	  (2-­‐carboxyethyl)phosphine	  hydrochloride	  
TCR	   T	  cell	  receptor	  
Tec	   tyrosine	  kinase	  expressed	  in	  hepatocellular	  carcinoma	  
TEMED	   N,N,N´,N´-­‐Tetramethylethylenediamine	  
TGN	   trans-­‐Golgi	  network	  
TH	   Tec	  homology	  
TIRF	   total	  internal	  reflection	  fluorescence	  
TRIS	   Tris[hydroxymethyl]aminoethane	  
UAC	   uranyl	  acetate	  
V	   volt	  
v/v	   volume/volume	  
w/v	   weight/volume	  
WT	   wild	  type	  
ZAP70	   ζ-­‐chain-­‐associated	  protein	  kinase	  of	  70	  kDa	  
α	   anti	  
α-­‐MEM	   α-­‐modified	  minimal	  essential	  medium	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   EMBL	   bedanke	   ich	   mich	   für	   die	   nette	   Colaboration	   und	  
mikroskopische	  Unterstützung.	  
	  
Außerdem	   bedanke	   ich	   mich	   bei	   allen	   Mitgliedern	   der	   Arbeitsgruppe	   für	   die	   gute	  
Arbeitsatmosphäre	   die	   ich	   in	   den	   Jahren	   der	   Doktorarbeit	   erleben	   durfte:	   Helena	  
Andreas,	   Lucía	   Cespon	   Torrado,	   Antje	   Ebert,	   Giuseppe	   La	   Venuta,	   Hans-­‐Michael	  
Müller,	   Julia	   Ritzerfeld,	   Christina	   Sendlmeier,	   Julia	   Steringer,	   Koen	   Temmerman,	  
Paulina	  Turcza,	  Tao	  Wang,	  Sabine	  Wegehingel,	  Georg	  Weidmann,	  Sonja	  Zacherl	  und	  
Marcel	  Zeitler.	  
	  
Mein	   besonderer	   Dank	   geht	   an	   Heli,	   Michael,	   Julia	   S.,	   Georg	   und	   Sonja,	   nicht	   nur	  
dafür,	  dass	  ihr	  das	  Laborleben	  so	  sympathisch	  gestaltet	  habt,	  sondern	  auch,	  dass	  ihr	  
mich	  persönlich	  ernst	  genommen	  und	  so	  stark	  unterstützt	  habt.	  Wirklich,	  1000	  Dank!	  
	  
Bedanken	  möchte	   ich	  mich	   auch	   bei	   Julia	   S.	   und	  Heli	   für	   das	   Korrekturlesen	   dieser	  
Arbeit	  und	  ihre	  guten	  Ideen.	  
	  
Meiner	   Familie	   gilt	   besonderer	   Dank	   für	   die	   unermüdliche	   Unterstützung	   und	   den	  
großen	  Rückhalt	   in	  guten	  und	  in	  schwierigen	  Zeiten.	  Ohne	  euch	  wäre	  das	  alles	  nicht	  
möglich	  gewesen!	  
	  
Zum	  Schluss	  möchte	  ich	  mich	  bei	  Timo	  für	  seine	  großartige	  Unterstützung,	  das	  nicht	  
zu	  erschütternde	  Verständnis	  und	  die	  Liebe	  sehr	  bedanken.	  Du	  bist	  mein	  Fels	   in	  der	  
Brandung!	  
